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A B S T R A C T
Background
Micronutrient deficiencies are common among adults living with HIV disease, particularly in low-income settings where the diet may
be low in essential vitamins and minerals. Some micronutrients play critical roles in maintenance of the immune system, and routine
supplementation could therefore be beneficial. This is an update of a Cochrane Review previously published in 2010.
Objectives
To assess whether micronutrient supplements are effective and safe in reducing mortality and HIV-related morbidity of HIV-positive
adults (excluding pregnant women).
Search methods
Weperformed literature searches from January 2010 to18November 2016 for new randomized controlled trials (RCTs) ofmicronutrient
supplements since the previous review included all trials identified from searches prior to 2010. We searched the CENTRAL (the
Cochrane Library), Embase, and PubMed databases. Also we checked the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) and the ClinicalTrials.gov trials registers. We also checked the reference lists of all new included trials.
Selection criteria
We includedRCTs that compared supplements that contained either single, dual, ormultiplemicronutrients with placebo, no treatment,
or other supplements. We excluded studies that were primarily designed to investigate the role of micronutrients for the treatment
of HIV-positive participants with metabolic morbidity related to highly active antiretroviral therapy (HAART). Primary outcomes
included all-cause mortality, morbidity, and disease progression.
Data collection and analysis
Two review authors independently selected trials for inclusion, and appraised trial quality for risk of bias. Where possible, we presented
results as risk ratios (RR) for dichotomous variables, as hazard ratios (HRs) for time-to-event data, and as mean differences (MD) for
continuous variables, each with 95% confidence intervals (CIs). Since we were often unable to pool the outcome data, we tabulated it
for each comparison. We assessed the certainty of the evidence using the GRADE approach.
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Main results
We included 33 trials with 10,325 participants, of which 17 trials were new trials. Ten trials compared a daily multiple micronutrient
supplement to placebo in doses up to 20 times the dietary reference intake, and one trial compared a daily standard dose with a high
daily dose of multivitamins. Nineteen trials compared supplementation with single or dual micronutrients (such as vitamins A and D,
zinc, and selenium) to placebo, and three trials compared different dosages or combinations of micronutrients.
Multiple micronutrients
We conducted analyses across antiretroviral therapy (ART)-naive adults (3 trials, 1448 participants), adults on antiretroviral therapy
(ART) (1 trial, 400 participants), and ART-naive adults with concurrent active tuberculosis (3 trials, 1429 participants). Routine
multiple micronutrient supplementation may have little or no effect on mortality in adults living with HIV (RR 0.91, 95% CI 0.72
to 1.15; 7 trials, 2897 participants, low certainty evidence).
Routine supplementation for up to two years may have little or no effect on the average of mean CD4+ cell count (MD 26.40 cells/
mm³, 95% CI −22.91 to 75.70; 6 trials, 1581 participants, low certainty evidence), or the average of mean viral load (MD −0.1
log10viral copies, 95% CI −0.26 to 0.06; 4 trials, 840 participants, moderate certainty evidence). One additional trial in ART-naïve
adults did report an increase in the time to reach a CD4+ cell count < 250 cells/mm³ after two years of high dose supplementation in
Botswana (HR 0.48, 95% CI 0.26 to 0.88; 1 trial, 439 participants). However, the trial authors reported this effect only in the trial
arm that received multiple micronutrients plus selenium (not either supplementation alone), which is inconsistent with the findings of
other trials that used similar combinations of micronutrients and selenium.
In one additional trial that compared high-dose multiple micronutrient supplementation with standard doses in people on ART,
peripheral neuropathy was lower with high dose supplements compared to standard dose (incidence rate ratio (IRR) 0.81, 95% CI 0.7
to 0.94; 1 trial, 3418 participants), but the trial was stopped early due to increased adverse events (elevated alanine transaminase (ALT)
levels) in the high dose group.
Single or dual micronutrients
None of the trials of single or dual micronutrient supplements were adequately powered to assess for effects on mortality or morbidity
outcomes. No clinically significant changes in CD4 cell count (data not pooled, 14 trials, 2370 participants, very low or low certainty
evidence) or viral load (data not pooled, seven studies, 1334 participants, very low or low certainty evidence), were reported. Supple-
mentation probably does increase blood concentrations of vitamin D and zinc (data not pooled, vitamin D: 4 trials, 299 participants,
zinc: 4 trials, 484 participants, moderate certainty evidence) and may also increase blood concentrations of vitamin A (data not pooled,
3 trials, 495 participants, low certainty evidence), especially in those who are deficient.
Authors’ conclusions
The analyses of the available trials have not revealed consistent clinically important benefits with routine multiple micronutrient
supplementation in people living with HIV. Larger trials might reveal small but important effects.
These findings should not be interpreted as a reason to deny micronutrient supplements for people living with HIV where specific
deficiencies are found or where the person’s diet is insufficient to meet the recommended daily allowance of vitamins and minerals.
P L A I N L A N G U A G E S U M M A R Y
Micronutrient supplements for non-pregnant adults with HIV infection
Cochrane researchers conducted a review of the effects of micronutrient supplements for people living with HIV. This is an update
of a Cochrane Review previously published in 2010. After searching for relevant trials up to 18 November 2016, the review authors
included 33 trials. Thirteen of these trials included people not on HIV treatment and were conducted in Thailand, Peru, and eight
African countries. Nineteen trials included people on HIV treatment and were conducted in North America, Europe, Brazil, Singapore,
Thailand, Botswana, and Uganda. One trial from China did not state whether people living with HIV were on treatment or not. Some
trials looked at the effects of taking supplements with multiple micronutrients whereas others looked at supplementation with single
vitamins or minerals.
What are micronutrient supplements and how might they help people living with HIV?
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Micronutrient supplements contain vitamins or minerals, or both, that are essential to good health. Many of these vitamins play
important roles in maintaining the human immune system, which helps to fight off infections.
Infection with HIV causes a progressive destruction of the immune system, which leaves people vulnerable to frequent infections.
Many people living with HIV, especially in low-income countries, are also undernourished and many consume diets deficient that these
essential micronutrients. Supplementation could therefore help people living with HIV to stay healthy for longer by strengthening their
immune system or assisting recovery from infections.
What the research says
Multiple micronutrients
Providing a daily supplement that contains multiple vitamins and minerals may have little or no effect on reducing deaths in people
living with HIV, whether they are taking antiretroviral drugs or not (low certainty evidence). Daily supplements may have little or no
effect on HIV disease progression as measured by CD4 cell count (low certainty evidence) or HIV viral load (low or moderate certainty
evidence).
Single or dual micronutrients
We do not know whether supplements that contain single vitamins or minerals reduce deaths (very low certainty evidence) or slow disease
progression (very low/low certainty evidence) in people living with HIV. Supplementation with vitamin A, D, zinc, or selenium may
improve the level of each vitamin in a person’s blood, especially those with low levels before supplementation (low/moderate certainty
evidence).
These findings do not mean that an adequate dietary intake for people living with HIV is not important. It is also not a reason to
deny micronutrient supplements for those in whom a deficiency has been clinically demonstrated, or who are unlikely to meet the
recommended daily allowance of vitamins and minerals.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M ultiple micronutrients compared to placebo for adults with HIV infection
Participant or population: adults with HIV infect ion (with and without concurrent tuberculosis, with and without ART)
Settings: all sett ings
Intervention: mult iple micronutrient supplementat ion (standard or high dose daily)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo M icronutrients
M ortality
Follow-up: 8 to 24
months
100 per 1000 91 per 1000
(72 to 115)
RR 0.91
(0.72 to 1.15)
2897
(7 trials)
⊕⊕©©
low1,2,3,4
due to indirectness and
imprecision
Mult iple micronutrients
may have lit t le or no ef -
fect on mortality
Hospital admissions
Follow-up: 11 to 18
months
139 per 1000 120 per 1000
(85 to 170)
RR 0.86
(0.61 to 1.22)
881
(2 trials)
⊕©©©
very low1,4,5
due to indirectness and
imprecision
We don’t know if mult i-
ple micronutrients have
any ef fect on hospital
admissions
CD4 cell count
Follow-up: 6 weeks to 2
years
The mean in the
placebo groups ranged
f rom
147 to 483 cells/ mm³
The mean in the mult i-
ple micronutrient group
was
26.40 cells/ mm³ higher
(22.91 lower to 75.70
higher)
- 1581
(6 trials)
⊕⊕©©
low1,3,6
due to indirectness and
inconsistency
Mult iple micronutrients
may have lit t le or no ef -
fect on CD4 cell count
Viral load
Follow-up: 6 weeks to 2
years
The mean in the
placebo groups ranged
f rom
4.1 to 5.4 log10copies/
mL
The mean in the
mult iple micronutrient
groups was
0.10 log10copies/ mL
lower
- 840
(4 trials)
⊕⊕⊕©
moderate1,7
due to indirectness
Mult iple micronutrients
probably have lit t le or
no ef fect on viral load
4
M
ic
ro
n
u
trie
n
t
su
p
p
le
m
e
n
ta
tio
n
in
a
d
u
lts
w
ith
H
IV
in
fe
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
(0.26 lower to 0.06
higher)
Nutritional status
Follow-up: 4 weeks to
1.9 years
- - Not pooled 1007
(3 trials)
⊕©©©
very low1,8,9
due to indirectness and
imprecision
We don’t know if mult i-
ple micronutrients have
any ef fect on nutrit ional
status parameters
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group
and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: ART: ant iretroviral therapy; BMI: body mass index; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: most trials were at low risk of select ion bias and used placebos to prevent performance or detect ion
bias.
2No serious heterogeneity: none of the trials found stat ist ically signif icant ef fects overall (although one small subgroup f rom
one trial in Tanzania did f ind a stat ist ically signif icant dif f erence this is probably a chance f inding).
3Downgraded by 1 for serious indirectness: although most trials reported this outcome, only one of these (f rom Uganda using
standard dose micronutrients) included a substant ial number of adults on ART in line with current recommendations. The
other trials used standard or high dose micronutrients and were conducted in ART-naive adults (in Botswana, Zambia, and
Thailand), and adults with concurrent tuberculosis (in Tanzania and Malawi).
4Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important ef fects and no ef fect.
The overall meta-analysis remains underpowered to conf ident ly exclude ef fects.
5Downgraded by 2 for very serious indirectness: these two trials were conducted in Thailand (high dose micronutrients in
ART-naive adults) and Uganda (standard dose micronutrients in adults on ART). The f inding of no ef fect may not apply to all
populat ions and sett ings.
6Downgraded by 1 for serious inconsistency: in total eight trials reported a measure of CD4+ cell count although we could
only include six trials in this meta-analysis. Of note, one recent trial in Botswana among ART-naive adults (not included in the
meta-analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/ mm³ af ter two years of high dose
supplementat ion. This f inding is inconsistent with other trials that used sim ilar combinat ions of m icronutrients and selenium.
7Downgraded by 1 for serious indirectness: in total four trials in ART-naive adults, with concurrent TB (in Tanzania and Malawi)
or without TB (in Kenia and Thailand), reported viral load. The f inding of no ef fect may not apply to people on ART or other
populat ions and sett ings.5
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8Downgraded by 2 for serious indirectness: only three trials (f rom Uganda, Zambia, and Tanzania) reported measures of
nutrit ional status (BMI, weight, m id-upper arm circumference (MUAC), lean body mass). The f inding of no ef fect may not
apply to all populat ions and sett ings.
9Downgraded by 1 for serious imprecision: we were unable to pool data but the 95% CIs of the individual trials were wide and
included clinically important ef fects and no ef fect.
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B A C K G R O U N D
Description of the condition
Despite a substantial decrease in the number of new HIV infec-
tions during the past decade, recent estimates from the United
Nations Joint Programme onHIV/AIDS (UNAIDS) indicate that
35 million people were still living with HIV worldwide in 2013
(UNAIDS 2014). The HIV/AIDS pandemic has severely affected
sub-Saharan Africa, more than any other part of the world. With
about a tenth of the world’s population, the region is home to
more than two-thirds of all people living with HIV worldwide,
an estimated 24.7 million adults and children (UNAIDS 2014).
Globally, more than one-third of HIV-positive adults receive an-
tiretroviral therapy (ART) (UNAIDS 2014). Earlier initiation of
ART, in line with recent recommendations, is a challenge to im-
plement in many countries, especially those in resource-limited
settings (WHO 2015).
Adults living with HIV may also have micronutrient deficiencies,
particularly those from communities at high risk of food inse-
curity since diets are frequently inadequate to meet the recom-
mended daily requirements (Gebrehiwot 2014). A recent review
reported that people living with HIV who experience food inse-
curity tended to have lower CD4 counts than their counterparts
(Aibibula 2016). Deficiencies of micronutrients are more pro-
nounced in individuals with advanced disease, as a consequence of
reduced nutrient intake due toAIDS and opportunistic infections,
and excessive losses due to diarrhoea, malabsorption, and parasitic
infections. Furthermore, in sub-Saharan Africa, a region severely
affected by theHIV/AIDS pandemic, protein energymalnutrition
(PEM) is common. PEM refers to inadequate protein and energy
intake and is usually associated with multiple micronutrient in-
sufficiency (Irlam 2007).
Description of the intervention
Micronutrient supplements are either single or multiple formula-
tions of vitamins and trace elements.
How the intervention might work
Micronutrients play a critical role in the maintenance of a func-
tional immune system. The interactions between micronutrients
and the components of the immune response are multifaceted and
complex Chandra 1997; Raiten 2015). Several observational stud-
ies have suggested that micronutrient deficiencies may hasten clin-
ical disease progression inHIV-positive adults. Low blood levels of
vitamin A, B12, zinc, and selenium have been related to increased
HIV progression (Graham 1991; Kupka 2004; Tang 1997) or
death in this population (Baum 1997; Baum 2003; Semba 1993).
Most participants in these earlier studies were not receiving ART
at the time. More recently, vitamin D deficiency, which is assessed
by low 25-hydroxy vitamin D levels, has been associated with in-
creased disease progression of untreated (Mehta 2010) or treated
HIV disease (Sudfeld 2012; Viard 2011), and impaired CD4 cell
count recovery of HIV-positive men and women on antiretroviral
therapy (ART) (Aziz 2013; Ross 2011).
Widespreadmicronutrient supplementation may lessen the effects
of concurrent micronutrient deficiency and help to reduce the
morbidity and mortality due to HIV (Semba 1999). It has also
been suggested that micronutrient supplementation may enhance
the CD4 cell responses of individuals on ART who demonstrate
adequate viral suppression (Tang 2005).
Assessing the effectiveness of micronutrient supplementation in
participants with inflammation requires special consideration.
Acute inflammation results in the redistribution of micronutrients
due to changes in plasma proteins and may therefore impact on
the validity of nutrient biomarkers, such as serum micronutrient
concentrations (Raiten 2015).
Why it is important to do this review
A previous version of this Cochrane review included 30 trials:
20 trials of single micronutrient supplements (vitamin A, vitamin
D, zinc, and selenium) and 10 of multiple micronutrient supple-
ments. Eight trials were undertaken in child populations and four
trials were conducted among pregnant and lactatingwomen (Irlam
2010). The review found no conclusive evidence that micronutri-
ent supplementation effectively reduces or increases morbidity or
mortality in HIV-positive adults.
The HIV/AIDS pandemic has had a major impact on global
health, nutrition, and overall socioeconomic development. An up-
date of the reviewbased on recent, valid research is therefore impor-
tant. Micronutrient supplements have potential benefit for people
living with HIV infection. However, in order to understand the
magnitude of this benefit and how supplements should be posi-
tioned alongside the proven advantages of antiretroviral drugs, a
robust evidence-base to guide policy and practice is required.
At the request of the World Health Organization (WHO), two
separate Cochrane Reviews on the role of micronutrient sup-
plementation were published for HIV-positive pregnant women
(Siegfried 2012) and children (Irlam 2013). The primary focus
of this Cochrane review is therefore on the role of micronutrient
supplementation in HIV-positive non-pregnant adults.
O B J E C T I V E S
To assess whethermicronutrient supplements are effective and safe
in reducing mortality and HIV-related morbidity in HIV-positive
adults (excluding pregnant women).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) of micronutrient supple-
ments comparedwith placebo, no treatment, or other supplements
(including variations in quantity or formulation).
Types of participants
HIV-positive adults, defined as people≥ 15 years of age who were
HIV-positive (WHO 2007). Two other Cochrane reviews have
addressed micronutrient supplementation for HIV-positive chil-
dren and pregnant women (Irlam 2013; Siegfried 2012). We in-
cluded trials that recruited both HIV-positive adults and children
if 80% or more of the participants were HIV-positive adults.
We included trials that recruited antiretroviral therapy (ART)-
naive participants, as well as those that recruited participants on
ART. Since the objective of this Cochrane Review is on the adjunc-
tive role of micronutrients on mortality and HIV-related morbid-
ity, we excluded studies that were primarily designed to investigate
the role of micronutrients for the treatment of HIV-positive par-
ticipants withmetabolic morbidity related to ART. ACochrane re-
view on treatment for dyslipidaemia inHIV infection is in progress
(Martí-Carvajal 2010).
We included trials conducted in populations with and without
HIV infection if outcome data were available for HIV-positive
participants.
We included trials that involved participants with tuberculosis
with and without HIV infection if outcome data were available
for participants with HIV, regardless of whether the trial authors
stratified the randomization of trial participants according to HIV
infection status. We excluded studies that did not report outcome
data for HIV-positive participants.
Types of interventions
We included trials of micronutrient supplementation that in-
cluded vitamins (A, D, E, C, B1, B2, niacin, B6, B12, K, folate,
beta-carotene), trace elements (zinc, selenium, magnesium, iron,
iodine, copper, manganese, chromium, cobalt, molybdenum), or
combinations of the above only. We described a supplement as a
standard dose supplement if the trial provided a single micronu-
trient, or a combination of micronutrients, at the level of the Rec-
ommended Daily Intake (RDA). We described any supplement
containing a single micronutrient, or a combination of micronu-
trients in multiples of the RDA, as a high-dose supplement. We
excluded studies that assessed the effect of adding micronutrients
to foods (food fortification).
Types of outcome measures
Primary outcomes
• All-cause mortality
• Morbidity (frequency, types, and duration of episodes of
opportunistic infections; incidence of AIDS as defined by each
trial; hospital admissions; and other types of illnesses related to
HIV infection as reported in each study)
• Disease progression according to either the World Health
Organization (WHO 2007), or the Centers for Disease Control
and Prevention (CDC) clinical staging system (Schneider 2008),
as reported in each included trial
Secondary outcomes
• Virological response: proportion of participants who
maintained an undetectable viral load and change in HIV-RNA
levels (mean relative change (percent) or mean absolute change,
compared with baseline, and standard deviation (SD))
• Virological failure: proportion of participants who
discontinued or switched ART due to virological failure, as
defined by each included trial
• Markers of immune response, such as change in absolute
CD4+ T lymphocyte count (mean relative change (percent) or
mean absolute change, compared with baseline, and SD)
• Nutritional status, including measurements such as
bodyweight, Body Mass Index (BMI), and body composition
• Biochemical markers, such as serum micronutrient
concentrations
We excluded studies that only reported data that related to bio-
chemical markers from this review.
Adverse events
We extracted data on all adverse events that we judged to be asso-
ciated with micronutrient supplementation, as reported by each
included trial. If the trial authors had classified these events ac-
cording to the Adverse Event Toxicity Scale, we extracted the data
accordingly: grade 1 or 2 (mild to moderate symptoms), grade 3
(serious symptoms), or grade 4 symptoms (denotes life-threaten-
ing events that require a significant clinical intervention) (DAIDS
2014).
Search methods for identification of studies
Electronic searches
We searched the CENTRAL (Appendix 1), PubMed (Appendix
2), and Embase (Appendix 3) databases from January 2010 up
to 18 November 2016. We limited the search date from January
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2010, since Irlam 2010 included all trials identified from searches
prior to and including January 2010. In addition we checked the
World Health Organization (WHO) International Clinical Tri-
als Registry Platform (ICTRP) (Appendix 4) and the ClinicalTri-
als.gov trial register (Appendix 5). We also searched the reference
lists of the included trials.
Searching other resources
For this update, we searched the reference lists of all the included
trials. We also contacted investigators of ongoing studies that have
been completed by email to enquire about any new or imminent
publications.
Data collection and analysis
Selection of studies
Two review authors (MV and SD) independently screened the
titles and abstracts identified through the electronic searches for
potentially eligible citations for full-text screening. In the case of
uncertainty regarding eligibility, we screened the full-text article(s).
Two review authors (MV and SD) screened full-text articles using
a standardized eligibility form based on the inclusion criteria of the
review. In the case of disagreement or uncertainty, a third review
author (NS) provided their opinion. We listed all studies that we
excluded after full-text assessment and their reasons for exclusion
in a ’Characteristics of excluded studies’ table. We constructed a
PRISMA diagram to illustrate the study selection process.
Data extraction and management
Two review authors (MV and SD) independently extracted data
from the included trials for the review update using an updated
standardized electronic data extraction form. We extracted the
following information from each trial.
• Administrative details: trial identification number;
author(s); published or unpublished; year of publication
• Details of the trial: country and location of trial, trial
design, duration and completeness of follow-up; informed
consent and ethics approval, source of funding
• Details of participants: age, gender, disease progression
according to clinical staging, relevant baseline characteristics
including CD4 count and viral load
• Details of intervention and control group: type, dosage, and
frequency of micronutrient(s); additional co-interventions (such
as ART, tuberculosis treatment, or other management of
opportunistic infections)
• Details of outcomes: all prespecified outcomes and any
additional outcomes reported in the study; adverse events and
toxicity
• Details of data analysis: numbers and reported statistics for
each reported outcome. Where trial outcomes were reported in
more than one reference, we used all the trial reports to extract
data as comprehensively as possible
We entered data into the Review Manager 5 (RevMan 5) software
(ReviewManager 5). The trial ID for each included trial consisted
of the name of the first trial author followed by the date of publi-
cation and the country code where the study was conducted (see
Appendix 6).
Assessment of risk of bias in included studies
Two review authors (MV and SD) independently assessed the risk
of bias of each new included trial using the Cochrane ’Risk of bias’
assessment tool (Higgins 2011). Please see Appendix 7 for the ad-
ditional assessment of risk of bias in included cluster-randomized
trials.For each trial we assessed the following domains as either
at high, low, or unclear risk of bias: sequence generation, alloca-
tion concealment, blinding (participants, personnel, and outcome
assessor), incomplete outcome data, selective outcome reporting,
and other sources of bias.
Measures of treatment effect
For the measures of treatment effect, we used the risk ratio (RR)
for dichotomous data, the weighted mean difference (WMD) for
continuous data measured on the same scale, and the standardized
mean difference (SMD) for continuous datameasured on different
scales, presentedwith 95%confidence intervals (CIs). For time-to-
event data we extracted the hazard ratio (HR). We used RevMan
5 for data analysis (Review Manager 5).
Unit of analysis issues
We included two trials with factorial designs (Baum 2013 BWA;
Range 2006 TZA). For Range 2006 TZA, we halved the number
of events and participants in the placebo group for dichotomous
outcomes and the number of participants for continuous outcomes
in our meta-analysis in order to avoid double counting. Since
Baum 2013 BWA reported time-to-event data we were unable to
incorporate the data into a meta-analysis.
We described the outcome data narratively for the cross-over trial
by Coodley 1993 USA, since the study authors did not report
outcome data before trial cross-over. For Kelly 2008 ZMB we did
not include the data after trial cross-over as the trial authors did
not clearly describe the wash-out period.
Dealing with missing data
We contacted the authors of three published conference abstracts
in order to obtain further information regarding the trial protocol
and study outcomes (Baum 2010 USA; Sales 2010; Scrimgeour
2010).We also contacted other trial authors in order to clarify data
9Micronutrient supplementation in adults with HIV infection (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
or statistical analysis where needed.Where possible, we conducted
a complete-case analysis. For trial outcomeswhere this was unclear,
we used the number of participants randomized to each trial arm.
We documented the attrition rate for each included trial in the
’Risk of bias’ table.
Assessment of heterogeneity
First we assessed trials for clinical heterogeneity by examining vari-
ability in the participants, interventions, and outcomes. We as-
sessed statistical heterogeneity visually and by means of the Chi²
test for heterogeneity and the I² statistic. We classified heterogene-
ity according to the I² statistic values as follows (Higgins 2002).
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
Assessment of reporting biases
To prevent reporting biases we searched multiple sources and
searched for unpublished studies in trials registers. We did not
examine funnel plots to assess the likelihood of publication bias
as there were an insufficient number of trials per outcome.
Data synthesis
In view of the anticipated heterogeneity between trial populations
and interventions, we used a random-effectsmodel.Whenwewere
unable to pool data due to differences in the statistical methods
and measures the study authors used, we presented the data in
tables with a narrative summary.
Subgroup analysis and investigation of heterogeneity
Weconducted stratified analyses according towhether participants
were taking ART or not, and whether they were on concurrent
treatment for tuberculosis or not.We stratified outcome data, such
as CD4+ cell count and viral load, by time points (baseline and
at longest time follow-up) in order to demonstrate changes over
time.
Certainty of the evidence
Two review authors (MV and SD) independently assessed the cer-
tainty of the evidence for the outcomes under each comparison
(type of micronutrient intervention) using the Grading of Recom-
mendations, Assessment,Development andEvaluation (GRADE)
approach. According to this approach the certainty rating of ev-
idence for each outcome is determined by an assessment of the
available study data in terms of its risk of bias, inconsistency, indi-
rectness, imprecision, and publication bias. We used GRADEpro
GuidelineDevelopmentTool (GDT) software to create ’Summary
of findings’ tables for each comparison (GRADEpro 2014).
Sensitivity analysis
We could not perform a sensitivity analysis to assess the robustness
of the results against the ’Risk of bias’ domains as there were too
few studies for each comparison.
R E S U L T S
Description of studies
Results of the search
The previous version of this review, which included pregnant
women and children, included 30 trials (Irlam 2010). Only 16 of
these were eligible for inclusion in this Cochrane Review.
The PRISMA flow diagram summarizes the results of the searches
for this update (Figure 1). Electronic database searches identified
1835 records, of which there were 1572 records after we removed
duplicates. After we screened these records by title/abstract, we
identified 68 articles for full-text assessment. Handsearching iden-
tified three new trials. Seventeen new trials met the inclusion cri-
teria of this review, which gave a total of 33 included trials. Of
the new included trials, four reported outcome data in two articles
(Asdamongkol 2013 THA; Bang 2012 DEN; Baum 2010 USA;
Baum 2013 BWA), and two letters of correspondence were related
to one included trial (Isanaka 2012 TZA). Two included trials
published their trial protocols (Guwatudde 2015 UG; Kamwesiga
2015 RWA). We identified one additional trial from our most
recent search (18 November 2016), which we included in the
’Characteristics of studies awaiting classification’ section.We iden-
tified six ongoing trials from searching trial registries.
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Figure 1. Study flow diagram
Included studies
Participants
Thirteen trials, which included 4493 participants, were conducted
in antiretroviral therapy (ART)-naive participants (Baeten 2002
KEN; Baum 2013 BWA; Cárcamo 2006 PER; Jiamton 2003
THA; Kamwesiga 2015 RWA; Kelly 1999 ZMB; Kelly 2008
ZMB; Lawson 2010 NIG; McClelland 2004 KEN; Range 2006
TZA; Semba 2007 MWI; Villamor 2008 TZA; Wejse 2009
GNB). One small trial did not state whether participants received
ART or not (Zhao 2010 CHN).
The remaining 19 trials included 5730 participants, with most
receiving either mono- or combination ART (Allard 1998 CAN;
Coodley 1993 USA; Coodley 1996 USA; Humphrey 1999
USA; Semba 1998 USA), or highly active antiretroviral therapy
(HAART) (Asdamongkol 2013 THA; Bang 2012 DEN; Baum
2010 USA; Burbano 2002 USA;Dougherty 2015USA;Giacomet
2013 ITA; Guwatudde 2015 UG; Green 2005 SGP; Grigoletti
2013 BRA; Hurwitz 2007 USA; Isanaka 2012 TZA; Overton
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2015 USA; Semba 2007 USA; Stallings 2014 USA). Many of
these trials were small with fewer than 100 participants, with the
exception of Isanaka 2012 TZA which had more than 3000 par-
ticipants.
In five trials participants were on concurrent treatment for active
tuberculosis (Lawson 2010 NIG; Range 2006 TZA; Semba 2007
MWI; Villamor 2008 TZA; Wejse 2009 GNB).
Trial site
Trials were undertaken in the following places.
• Africa: Botswana (Baum 2013 BWA), Kenya (Baeten 2002
KEN; McClelland 2004 KEN), Guinea-Bissau (Wejse 2009
GNB), Malawi (Semba 2007 MWI), Nigeria (Lawson 2010
NIG), Rwanda (Kamwesiga 2015 RWA), Tanzania (Range 2006
TZA; Isanaka 2012 TZA; Villamor 2008 TZA), Uganda
(Guwatudde 2015 UG), and Zambia (Kelly 1999 ZMB; Kelly
2008 ZMB)
• Asia: China (Zhao 2010 CHN), Singapore (Green 2005
SGP), and Thailand (Asdamongkol 2013 THA; Jiamton 2003
THA)
• North America: Canada (Allard 1998 CAN) and USA
(Baum 2010 USA; Burbano 2002 USA; Coodley 1993 USA;
Coodley 1996 USA; Dougherty 2015 USA; Humphrey 1999
USA; Hurwitz 2007 USA; Overton 2015 USA; Semba 1998
USA; Semba 2007 USA; Stallings 2014 USA)
• South America: Brazil (Grigoletti 2013 BRA) and Peru
(Cárcamo 2006 PER)
• Europe: Denmark (Bang 2012 DEN) and Italy (Giacomet
2013 ITA)
Interventions
Twenty-nine placebo-controlled studies met the inclusion criteria.
Of these, two had factorial designs (Baum 2013 BWA;Range 2006
TZA). For both of these trials we extracted data for two treatment
comparisons. Trials assessed the effectiveness of the supplementa-
tion of the following.
• Multiple micronutrients (10 trials; 3533 participants: Baum
2013 BWA; Guwatudde 2015 UG; Jiamton 2003 THA; Kelly
1999 ZMB; Kelly 2008 ZMB; McClelland 2004 KEN; Range
2006 TZA; Semba 2007 MWI; Villamor 2008 TZA; Zhao 2010
CHN)
• Vitamin A (4 trials; 581 participants: Baeten 2002 KEN;
Coodley 1993 USA; Humphrey 1999 USA; Semba 1998 USA)
• Vitamin D (5 trials; 447 participants: Bang 2012 DEN;
Giacomet 2013 ITA; Overton 2015 USA; Stallings 2014 USA;
Wejse 2009 GNB)
• Vitamin E combined with vitamin C (1 trial, 49
participants: Allard 1998 CAN)
• Folinic acid (1 trial, 30 participants: Grigoletti 2013 BRA)
• Zinc (6 trials, 826 participants: Asdamongkol 2013 THA;
Baum 2010 USA; Cárcamo 2006 PER; Green 2005 SGP;
Lawson 2010 NIG, Range 2006 TZA)
• Selenium (4 trials, 1308 participants: Baum 2013 BWA;
Burbano 2002 USA; Hurwitz 2007 USA; Kamwesiga 2015
RWA)
In addition, we identified four trials that assessed the effectiveness
of the supplementation of the following.
• High dose versus standard dose multiple micronutrients
(Isanaka 2012 TZA)
• 4000 IU vitamin D versus 7000 IU vitamin D (Dougherty
2015 USA)
• Multiple micronutrients with iron versus multiple
micronutrients (Semba 2007 USA)
• β-carotene with multivitamins versus multivitamins
(Coodley 1996 USA)
The follow-up periods of these trials ranged from two weeks to 24
months.
Sample size
Trials were generally underpowered to demonstrate effects onmor-
tality. For example, to demonstrate a 25% reduction in deaths
of HIV-positive participants not on ART 2412 trial participants
would be required, and to identify the same reduction for those
on ART 7314 trial participants would be required (Table 1). This
far exceeds the number of participants in the three included trials
that reported on this outcome (Isanaka 2012 TZA; Jiamton 2003
THA; Villamor 2008 TZA). Isanaka 2012 TZA based their sam-
ple calculation of 3000 participants on the basis of a 25% reduc-
tion in the composite outcome of death and disease progression
(any new or recurrent AIDS-defining illness). We have provided
the optimal information sizes for nutritional outcomes in Table 2.
For full details of the included studies refer to the ’Characteristics
of included studies’ section.
Excluded studies
We excluded 14 trials that were included in the previous version
of this review, Irlam 2010, from the current version. Eight trials
were in HIV-positive children; four trials were in HIV-positive
pregnant women; and in two trials the study participants received
micronutrient supplements that did not contain micronutrients
exclusively (Austin 2006; Kaiser 2006).
We excluded 46 records after full-text assessment, 13 of which
were not RCTs. We excluded the remaining studies because they
addressed interventions that were not exclusively micronutrients
(n = 10), had a co-intervention (n = 4), involved trial participants
aged less than 15 years (n = 4) or those with HAART co-morbidity
(n = 3), or reported study outcomes not relevant to this review (n
= 12) (Figure 1).
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See the ’Characteristics of excluded studies’ table.
Risk of bias in included studies
We evaluated the risk of bias of included studies for each of the six
domains in the Methods section above (see the ’Characteristics of
included studies’ table). Figure 2 and Figure 3 present a graphical
summary of the ’Risk of bias’ assessments.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
Overall 20 trials adequately described a low risk method of ran-
dom sequence generation. In 13 trials the methods were unclear.
Fourteen trials adequately described a method of allocation con-
cealment, and in 19 the methods were unclear.
Blinding
Blinding of participants, treatment providers and outcome asses-
sors was well described in 25 trials, which we judged to be at low
risk of detection and performance bias. The remaining trials were
at unclear risk except Kelly 1999 ZMB, which we considered to
be high risk due to the use of a non-identical placebo. The main
reason for trials being at unclear risk was that no information was
provided about the blinding of the investigators or outcome asses-
sors.
Incomplete outcome data
We judged 14 trials to be at high risk of attrition bias due to
incomplete outcome data. In two trials this risk only applied to
the measures of viral load which were only reported on a subset
of trial participants (Isanaka 2012 TZA; Jiamton 2003 THA).
Eleven trials had high attrition overall or differential attrition, or
both (Allard 1998 CAN; Bang 2012 DEN; Burbano 2002 USA;
Cárcamo 2006 PER; Coodley 1996 USA; Kelly 1999 ZMB; Kelly
2008 ZMB; Lawson 2010 NIG; Range 2006 TZA; Semba 2007
MWI; Semba 2007 USA), and in Baeten 2002 KEN participants
lost to follow-up had more advanced HIV disease and vitamin A
deficiency. Thus we considered these trials to be at high risk for
attrition bias.
Selective reporting
Insufficient information was available to permit judgment about
the extent of bias due to selective outcome reporting in all but
11 included studies. We judged 10 of these as at low risk (Baum
2010 USA; Giacomet 2013 ITA; Guwatudde 2015 UG; Isanaka
2012 TZA; Kamwesiga 2015 RWA; Lawson 2010 NIG; Overton
2015 USA; Semba 2007 MWI; Stallings 2014 USA; Wejse 2009
GNB), and one as at high risk of reporting bias (Hurwitz 2007
USA).
Other potential sources of bias
One trial was stopped early due to evidence of increased alanine
transaminase (ALT) levels with the intervention (Isanaka 2012
TZA).
Fourteen trials did not declare potential conflicts of interest (Allard
1998 CAN; Asdamongkol 2013 THA; Baeten 2002 KEN; Bang
2012 DEN; Burbano 2002 USA; Cárcamo 2006 PER; Coodley
1993 USA; Coodley 1996 USA; Humphrey 1999 USA; Kelly
1999 ZMB; Lawson 2010 NIG; McClelland 2004 KEN; Semba
1998 USA; Semba 2007 MWI).
All but 19 trials were funded either fully or partly from gov-
ernment sources (Allard 1998 CAN; Asdamongkol 2013 THA;
Baeten 2002 KEN; Baum 2010 USA; Baum 2013 BWA; Burbano
2002 USA; Coodley 1993 USA; Coodley 1996 USA; Green 2005
SGP; Grigoletti 2013 BRA;Humphrey 1999 USA; Hurwitz 2007
USA; Isanaka 2012 TZA; Jiamton 2003 THA; Kelly 1999 ZMB;
McClelland 2004 KEN; Semba 1998 USA; Stallings 2014 USA;
Villamor 2008 TZA); five were fully or partly funded by phar-
maceutical companies (Bang 2012 DEN; Coodley 1993 USA;
Jiamton 2003 THA; Kelly 1999 ZMB; Overton 2015 USA); and
one trial did not provide the source of funding (Zhao 2010 CHN).
Effects of interventions
See: Summary of findings for the main comparison Multiple
micronutrients compared to placebo for adults with HIV
infection; Summary of findings 2 Vitamin A compared to
placebo; Summary of findings 3VitaminDcompared to placebo;
Summary of findings 4 Zinc compared to placebo; Summary of
findings 5 Selenium compared to placebo
Comparison 1: Multiple micronutrients versus
placebo
Ten trials compared a daily multiple micronutrient supplement
to placebo, given for between two weeks and two years (see Table
3). Most participants were ART-naive HIV-positive adults, and in
three trials all participants were on treatment for active pulmonary
tuberculosis. Only Guwatudde 2015 UG recruited people already
taking ART (49.8% of trial participants), and the remaining par-
ticipants were commenced on ART at the start of this trial. Trials
were conducted in Africa (Baum 2013 BWA; Guwatudde 2015
UG; Kelly 1999 ZMB; Kelly 2008 ZMB;McClelland 2004 KEN;
Range 2006TZA; Semba2007MWI;Villamor2008TZA),Thai-
land (Jiamton 2003 THA), and China (Zhao 2010 CHN).
Four trials evaluated multiple micronutrient supplements in doses
consistent with the Recommended Daily Intake (RDA) (standard
dose supplements), and six trials used substantially higher doses
(high dose supplements). In summary, high dose supplements in-
cluded: vitamin A (2 to 3 x RDA), B vitamins (6 to 20 x RDA),
vitamin C (3 to 5 times x RDA), vitamin D (1 x RDA), Vitamin
E (2 to 20 x RDA), selenium (2 to 7 x RDA), and zinc (2 to 4 x
RDA) (see Table 4).
Of the ten trials, we judged four to be at low risk of selection bias
(Baum 2013 BWA; Guwatudde 2015 UG, Isanaka 2012 TZA;
Jiamton 2003 THA), and we considered seven to be at low risk
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of performance and detection bias as they adequately described
blinding (Baum 2013 BWA;Guwatudde 2015 UG; Jiamton 2003
THA; Kelly 2008 ZMB; Range 2006 TZA; Semba 2007 MWI;
Villamor 2008 TZA).
Mortality
Overall, statistically significant differences on mortality were not
demonstrated, but the trials were substantially underpowered to
confidently detect or exclude small but clinically important effects
(risk ratio (RR) 0.91, 95% confidence interval (CI) 0.72 to 1.15;
7 trials, 2897 participants, Analysis 1.1).
• In three trials in ART-naive adults, although the proportion
of deaths was lower with supplementation, the 95% confidence
interval (CI) was wide and included the possibility of both
clinically important effects and no effect (RR 0.60, 95% CI 0.31
to 1.15; 3 trials, 1068 participants; I² statistic = 0%). One
additional small trial from Zambia, with only four weeks follow-
up, also reported no difference in mortality but did not present
data that we could include in the meta-analysis (Kelly 1999
ZMB).
• In the only trial in adults on ART, Guwatudde 2015 UG,
the proportion of deaths was similar in both treatment arms, and
the 95% CI was very wide (RR 1.25, 95% CI 0.50 to 3.10; 1
trial, 400 participants).
• In three trials in adults on treatment for active tuberculosis
(and also not on ART), although the CI was narrower, there was
no effect of supplementation on mortality (RR 0.92, 95% CI
0.69 to 1.23; 3 trials, 1429 participants; I² statistic = 54%). One
small factorial trial from Tanzania, Range 2006 TZA, found a
statistically significant effect in a subgroup of HIV-positive
participants who received multiple micronutrients plus zinc, but
the CI was wide and the trial was underpowered (RR 0.29, 95%
CI 0.09 to 0.87; 1 trial, 84 participants). A positive result in an
underpowered study is not likely to reflect a true result (low
positive predictive value (PPV)) and the magnitude of the effect
estimate may also be exaggerated (Button 2013). Furthermore,
the trial authors reported differential attrition between treatment
groups.
Morbidity and clinical disease progression
Two trials reported the risk of hospital admission, and although
this was lower with multiple micronutrient supplementation, the
CIs were wide and included both clinically important benefits and
harms (RR 0.86, 95% CI 0.61 to 1.22; 2 trials, 881 participants,
Analysis 1.2). In one trial, Guwatudde 2015 UG, participants
commenced ART at the start of the trial and in the second trial,
Jiamton 2003 THA, participants were not on ART.
One additional trial in people on treatment for tuberculosis re-
ported no difference in the risk of clinical disease progression (haz-
ard ratio (HR) 1.08 95%CI 0.72 to 1.62; 1 trial, 313 participants,
Analysis 1.3).
Virological and immunological outcomes
Nine trials reported changes in CD4+ count over periods from
four weeks to two years (see Table 5). We could not incorporate
one additional trial from Botswana that reported time-to-event
analyses (time to reach CD4+ count < 250 cells/mm³) into the
meta-analyses (Baum 2013 BWA).
• Six trials reported data as means with standard deviation
(SD) and the pooled effect had a wide 95% CI including modest
benefits and harms (mean difference (MD) 24.79, 95% CI
−23.54 to 73.12; 6 trials, 1581 participants; Analysis 1.4,
Analysis 1.5). Only one small trial from China administering
multiple micronutrients at around the daily recommended
intake, reported a statistically significant effect with
supplementation after six months (1 trial, 99 participants, Zhao
2010 CHN). The other much larger trials that administered
higher doses of multiple micronutrients found no suggestion of
effects; including 808 participants with HIV alone, and 674
participants with HIV plus active tuberculosis
• Three trials reported data as medians and interquartile
range (IQR), and neither found a statistically significant result (3
trials, 911 participants, data not pooled, Table 5)
• One additional trial from Botswana reported data as the
HR of reaching a CD4+ count of less than 250 cells/mm³. The
hazard was lower with high dose supplements of multivitamins
plus selenium for two years (HR 0.48, 95% CI 0.26 to 0.88; 1
trial, 439 participants) and with multivitamins alone (HR 0.54;
95% CI 0.3 to 0.98; 1 trial, 436 participants) However, the trial
authors reported that this effect was only apparent with
supplementation of both multivitamins and selenium after
adjustment for multiple confounders (HR 0.46, 95% CI 0.25 to
0.85; 1 trial, 439 participants) (Baum 2013 BWA)
Five trials of high dose multiple micronutrients reported changes
in viral load at time points from six weeks to two years (see Table
6).
• Four trials reported data as means with SDs and the pooled
estimate was close to no effect with a CI which included a
modest benefit and no effect (MD −0.10, 95% CI −0.25 to
0.05; 4 trials, 1064 participants; Analysis 1.6,Analysis 1.7)
• The fifth trial reported no effect on viral load in a
multivariable random-effects regression model (1 trial, 437
participants, P = 0.4) (Baum 2013 BWA)
Nutritional status and blood micronutrient concentrations
Three trials reported changes in measures of body composition
(BMI,weight,mid-upper arm circumference (MUAC), fatmass or
leanbodymass)with no statistically significant differences between
groups (see Table 7).
Three trials reported changes in blood concentrations of vita-
min A, vitamin E, or selenium (see Table 7), with statistically
significant increases after 48 weeks supplementation in Thai-
land (Jiamton 2003 THA), and eight months supplementation in
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Malawi (Semba 2007 MWI). The third small trial from Zambia
reported no change in serum vitamin A or vitamin E concentra-
tions after four weeks supplementation, despite many being de-
ficient in one or both at baseline (1 trial, 135 participants, Kelly
1999 ZMB).
Adverse events associated with supplementation
One trial with high dose micronutrient supplements reported no
differences in serious adverse events such as acute diarrhoea, vom-
iting, or severely elevated ALT levels (Baum 2013 BWA). Gen-
ital HIV-shedding was increased after six weeks, following high
dose supplements in another trial (McClelland 2004 KEN). A
third trial of high dose supplementation reported discolouration
of urine more frequently in the intervention group, but no dif-
ferences for other minor adverse events such as nausea, headache,
dizziness, drowsiness, or rash (Jiamton 2003 THA). Three trials
that involved high dose supplementation did not report any ad-
verse events (Kelly 1999 ZMB; Range 2006 TZA; Villamor 2008
TZA).
High dose supplements was associated with a decrease in periph-
eral neuropathy in one trial, although this was not reported for
just the subgroup with HIV (RR 57%, 95% CI 41% to 69%;
1 trial, 887 participants) (Villamor 2008 TZA). Participants in
this trial were taking isoniazid for active tuberculosis which is a
known vitamin B6 antagonist and may cause neuropathy without
supplementation.
One trial with standard dose supplements reported no differences
in adverse events such as nausea and vomiting (Guwatudde 2015
UG). A cluster-randomized trial with standard dose supplements
reported four cases of pellagra in the placebo group (three were
associated with high ethanol intakes) (Kelly 2008 ZMB). Two
trials that involved standard dose supplementation did not report
any adverse events (Semba 2007 MWI; Zhao 2010 CHN).
Certainty of the evidence
For a critical appraisal of the summary of evidence, see the ’Sum-
mary of findings for the main comparison’ table (Summary of
findings for the main comparison) and Additional tables 8, 9, and
10 for the stratified analyses (participants taking ART or not, and
whether they were on concurrent treatment for tuberculosis or
not) (Table 8; Table 9; Table 10).
Comparison 2: High-dose versus standard dose
multivitamins
One large Tanzanian trial, Isanaka 2012 TZA, investigated the
effects of a standard versus a high-dose daily multivitamin sup-
plement for 24 months among participants starting HAART (see
Table 4).
Mortality
There were no statistically significant differences in all-cause mor-
tality (RR 1.06, 95% CI 0.89 to 1.26; 1 trial, 3418 participants;
Analysis 2.1), or AIDS-related mortality (RR 1.14, 95% CI 0.82
to 1.58; 1 trial, 3418 participants; Isanaka 2012 TZA).
Morbidity and clinical disease progression
There was no difference in clinical disease progression events com-
bined with death from any cause (RR 1.00, 95% CI 0.96 to 1.04;
1 trial, 3418 participants).
Immunological and virological outcomes
There was a small difference between groups in mean CD4+ cell
count at baseline (MD −7.00 cells/mm³, 95% CI −13.74 to
−0.26), and a similar difference at 15 months (MD−12.00 cells/
mm³, 95% CI−24.00 to−0.00; 1 trial, 3418 participants, Anal-
ysis 2.2). No differences were demonstrated in mean viral load at
baseline or end of follow-up (MD −0.20 log10copies/mL, 95%
CI −0.51 to 0.11; 1 trial, 236 participants, Analysis 2.3; Isanaka
2012 TZA).
Nutritional status and blood micronutrient concentrations
There was no difference in BMI between the two groups (MD 0
kg/m2; 95% CI −0.2 to 0.2; 1 trial, 3418 participants). Blood
concentrations of micronutrients were not reported.
Adverse events associated with supplementation
This trial was stopped early with a median length of follow-up of
15 months due to an increased risk of elevated ALT levels (greater
than 40 IU/L) among trial participants who received high dose
multivitamin supplements (incidence rate ratio (IRR) 1.44, 95%
CI 1.11 to 1.87; one trial, 2921 participants). No differences were
observed for other adverse events such as fatigue, nausea or vom-
iting, diarrhoea, severe anaemia, and rashes or lesions. The inci-
dence of peripheral neuropathy was lower with high dose supple-
ments (IRR 0.81, 95% CI 0.7 to 0.94; 1 trial, 3418 participants).
Comparison 3: Vitamin A versus placebo
Four trials compared a vitamin A supplement to placebo (see Table
11). Participants from two trials in the USA received a single high
dose of vitamin A (200,000 IU to 300,000 IU) and were followed
up for four to eight weeks (Humphrey 1999 USA; Semba 1998
USA). ART-naive women in one trial from Kenya received a daily
dose of vitamin A (10,000 IU) for six weeks (Baeten 2002 KEN).
The trial authors of a small cross-over trial of daily supplements
containing a vitamin A precursor (β-carotene) did not report data
before cross-over (Coodley 1993 USA).
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Of the four trials, we judged one to be at low risk of selection
bias (Semba 1998 USA), and all four that adequately described
blinding and were at low risk of performance and detection bias.
Mortality, morbidity, and clinical disease progression
The trials did not report these outcomes.
Immunological and virological outcomes
Two trials reported changes in CD4+ count at four and six weeks
follow-up, and neither reported statistically significant changes (2
trials, 464 participants, data not pooled, see Table 12). One trial
did report that mean CD4+ count was higher in the supplemented
group after six weeks (P = 0.04), but the difference was no longer
statistically significant after multivariate linear regression analysis
(Baeten 2002 KEN).
Three trials reported changes in viral load, with no statistically
significant differences at four to eight weeks (3 trials, 495 partici-
pants, data not pooled, see Table 13).
Nutritional status and blood micronutrient concentrations
Three trials reported changes in blood retinol concentrations (data
not pooled, see Table 14). In the only trial with a significant pro-
portion of participants with vitamin A deficiency at baseline (59%
<1.05 µmol/L),median serum concentrationswere higher after six
weeks of supplementation compared to placebo (P = 0.03) (Baeten
2002 KEN). In the other two trials, in which most participants
were not deficient, average blood retinol concentrations remained
unchanged after follow-up periods of four and eight weeks, re-
spectively (Humphrey 1999 USA; Semba 1998 USA).
Note: one further trial from the USA evaluated supplementation
with a vitamin A precursor, β-carotene (60 mg) three times daily
(Coodley 1996 USA). This trial reported an increase in blood
concentrations of β-carotene at three months but no statistically
significant effects on CD4+ cell count.
Adverse events associated with supplementation
Signs or symptoms of toxicity (headache, nausea, vomiting, diar-
rhoea, fever) were similar in the intervention and control groups
at 24 hours and one week after administration in one trial
(Humphrey 1999 USA). No adverse events were reported in the
other two trials of vitamin A supplementation (Baeten 2002 KEN;
Semba 2007 USA). Slight skin discolouration was reported by the
participants in the intervention group of a one small trial of β-
carotene supplementation (Coodley 1993 USA).
Certainty of the evidence
For a critical appraisal of the summary of evidence, see ’Summary
of findings’ table 2 (Summary of findings 2).
Comparison 4: Vitamin D versus placebo
Five trials compared a vitamin D supplement, with or without a
calcium supplement, to placebo (see Table 15). Participants in two
trials received a total of three or four doses of vitamin D (100,000
IU), given every three to five months (Giacomet 2013 ITA;Wejse
2009 GNB). Two trials from the USA used a daily supplement
containing 7000 IU vitaminDor 4000 IU vitaminDplus calcium
(1000 mg), respectively, for 12 months (Overton 2015 USA;
Stallings 2014USA). Afifth trial fromDenmark combined a single
dose of vitaminD (100,000 IU) at study entry with a daily vitamin
D supplement (1200 IU) plus calcium (1200 mg) for 16 weeks
(Bang 2012 DEN).
In one trial fromGuinnea-Bissau participants did not receive ART
and were on treatment for active pulmonary tuberculosis (Wejse
2009 GNB). In the other trials most participants were on ART
(see Table 15).
We considered only one of the five trials to be at low risk of selec-
tion bias (Wejse 2009 GNB), but three trials adequately described
blinding and we considered them to be at low risk of detection and
performance bias (Bang 2012 DEN; Giacomet 2013 ITA; Wejse
2009 GNB).
Mortality, morbidity, and clinical disease progression
Only a single trial reported mortality in people with active tuber-
culosis, which was significantly underpowered to evaluate mor-
tality (RR 1.15, 95% CI 0.65 to 2.02; 1 trial, 131 participants,
Analysis 3.1). The effect estimate has wide CIs which include both
important effects and no effect.
Immunological and virological outcomes
Four trials reported changes in the mean or median CD4+ cell
counts, over periods from four to 12months and found no statisti-
cally significant effects (4 trials, 288 participants, data not pooled;
see Table 16).
One very small study from the USA reported a reduction in viral
load over time in those participants with a detectable viral load,
using a multi-level regression model (1 trial, 28 participants, P <
0.05) (Stallings 2014 USA).
Nutritional status and blood micronutrient concentrations
Four trials reported changes in serum concentrations of 25-hy-
droxy vitamin D for periods that ranged from four to 12 months.
Both single dose supplements and daily supplements resulted in a
significant increase in mean or median blood concentrations (ng/
mL) (4 trials, 305 participants, data not pooled; see Table 17).
Note: one further trial from the USA compared supplementation
with 4000 IU vitamin D to 7000 IU vitamin D daily in partic-
ipants on ART (Dougherty 2015 USA). This trial reported an
increase in blood concentrations of 25-hydroxy vitamin D with
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both doses at three months, but no statistically significant effects
on viral load.
Adverse events associated with supplementation
One trial reported one case of hypercalcaemia in a trial participant
who received a single high dose of vitamin D, followed by daily
administration (Bang 2012DEN). The other four trials of vitamin
D supplementation did not report any cases of hypercalcaemia
(Giacomet 2013 ITA; Overton 2015 USA; Stallings 2014 USA;
Wejse 2009 GNB).
Certainty of the evidence
For a critical appraisal of the summary of evidence, see ’Summary
of findings’ table 3 (Summary of findings 3).
Comparison 5: Zinc versus placebo
Six trials compared a zinc supplement to placebo, given for be-
tween two weeks and 18 months (see Table 18). Two trials pro-
vided daily supplements at the level of the RDA (Asdamongkol
2013 THA; Baum 2010 USA), with one being a small trial from
Thailand in participants with immunological discordance on ART
(Asdamongkol 2013 THA).
Higher doses of zinc (50 mg to 100 mg) were given to ARV-
naive participants with persistent diarrhoea for 14 days in one trial
in Peru (Cárcamo 2006 PER) and to participants on ART from
Singapore for four weeks (Green 2005 SGP). In another two trials,
participants were on treatment for active pulmonary tuberculosis,
and received either a high daily dose of zinc (45 mg) or a weekly
dose (90 mg) for six to eight months (Lawson 2010 NIG; Range
2006 TZA).
We considered only one of the six trials to be at low risk of selection
bias (Cárcamo 2006 PER), but five trials adequately described
blinding and we judged them to be at low risk of performance or
detection bias.
Mortality
All three trials that reported deaths were substantially underpow-
ered to confidently detect or exclude effects. None of the trials
found statistically significant results and the 95% CI for the over-
all effect was wide, including both important effects and no effect
(RR 1.24, 95%CI 0.53 to 2.86; 3 trials, 433 participants, Analysis
4.1).
Morbidity and clinical disease progression
One trial from Peru in ART-naive adults with persistent diarrhoea
reported that a high daily dose of zinc (100 mg) had no effect on
the persistence of diarrhoea after two weeks (HR 0.91, 95% CI
0.5 to 1.66; 1 trial, 104 participants, Analysis 4.2; Cárcamo 2006
PER).
One trial from the USA reported that daily zinc supplementation
at the level of the DRI for 18 months significantly reduced the
proportion of participants with diarrhoea over time (odds ratio
(OR) 0.4, 95% CI 0.18 to 0.87; 1 trial, 231 participants, Analysis
4.3; Baum 2010 USA). However, the 95% CI was wide and the
trial was also underpowered to have confidence in this result.
Immunological and virological outcomes
Three trials reported changes in CD4+ cell count over periods
from 28 days to six months (3 trials, 192 participants, data not
pooled, see Table 19) . One trial reported a statistically significant
difference in one small subgroup (Asdamongkol 2013 THA). This
subgroup is substantially underpowered and therefore a positive
result is not likely to reflect a true result (low PPV) (Button 2013).
However, one additional trial from the USA in adults on ART
reported a statistically significant reduction in the risk of reaching a
CD4+ count less than 200 cells/mm³ after supplementation for 18
months (RR 0.24, 95% CI 0.10 to 0.56; 1 trial, 231 participants;
Table 19; Baum 2010 USA).
Three trials reported changes in viral load over periods from 28
days to 18months, and all three trials (includingBaum 2010USA)
reported no statistically significant differences with supplementa-
tion (3 trials, 400 participants, data not pooled, see Table 20).
Nutritional status and blood micronutrient concentrations
Two trials reported blood zinc concentrations at the trial endpoints
of 28 days and 6 months, respectively (two trials, data not pooled,
see Table 21) (Asdamongkol 2013 THA; Green 2005 SGP). No
difference in zinc concentrations were reported, except for a small
number of participants from one trial in Thailand who were defi-
cient in zinc at baseline (Asdamongkol 2013 THA).
In addition, the authors of one trial from Peru in adults with per-
sistent diarrhoea reported a smaller proportion of supplemented
participants with low blood zinc levels after 14 days (1 trial, 159
participants, P = 0.01, see Table 21) (Cárcamo 2006 PER). An-
other trial from the USA reported significantly higher blood zinc
concentrations in the supplemented group at the study endpoint
of 18 months, adjusted for C-reactive protein levels (1 trial, 231
participants, ß = 0.04; P = 0.047) (Baum 2010 USA).
Adverse events associated with supplementation
In one trial one participant in the intervention group developed
an erythematous rash after taking a standard dose supplement for
one month, which resolved when the supplement was discontin-
ued (Asdamongkol 2013 THA). Two trials of high dose supple-
mentation reported similar numbers of participants in the inter-
vention and control groups with gastrointestinal symptoms such
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as vomiting, diarrhoea or abdominal pain (Cárcamo 2006 PER;
Green 2005 SGP).
Certainty of the evidence
For a critical appraisal of the summary of evidence, see ’Summary
of findings’ table 4 (Summary of findings 4).
Comparison 6: Selenium versus placebo
Four trials compared a daily selenium supplement (200 µg) to
placebo, given for between nine and 24 months (see Table 22).
Two trials recruited only ART-naive participants (Baum 2013
BWA;Kamwesiga 2015 RWA), and two recruited both ART-naive
people and people on ART (Burbano 2002 USA; Hurwitz 2007
USA).
Of the four trials, we only judged one to be at low risk of selection
bias (Baum 2013 BWA), and three to be at low risk of performance
and detection bias as they adequately described blinding (Baum
2013 BWA; Burbano 2002 USA; Hurwitz 2007 USA).
Mortality
Not reported.
Morbidity and clinical disease progression
One trial inHIV-positive injection drug users in theUSA reported
a statistically significant reduction in the risk of hospital admis-
sions for opportunistic infections and HIV-related conditions af-
ter supplementation for 12 months (RR 0.40, 95% CI 0.21 to
0.75; 1 trial, 186 participants, Analysis 5.1). However, the trial
authors stated that fewer participants in the placebo group com-
pared to the selenium group were on ART at baseline (P < 0.05)
which may have influenced this result (Burbano 2002 USA).
Immunological and virological outcomes
All four trials reportedmeasures of change inCD4+ cell count with
mixed findings and poor reporting of baseline and end values (see
Table 23). In people not taking ART we observed the following.
• Baum 2013 BWA reported no significant reduction in the
risk of reaching a CD4+ count < 250 cells/mm³ with selenium
supplements for two years in people not on ART (HR 0.83 95%
CI: 0.48 to 1.42; 1 trial, 437 participants), and Kamwesiga 2015
RWA reported no significant reduction in the risk of reaching a
CD4+ count of less than 350 cells/mm³ (RR 0.81 95% CI 0.61
to 1.09; 1 trial, 300 participants)
• However, Kamwesiga 2015 RWA reported a reduction in
the monthly rate of CD4 cell depletion (MD 1.74, 95% CI 0.31
to 3.17; 1 trial, 300 participants)
In populations with mixed exposure to ART, we observed the
following.
• Burbano 2002 USA reported that fewer trial participants in
the supplemented group experienced a CD4 cell decline of
greater than 50 cells/mm³ (P = 0.01; authors’ own figures)
• Hurwitz 2007 USA reported a multiple regression model
that found higher selenium levels predicted a greater increase in
CD4+ cell counts at 9 months (P < 0.04; authors’ own figures).
However, this trial is at high risk of selective reporting as the
statistically significant results are only for a subgroup of
participants classified as ’selenium responders’. It is unclear if this
classification or analysis was planned a priori
Only three trials reported effects on viral load and statistically
significant benefitswere only reported from themultiple regression
model used by Hurwitz 2007 USA.
Nutritional status and blood micronutrient concentrations
Three trials reported statistically significant increases in blood se-
lenium concentrations of participants after supplementation for 6
to 12 months (527 participants, data not pooled, see Table 24)
Adverse events associated with supplementation
One trial reported no differences in symptoms such as nausea,
vomiting and skin andhair changes of participants, but those in the
intervention group were more likely to report anxiety (P = 0.04)
and sleep symptoms (P = 0.01). (Kamwesiga 2015 RWA). Another
trial stated that all serious adverse events reported (which included
acute diarrhoea, vomiting, or severely elevated ALT levels) were
adjudicated as having a remote relationship to the intervention
(Baum 2013 BWA). Two other selenium supplementation trials
reported no adverse events (Burbano 2002 USA; Hurwitz 2007
USA).
Certainty of the evidence
For a critical appraisal of the summary of evidence, see ’Summary
of findings’ table 5 (Summary of findings 5).
Comparison 7: Vitamin E plus vitamin C versus
placebo
One small Canadian trial compared high daily doses of vitamins
E (800 IU) and C (1000 mg) to placebo in adults on combina-
tion ART for three months. Participants were followed up for six
months because of a possible carry-over effect of the intervention
(Allard 1998 CAN).
Allocation concealment was not well described and so the risk of
selection bias was unclear, but the trial was adequately blinded.
Mortality
Not reported.
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Morbidity and clinical disease progression
Allard 1998 CAN reported that high daily doses of vitamin E and
C for three months had no effect on the risk of new AIDS defining
infections after six months (RR 3.54, 95% CI 0.43 to 29.43; 1
trial, 49 participants).
Immunological and virological outcomes
Allard 1998 CAN reported no effect on viral load (log10copies/
mL) after three months supplementation of high daily doses of
vitamin E and C (MD 0.95 log 10 copies/mL, 95% CI 0.14 to
2.04; 1 trial, 49 participants).
Nutritional status and blood micronutrient concentrations
This trial reported that high daily doses of vitamins E and C for
three months increased blood concentrations of vitamin E (µmol/
L) (MD 28.70, 95% CI 20.01 to 37.39; one trial, 49 participants)
and vitamin C (µmol/L) (MD 27.30, 95% CI 12.88 to 41.72; 1
trial, 49 participants) of adults on ART (Allard 1998 CAN).
Adverse events associated with supplementation
Two participants in the intervention group reported epigastric
discomfort (Allard 1998 CAN).
Comparison 8: Folinic acid versus placebo
One small Brazilian trial compared the effect of a daily folinic acid
supplement (5mg) to placebo on the vascular response of 30HIV-
positive adults on ART (Grigoletti 2013 BRA). This trial was at
low risk of selection bias, and detection and performance bias.
Mortality
Not reported.
Morbidity and clinical disease progression
Not reported.
Immunological and virological outcomes
This trial reported no difference in median CD4 cell counts after
daily supplementation of folinic acid for four weeks (1 trial, 30
participants, P = 0.994) (Grigoletti 2013 BRA).
Nutritional status and blood micronutrient concentrations
This trial reported increases in blood concentrations of folate and
vitamin B12 after supplementation of folinic acid for four weeks
(1 trial, 30 participants, P < 0.001) (Grigoletti 2013 BRA).
Adverse events associated with supplementation
No adverse events were reported (Grigoletti 2013 BRA).
Comparison 9: Iron versus no iron
One trial in the USA compared the effect of a daily micronutri-
ent supplement containing iron to a supplement without iron in
female injection drug users for 12 months. Of the trial partici-
pants who were HIV-positive, approximately one-third were on
HAART at baseline and during the study (Semba 2007 USA).
Mortality
Not reported.
Morbidity and clinical disease progression
Not reported.
Immunological and virological outcomes
This trial reported no difference in CD4 cell counts or viral load
measurements in participants who received themicronutrient plus
iron supplement compared to those who received the supplement
without iron for 12 months (CD4 cell count (cells/mm³): MD
35, 95% CI −83.5 to 153.5; viral load (log10copies/mL): MD
−0.4, 95% CI −0.99 to 0.19; 1 trial, 103 participants; Semba
2007 USA).
Adverse events associated with supplementation
No adverse events were reported (Semba 2007 USA).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vitamin A compared to placebo for adults with HIV infection currently taking ART or not
Participant or population: adults with HIV infect ion
Settings: any
Intervention: vitamin A (single dose or daily dose)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Vitamin A
M ortality - - - (0 trials) - -
M orbidity - - - (0 trials) - -
CD4 cell count (cells/
mm³)
Follow-up: 6 to 8 weeks
- - Not pooled 464
(2 trials)
⊕⊕©©
low1,2,3,4
due to risk of bias and
indirectness
Vitamin A may have lit t le
or no short-term ef fect
on CD4 cell count
Viral load (log10copies/
mL)
Follow-up: 6 to 8 weeks
- - Not pooled 495
(3 trials)
⊕⊕©©
low1,2,3,4
due to risk of bias and
indirectness
Vitamin A may have lit t le
or no short-term ef fect
on viral load
Change in vitamin A
concentrations (µmol/
L)
Follow-up: 6 to 8 weeks
- - Not pooled 495
(3 trials)
⊕⊕©©
low1,3,4,5
due to risk of bias and
indirectness
Vitamin A may increase
blood concentrat ions of
persons with HIV with
low baseline concentra-
t ions
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* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: ART: ant iretroviral therapy; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1Downgraded by 1 for serious risk of bias: one trial in Kenya with 400 part icipants reported high attrit ion overall (11.5%) and
the trial authors stated that part icipants who were lost to follow-up had more advanced HIV disease and were more likely
to be vitamin A def icient (Baeten 2002 KEN).
2No serious heterogeneity: none of the trials found stat ist ically signif icant ef fects.
3Downgraded by 1 for serious indirectness: trials were conducted in the USA and Kenya, and most part icipants were not on
ant iretroviral therapy (ART). This may not completely exclude the possibility of ef fects in some sett ings or populat ions.
4No serious imprecision: no stat ist ically signif icant dif f erences were seen. Although two trials were underpowered, one trial
in Kenya with 400 part icipants was adequately powered to reliably detect a clinically benef icial ef fect on CD4 cell count, viral
load, and blood vitamin A concentrat ions (Baeten 2002 KEN).
5No serious heterogeneity: a stat ist ical signif icant increase in blood vitamin concentrat ions was reported in one trial f rom
Kenya with 400 part icipants. Baseline blood vitamin concentrat ions of these part icipants were much lower than the 95
part icipants in the other two trials in the USA.
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Vitamin D compared to placebo for adults with HIV infection
Participant or population: adults with HIV infect ion
Settings: any
Intervention: vitamin D (repeated single doses or daily dose with or without addit ional calcium)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Vitamin D
M ortality
Follow-up: 12 months
254 per 1000 292 per 1000
(165 to 513)
RR 1.15
(0.65 to 2.02)
131
(1 trial)
⊕©©©
very low1,2,3
due to indirectness and
imprecision
We don’t know if vi-
tamin D supplements
have any ef fect on mor-
tality
M orbidity - - - (0 trials) - -
CD4 cell count (cells/
mm³)
Follow-up: 16 weeks to
12 months
- - Not pooled 288
(4 trials)
⊕⊕©©
low1,4
due to indirectness
Vitamin D supplements
may have lit t le or no ef -
fect on CD4 cell count
Viral load (log10copies/
mL)
Follow-up: 12 months
The mean in the
placebo group was
3.78
The mean in the
mult iple micronutrient
groups was
0.66 lower
(1.37 lower to 0.05
higher)
- 28 part icipants
(1 trial)
⊕©©©
very low1,5,6
due to indirectness and
imprecision
We don’t know if vi-
tamin D supplements
have an ef fect on viral
load
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Change in 25(OH) vi-
tamin D concentrations
(ng/ mL)
Follow-up: 16 weeks to
12 months
- - Not pooled 299
(4 trials)
⊕⊕⊕©
moderate1,7,8
due to indirectness
Vitamin D supple-
ments probably in-
crease blood 25(OH) vi-
tamin D levels
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: the included trials were generally at low risk of bias.
2Downgraded by 2 for serious indirectness: only a single trial f rom Guinea-Bissau reports the number of deaths af ter 12
months follow-up in HIV-posit ive part icipants on treatment for act ive tuberculosis (Wejse 2009 GNB).
3Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both a relat ive risk reduct ion and relat ive risk
increase of greater than 25%.
4Downgraded by 2 for serious indirectness: no changes in mean or median CD4 cell counts were reported f rom these four
small t rials f rom Italy (Giacomet 2013 ITA), the USA (Overton 2015 USA), Guinea-Bissau (Wejse 2009 GNB), or Denmark (Bang
2012 DEN). This doesn’t exclude the possibility of ef fects in some populat ions.
5Downgraded by 2 for very serious indirectness: this is a single very small t rial f rom the USA.
6Downgraded by 1 for serious imprecision: the trial is very small, and the 95% CI is wide and includes no ef fect.
7No serious heterogeneity: all f our studies report a stat ist ical signif icant increase in blood 25(OH) vitamin D concentrat ions
(ng/ mL).
8Downgrade by 1 for serious risk of indirectness: all studies were conducted in high income countries (Italy, Canada, Denmark,
and the USA).
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Zinc compared to placebo for adults with HIV infection
Participant or population: adults with HIV infect ion
Settings: any
Intervention: zinc (daily or weekly dose)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Zinc
M ortality
Follow-up: 6 to 18
months
110 per 1000 135 per 1000
(58 to 315)
RR 1.24
(0.53 to 2.86)
433
(3 trials)
⊕©©©
very low1,2,3
due to indirectness and
imprecision
We don’t know if zinc
supplements have any
ef fect on mortality
Rate of diarrhoea
Follow-up: 18 months
- - OR 0.40
(0.18 to 0.87)
231
(1 trial)
⊕©©©
very low1,4,5
due to indirectness and
imprecision
We don’t know if zinc
supplements have any
ef fect on the f requency
of diarrhoea
Change in CD4 cell
count (cells/ mm³)
Follow-up: 1 to 18
months
- - Not pooled 431
(4 trials)
⊕⊕©©
low1,2,6
due to indirectness and
inconsistency
Zinc supplements may
have lit t le or no ef fect
on CD4 cell count
Change in viral load
(log10copies/ mL)
Follow-up: 1 to 18
months
- - Not pooled 400
(3 trials)
⊕⊕©©
low1,2,7
due to indirectness and
imprecision
Zinc supplements may
have lit t le or no ef fect
on viral load
2
6
M
ic
ro
n
u
trie
n
t
su
p
p
le
m
e
n
ta
tio
n
in
a
d
u
lts
w
ith
H
IV
in
fe
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Change in blood zinc
concentrations
Follow-up: 1 to 18
months
- - Not pooled 484
(4 trials)
⊕⊕⊕©
moderate1,2,8
due to indirectness
Zinc supplements prob-
ably increase blood
zinc concentrat ions of
persons with HIV with
low baseline concentra-
t ions
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; OR: odds rat io; HR: hazard rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: the included studies were generally at low risk of bias.
2Downgraded by 1 for serious indirectness: the available data is f rom lim ited sett ings and populat ions. The f indings are not
easily generalized to other populat ions.
3Downgraded by 2 for serious imprecision: the 95% CI around the absolute ef fect is very wide and crosses 1. The overall
meta-analysis is underpowered to conf ident ly exclude ef fects.
4Downgraded by 2 for very serious indirectness: this f inding is f rom a single study in the USA and may not be applicable to
other sett ings.
5Downgraded by 1 for serious imprecision: although the 95% CI does not cross the line of no ef fect this trial is underpowered
to detect or exclude clinically important dif f erences.
6Downgrade by 1 for serious inconsistency: one very small t rial f rom Singapore reports a marginal improvement in median
CD4 count af ter 6 months of standard dose supplements (Asdamongkol 2013 THA), and one study reports a signif icant
reduct ion in the risk of decline of CD4+ to < 200 in those taking standard supplements (Baum 2010 USA). Two other small
studies using high dose supplements report no stat ist ically signif icant dif f erence (Green 2005 SGP; Range 2006 TZA).
7Downgraded by 1 for serious imprecision: all three trials were underpowered to include or exclude clinically important ef fects
(Baum 2010 USA; Green 2005 SGP; Range 2006 TZA).
8No serious inconsistency: three trials report an increase in blood zinc concentrat ions over t ime. The part icipants in one trial
that did not report an increase in blood concentrat ions af ter supplementat ion, were not def icient in zinc at baseline (Green
2005 SGP).
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Selenium compared to placebo for adults with HIV infection
Participant or population: adults with HIV infect ion
Settings: all sett ings
Intervention: selenium (daily dose)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Selenium
M ortality - - - (0 trials) - -
Hospital admissions
Follow-up: 12 months
309 per 1000 124 per 1000
(65 to 232)
RR 0.4
(0.21 to 0.75)
186
(1 trial)
⊕©©©
very low1,2,3
due to risk of bias, in-
directness, and impre-
cision
We don’t know if se-
lenium supplements re-
duce hospital admis-
sions
Change in CD4 cell
count (cells/ mm³)
Follow-up: 9 to 24
months
- - Not pooled 1187 part icipants
(4 trials)
⊕⊕©©
low4,5
due to risk of bias and
imprecision
Selenium supplements
may have lit t le or no ef -
fect on CD4 cell count
Change in viral load
(log10copies/ mL)
Follow-up: 24 months
- - Not est imable 439 part icipants
(1 trial)
⊕⊕©©
low6,7
Selenium supplements
may have lit t le or no ef -
fect on viral load
Change in selenium
concentrations (µg/ L)
Follow-up: 6 to 12
months
- - Not pooled 527
(3 trials)
⊕⊕©©
low4,8,9
Selenium supplements
may increase blood se-
lenium concentrat ions
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* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95% CI).
Abbreviations: ART: ant iretroviral therapy; CI: conf idence interval; RR: risk rat io; HR: hazard rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1Downgraded by 1 for serious risk of bias: high attrit ion due to part icipants with incomplete medical records. In addit ion,
fewer part icipants in the placebo group compared to the selenium group were on ant iretroviral therapy (ART) at baseline
(Burbano 2002 USA).
2Downgraded by 1 for serious indirectness: only a single trial is available f rom the USA in HIV-posit ive intravenous drugs
users. This is not easily generalized to other HIV-posit ive populat ions.
3Downgraded by 1 for serious imprecision: this trial is underpowered to detect clinically important dif f erences.
4Downgraded by 1 for serious risk of bias: two of the three trials reported high attrit ion rates (Burbano 2002 USA; Hurwitz
2007 USA). In one trial fewer part icipants in the placebo group compared to the selenium group were on ART at baseline
(Burbano 2002 USA).
5Downgraded by 1 for serious imprecision: three of the four trials were underpowered to include or exclude clinically important
ef fects (Burbano 2002 USA; Hurwitz 2007 USA; Kamwesiga 2015 RWA). One trial f rom Botswana was adequately powered
and reported no ef fect on the decline in CD4 cell counts of ART-naive part icipants (Baum 2013 BWA).
6No serious risk of bias: the included trial was at low risk of select ion and performance bias (Baum 2013 BWA). The trial
authors performed mult iple imputat ion of viral load data. The trial authors did not provide details.
7Downgraded by 2 for serious indirectness: only a single trial is available f rom Botswana in part icipants not on ART (Baum
2013 BWA).
8No serious heterogeneity: all three trials reported either an increase in the mean blood selenium concentrat ion of part icipants
or the proport ion of part icipants with selenium concentrat ions above a certain threshold level.
9Downgraded by 1 for indirectness: part icipants in two of the three included trials were not def icient in selenium at baseline
(Burbano 2002 USA; Hurwitz 2007 USA). The third trial reported data on part icipants who were selenium def icient at baseline;
however it was a small subsample of the main trial f rom Botswana (Sales 2010).
2
9
M
ic
ro
n
u
trie
n
t
su
p
p
le
m
e
n
ta
tio
n
in
a
d
u
lts
w
ith
H
IV
in
fe
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
D I S C U S S I O N
Summary of main results
Multiple micronutrients
Routine multiple micronutrient supplementation may have little
or no effect on mortality in adults living with HIV, but the pooled
analysis remains underpowered to confidently exclude small ef-
fects (low certainty evidence). Trials were conducted in antiretro-
viral therapy (ART)-naïve adults (3 trials, 1068 participants, low
certainty evidence), adults on ART (1 trial, 400 participants, very
low certainty evidence), and adults with concurrent active tubercu-
losis (3 trials, 1429 participants, low certainty evidence).
Routine supplementation for up to two years, has also not been
shown to have consistent benefits on either mean CD4+ cell count
(low certainty evidence) or mean viral load (moderate certainty evi-
dence). One recent trial in ART-naïve adults reported a reduction
in the risk of reaching a CD4+ cell count of less than 250 cells/
mm³ after two years of high dose supplementation in Botswana.
However, this effect was only robust in the trial arm receiving mul-
tiple micronutrients plus selenium (not either supplementation
alone) and is inconsistent with the findings of other trials using
similar combinations of micronutrients and selenium.
In one additional trial that compared high dose multiple micronu-
trient supplementationwith standard doses in people on antiretro-
viral therapy (ART), peripheral neuropathy was reduced with high
dose supplements compared to standard dose, but the trial was
stopped early due to increased adverse events in the high dose
group.
Single or dual micronutrients
None of the trials of single or dualmicronutrient supplementswere
adequately powered to assess for effects on mortality or morbidity
outcomes such as hospital admissions and persistence or rate of
diarrhoea. Clinically important effects on CD4+ cell count or viral
load were not reported. Supplementation probably does increase
blood concentrations of vitamin D and zinc, andmay also increase
blood concentrations of vitamin A, especially in those who are
deficient at baseline.
Overall completeness and applicability of
evidence
The included trials of multiple micronutrient supplements were
predominantly conducted in people who either were not tak-
ing ART or were on concurrent treatment for tuberculosis. In
these populations, routine supplementation has not been shown
to consistently improve disease progression asmeasured by average
CD4+ cell count. One recent well-conducted trial, fromBotswana
detected a benefit in the group receiving multivitamins with se-
lenium but not with multivitamins alone. However, the lack of
demonstrable benefit in other trials with similar selenium content,
suggest that this effect should be repeated before reliable conclu-
sions can be drawn.
The trials of single or dual micronutrient supplements included
more participants on ART, and several were conducted in popula-
tions with provenmicronutrient deficiencies. Despite this the only
demonstrable benefits were improvements in serum levels of some
micronutrients. However, these effects may be enough for some
to recommend routine supplementation in similar populations.
There are several possible explanations for the lack of benefit seen
in many of these trials.
• The period of supplementation may have been insufficient
to demonstrate effects, with benefits only accruing over
prolonged periods of supplementation. Supplementation ranged
from as little as four weeks up to two years.
• The prevalence of micronutrient deficiencies may have been
too low in some of these populations to demonstrate an effect.
Baseline micronutrient status was poorly assessed in many of the
included trials, particularly those evaluating multiple
micronutrients, so it is difficult to determine which populations
these negative results should be applied to. Only one trial
reported adjustment of their analysis of blood micronutrient
concentrations for the effect of inflammation, an important
confounder.
• The doses supplemented varied considerably. Many trials
evaluated doses significantly higher than the daily recommended
intake, and one trial of multiple micronutrients directly
compared high doses with standard doses to investigate this.
However, it should be noted that the high doses were not well-
tolerated in this trial.
• The trials may simply be too small to demonstrate effects.
Certainly there is insufficient evidence to say that micronutrients
could never have effects.
Given the lack of benefit in those not on ART, it seems unlikely
that large effects would be seen in those who are taking ART, but
adequately powered trials may still be justifiable to explore this.
There may be a number of ways by which specific micronutrients
may impact on or interact with ART, including aspects of drug
pharmacokinetics. However, the clinical significance of these in-
teractions remains to be determined (Raiten 2011).
Quality of the evidence
We considered the certainty of the evidence for most of the out-
comes in this review to be low or very low, meaning that we can
have only minimal confidence in these effects. We downgraded
the certainty of the evidence mainly for the following reasons.
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• Indirectness: since micronutrient deficiencies differ widely
among populations it is difficult to generalize the findings of a
single trial, or even a few trials, to all settings, and all populations.
• Imprecision: most included trials were small and well below
the optimal information size for the outcomes that were being
measured and therefore not able to reliably detect or exclude an
effect.
Potential biases in the review process
We tried to minimize any biases in the review process by perform-
ing a comprehensive search of the literature, and by independently
selecting studies, appraising studies, and extracting data. Two re-
view authors, MV and SD, assessed the risk of bias of the new
included studies using the updated ’Risk of bias’ tool (Higgins
2011).
This review included outcome data for HIV participants from
four RCTs that included both HIV-positive and HIV-negative
participants without stratified randomization (Kelly 2008 ZMB;
Lawson 2010 NIG; Range 2006 TZA; Semba 2007 MWI).
Agreements and disagreements with other
studies or reviews
In the previous version of this Cochrane Review, Irlam 2010 con-
cluded that further trials of single supplements (vitamin D, zinc,
and selenium) were required to build the evidence base for adults
and that the long-term clinical benefits, adverse effects, and opti-
mal formulation of multiple micronutrient supplements required
further investigation.
Forrester 2011 conducted a narrative review to investigate whether
the 2003 WHO recommendations for micronutrient intake in
HIV-positive adults should change. This review focused primarily
on the results of nine trials of multiple micronutrient supplemen-
tation; seven trials in non-pregnant HIV-positive adults, and two
in pregnant HIV-positive women. The authors noted that “five of
the six trials that used high-dose multiple micronutrients showed
benefits in terms of either improved CD4 cell counts or survival”,
but also that “many of these trials were small and of short dura-
tion, and the long-term risks and benefits of high-dose multiple
micronutrients are not established”. Our analysis and appraisal of
the evidence agrees that there is currently insufficient evidence to
make firm conclusions about the effects of supplementation.
For the effects of micronutrient supplementation in pregnant
women and children with HIV, see the separate Cochrane reviews
by Siegfried 2012 and Irlam 2013.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
To date trials of routine multiple micronutrient supplementation
have not demonstrated consistent clinically important benefits on
HIV disease progression or mortality. However, the trials are gen-
erally too small to confidently exclude the possibility of important
effects.
These findings should not be interpreted as a reason to deny sup-
plementation where specific deficiencies have been demonstrated
(such as vitamin D, zinc, and selenium), or where the person’s diet
is unlikely to meet the recommended daily allowance of vitamins
and minerals.
Implications for research
Furthermore, adequately powered studies with sufficient follow-
up periods are still required to confidently prove or exclude any
long-term clinical benefit of routine supplementation.
Such research should not be to the detriment of ART, as this
remains the one intervention to date that has consistently been
shown to reduce morbidity and mortality, and improve the nutri-
tional status of adults living with HIV/AIDS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allard 1998 CAN
Methods Country: Canada
Setting: primary care physicians
Duration of recruitment: April 1995 to August 1996
Duration of follow-up: 6 months
Design: randomized placebo-controlled trial
Participants Inclusion criteria: patients of participating physicians with stable HIV-infection
Exclusion criteria: active opportunistic infection, smoking, prior antioxidant therapy,
hyperlipidaemia, kidney/liver dysfunction, intractable diarrhoea (≥ 6 liquid stools/day)
, vomiting, gastrointestinal (GI) bleeding
Participants randomized: 49; 47 males and 2 females; mean age = 39 years
Loss to follow-up/withdrawal: 0
Exclusions postrandomization: 0
Interventions Intervention: 800 IU vitamin E and 1000 mg vitamin C
Control: placebo
Duration: daily for 3 months
Outcomes Primary outcomes
• Viral load, oxidative stress (lipid peroxides, malondialdehyde, breath pentane)
Secondary outcomes
• Plasma micronutrients (vitamin E, C, A carotenoids, zinc, selenium); new and
recurrent infections (AIDS-defining, HIV-associated, and other)
Adverse events Two participants in the intervention group reported epigastric discomfort
Notes Number of participants on antiretroviral therapy (ART)
• Supplement group: 22/23 (85%).
• Control group: 18/26(78%).
Controlled diet 2weeks prior to randomization and throughout study period, and dietary
counselling
Source of funding: Canadian Foundation for AIDS Research
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used a random number
table to perform randomization
Allocation concealment (selection bias) Unclear risk The trial authors did not adequately de-
scribe allocation concealment
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Allard 1998 CAN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors blinded the participants
and investigators to treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk There were high and unequal proportions
of missing outcomes (3/23 intervention
group versus 6/26 control group)
Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was unavailable
Other bias Unclear risk The trial authors did not declare their con-
flicts of interest, if any
Asdamongkol 2013 THA
Methods Country: Bangkok, Thailand
Setting: HIV Clinic, Ramathibodi Hospital, Mahidol University
Duration of recruitment: May 2011 to April 2012
Duration of trial: 6 months
Duration of follow-up: 6 months
Design: randomized placebo-controlled trial, stratified according to baseline blood zinc
levels
Follow-up: monitoring of clinical condition, adverse events, and adherence every 3
months
Participants Inclusion criteria: HIV-positive people aged ≥ 18 years who were on ART for at least
12 months, with complete viral suppression (HIV RNA 40 copies/mL), and having
CD4 cell count < 200 cells/mm³ that increased < 30% from baseline after achieving
undetectable HIV RNA after 12 months of ART
Exclusion criteria: pregnancy or women planning to become pregnant, and participants
who previously received zinc supplements (duration not stated)
Participants screened: 70
Participants eligible for randomization: 31
Participants randomized: 31 (low blood zinc levels (N = 12); normal blood zinc levels
(N = 19))
Mean age at randomization: 45 ± 11 years
21 female/10 male
62.3% (144/231) of participants were receiving ART at baseline
The trial authors reported that the distribution of the ART regimens was similar between
the 2 groups at baseline
Interventions InterventionS: 15 mg chelated zinc daily
Control: placebo daily
Duration: 6 months
Compliance: participants were asked to return any unused study medication every 3
months and pill counts were conducted. The trial authors did not report compliance
rates
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Asdamongkol 2013 THA (Continued)
Outcomes Primary
• Blood zinc levels
Secondary
• CD4 count, CD4 %
Adverse events One participant in the zinc group developed an erythematous rash after supplementa-
tion for 1 month, which resolved when the participants discontinued taking the zinc
supplement
Notes Links to other studies (study ID): Asdamongkol 2012 under Asdamongkol 2013 THA
Source of funding: research grant of Faculty ofMedicine RamathibodiHospital,Mahidol
University, Bangkok, Thailand
Conflict of interest: None
Ethics: Ramathibodi Hospital, Mahidol University Institutional Ethics committee but
type of consent not stated
Trial registration: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial randomized participants to re-
ceive zinc supplements or placebo in a 1:
1 ratio in blocks of 4. However, the trial
authors did not clearly describe the process
of selecting the blocks
Allocation concealment (selection bias) Unclear risk Although the trial authors stated that
the pharmacy bottled the supplements,
they did not provide any information on
whether the bottles were prelabelled in a
sequential order
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors stated that the zinc
or placebo pills were indistinguishable in
shape, size, and colour. Outcome measures
(laboratory assays) were unlikely to have
been affected by detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant in the zinc group was
withdrawn from the trial during the follow-
up period
Selective reporting (reporting bias) Unclear risk The trial protocol was unavailable.
Other bias Low risk The trial authors declared that they had no
conflicts of interest
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Baeten 2002 KEN
Methods Country: Kenya
Setting: hospital outpatient clinic
Duration of recruitment: September 1998 to June 2000
Median duration of follow-up: 42 days (32 to 445 days)
Design: randomized placebo-controlled trial
Participants Inclusion criteria: HIV-1 seropositive women attending Coast Provincial General Hos-
pital outpatient clinics in Mombasa, Kenya
Exclusion criteria: age < 18 or > 45; pregnancy, or use of vitamin supplements or oral
contraceptive pills
Participants randomized: 400; 400 females; median age = 28 years
Loss to follow-up/withdrawal: 46
Exclusions postrandomization: 0
Interventions Intervention: vitamin A (10,000 IU retinyl palmitate)
Control: placebo
Duration: daily for 6 weeks
Outcomes Primary outcomes:
• Vaginal HIV DNA and RNA
Secondary outcomes
• Plasma viral load
CD4 and CD8 counts
Adverse events None reported
Notes Source of funding: research grants from NIH, University of Washington, and Fogarty
International Center; International AIDS Research and Training Program scholarships;
Gen-Probe (reagents)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used computer-generated
block randomization
Allocation concealment (selection bias) Unclear risk The trial authors did not describe how they
performed allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk The participants and investigators were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition in both treatment groups (vi-
tamin A group: 12%; placebo group: 11%)
. The trial authors stated that those lost to
follow-up had more advanced HIV disease
and were more likely to be vitamin A-defi-
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Baeten 2002 KEN (Continued)
cient
Selective reporting (reporting bias) Unclear risk There was insufficient information regard-
ing selective reporting; the trial protocol
was not available
Other bias Unclear risk The trial authors did not declare whether
or not they had conflicts of interest
Bang 2012 DEN
Methods Country: Denmark
Setting: outpatient clinic, Department of Infectious Diseases, Hvidovre Hospital
Duration of recruitment: July 2008 to September 2009
Duration of trial: 15 months
Duration of follow-up: 16 weeks
Design: randomized placebo-controlled trial with 3 intervention arms
Follow-up: at baseline, a medical history and assessment of total calcium intake was
performed for each participant
At baseline and at 16 weeks, bloods were taken to measure immunological parameters,
HIV-viral load, parathyroid hormone, calcium, vitamin D, and biochemical bone mark-
ers. The trial assessed quality of life of each participant at baseline and at 16 weeks (Med-
ical Outcomes Study (MOS) 36-item Short Form Health Survey (SF-36) questionnaire)
Participants Inclusion criteria: HIV-positive males aged ≥ 18 years who were receiving highly active
antiretroviral therapy (HAART)
Exclusion criteria: previous bone disease, tuberculosis, sarcoidosis, active malignancy
with bone metastasis, elevated serum calcium
Participants randomized: 61
Mean age at randomization: 48 ± 9 years
No reported baseline differences between treatment groups in terms of time since HIV
diagnosis, type of HAART, CD4 and CD8 cell counts, HIV viral load, calcium intake
Treatment assignment of 2 participants who used vitamin D supplementation prior to
the study not reported
Interventions InterventionS: calcitriol and vitamin D: 100,000 IU vitamin D at study entry; tablets
containing 1200 mg calcium plus 1200 IU vitamin D and 0.5 µg to 1.0 µg calcitriol
daily
Vitamin D: 100,000 IU vitamin D at study entry; tablets containing 1200 mg calcium
plus 1200 IU vitamin D and placebo daily
Control: placebo at trial entry; tablets containing 1200 mg calcium and placebo daily
Duration: 16 weeks
Compliance: participants were asked to return any unused trial medication after 16
weeks. Compliance rates with the daily study tablets were not reported for each treatment
group. According to the trial authors, 77%and67%of participants achieved a satisfactory
compliance (defined by the trial authors as ≥ 80% of the number of tablets dispensed)
for the calcitriol/placebo tablet and cholecalciferol/placebo tablet, respectively
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Bang 2012 DEN (Continued)
Outcomes Primary outcome
• Changes in absolute CD4 and CD8 count, changes in % CD4 and % CD8
Secondary outcome:
• Changes in HIV viral load and blood concentrations of parathyroid hormone
(PTH), calcium, 25 hydroxyvitamin D (25-OHD), and 1,25 hydroxyvitamin D 1,25
(OH)D2
• Changes in quality of life
• Changes in biochemical bone markers of bone formation (P1NP) and bone
resorption (CTx)
Adverse events Hypercalcaemia (calcitriol + vitamin D group (2 events); vitamin D group (1 event),
constipation (8 events))
11 adverse events were only reported as unrelated to the study medication (calcitriol +
vitamin D group (6 events); vitamin D group (3 events); control group (2 events))
Notes Source of funding: Pharma-Vinci, Roche (sponsorship of trial supplements)
Conflict of interest: nothing declared
Ethics: regional ethics committee and the National Board of Health
Trial registered at clinicaltrials.gov (NCT00990678)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is unclear how the trial generated ran-
domization codes.
Allocation concealment (selection bias) Unclear risk The trial authors did not provide any infor-
mation regarding allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors reported that participants
and investigators were blinded throughout
the trial. For the outcomes of CD4/CD8
cell counts and viral loads, lack of blinding
of outcome assessors was unimportant
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition was not similar across treatment
groups: (19/20 (95%) for calcitriol and vi-
taminDgroup; 17/19 (89%) for vitaminD
group, and 15/22 (68%) for control group)
. The reasons for attrition in each group
were unclear
Selective reporting (reporting bias) Unclear risk The trial protocol from clinicaltrials.gov
states the measurement of all outcomes at
baseline and at 2, 4, 8, 12, and 16 weeks.
However, the trial authors reported data for
baseline and 16 weeks only. Although the
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Bang 2012 DEN (Continued)
trial authors reported T lymphocyte sub-
sets (CD4, CD8) as the primary outcome,
the trial protocol describes blood vitamin
D concentrations as the primary outcome
Other bias Unclear risk The trial authors did not include any state-
ment on conflicts of interest. It was unclear
whether study sponsors played any role in
the study design or reporting of study find-
ings
Baum 2010 USA
Methods Country: USA
Setting: primary health care clinic, Miami
Duration of recruitment:March 2002 to December 2005
Duration of trial: 46 months
Duration of follow-up: 18 months
Design: randomized placebo-controlled trial
Follow-up: a nurse practitioner performed a physical examination, medical history, urine
toxicology, and took bloods (CD4 count, HIV viral load, C-Reactive protein, zinc) from
participants at baseline and every 6 months. The trial assessed participants’ morbidity
during monthly visits to clinic by means of a questionnaire, which was confirmed by
information recorded in medical charts. Cause of death was determined by means of
authorized contacts, medical records, and death certificates
Participants Inclusion criteria: HIV-positive people aged ≥ 18 years with low plasma zinc levels (<
0.75 mg/L) and no history of endocrine or psychiatric disorders
Exclusion criteria: premenopausal women who were pregnant or had an intention to
become pregnant; plasma zinc levels≤ 0.35 mg/L at any time during the trial
Participants screened: 557
Participants eligible for randomization: 246
Participants randomized: 231; 62 female and 169 male
Mean age at randomization: 42.7 ± 7 years
62.3% (144/231) of participants were receiving ART at baseline
There were no reported baseline differences in demographic characteristics, clinical dis-
ease stage, CD4 cell count, HIV viral load, adherence to ART, drug or alcohol use,
cigarette use, or plasma zinc levels
Interventions Intervention: 12 mg of elemental zinc for women; 15 mg for men daily
Control: placebo daily
Duration: 18 months
Compliance: assessed monthly with questionnaires and pill counts. 3.65 ± 0.31 pills
returned out of a possible 4 pills per month
After completion of the trial it is reported that participants who received zinc had higher
blood zinc concentrations over time compared to those who received placebo, after
controlling for C-Reactive protein concentrations (data not provided)
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Baum 2010 USA (Continued)
Outcomes Primary outcomes:
• Immunological failure (CD4 count < 200 cells/mm³)
Secondary outcomes:
• HIV viral load
• Morbidity (incidence of diarrhoea, upper and lower respiratory infections, and
other health events (not specified))
• Prevalence of hypertension
• Mortality
Adverse events None
Notes Source of funding: National Institute on Drug Abuse
Conflict of interest: none
Ethics: Florida International University Institutional Review Board
Trial registered at clinicaltrials.gov (NCT00149552)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It was unclear how the trial generated ran-
domization codes.
Allocation concealment (selection bias) Low risk A pharmacist bottled and precoded the trial
supplements for each participant for the en-
tire trial period according to the random-
ization code
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors reported that the clinical
and study personnel and participants were
blinded. Only the pharmacist and statisti-
cian were aware of treatment assignments
during the trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was low attrition. However, the un-
even numbers, deaths, plasma zinc, and
dropouts may be related to main outcome
Selective reporting (reporting bias) Low risk The primary and secondary outcomes as
reported are consistent with the trial pro-
tocol from www.clinicaltrials.gov.
Other bias Low risk The trial authors declared that they had no
conflicts of interest. An independent com-
pany that was not involved in the design or
implementation of the study, or the analy-
sis and reporting of the findings. manufac-
tured the trial supplements
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Baum 2013 BWA
Methods Country: Botswana
Setting:Princess Marina Hospital, Gaborone, Botswana
Duration of recruitment:
Duration of trial: 4 years and 7 months (December 2004 to July 2009)
Duration of follow-up: 24 months
Design: randomized placebo-controlled factorial trial with 3 intervention arms
Follow-up: a monthly questionnaire was administered about acceptability of the supple-
ment, adherence, adverse effects, and intercurrent morbidity (health events occurring
between the trial visits; confirmed by documentation in medical record)
Every 3 months: physical examination and medical history performed by a nurse or
physician, blood sample taken for CD4 cell count
Every 6 months: HIV viral load, plasma micronutrient levels (20% subsample), and
blood chemistries
Participants Inclusion criteria: HIV-positive participants aged 18 years and older, ART-naive and
CD4 cell count > 350 /µL
Exclusion criteria: pregnancy
Participants screened: 1003
Participants eligible for randomization: 922
Participants randomized: 878
Median age at randomization: 31 to 33 years
The trial authors reported no statistically differences in baseline CD4 cell count, HIV
viral load, Body Mass Index (BMI), haemoglobin, albumin, total cholesterol, and HDL-
cholesterol levels
Interventions Intervention (multivitamins group): thiamin 20 mg, riboflavin 20 mg, vitamin B6 25
mg, niacin 100 mg, vitamin B12 50 µg, folic acid 0.8 mg, vitamin C 500 mg, vitamin
E 30 mg
Intervention (selenium group): 200 µg daily
Intervention (multivitamins plus selenium group): as above
Control: placebo daily
Administered as 1 pill daily. Pills were indistinguishable in shape, size, and colour
Duration: 24 months
Compliance: pill counts at each follow-up visit, Adherence reported as 96% (no standard
deviation (SD) stated)
The trial measured plasma micronutrient levels (subsample of participants) but the trial
authors did not report this information
All participants received isoniazid (INH) prophylaxis
Outcomes Primary outcome
• Time from randomization to reaching CD4 cell count of 200 cells/µL or less. In
March 2008, this outcome was changed to reaching a CD4 cell count of 250/µL or less
due to change in ART policy
Secondary outcomes:
• HIV viral load
• Composite of time from randomization to reaching CD4 cell count of 200/ µL or
less or AIDS defining conditions or AIDS-defining death
• Time from randomization to reaching CD4 cell count of 350/ µL or less
• Composite of time from randomization to reaching CD4 cell count of 350/ µL or
less or AIDS defining conditions or AIDS-defining death
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Baum 2013 BWA (Continued)
Adverse events The trial authors reported a total of 79 adverse events which they judged as having a
remote relationship with the trial intervention
Acute diarrhoea/vomiting: 5 events (3 in multivitamins plus selenium group; 2 placebo
group)
Severely elevated alanine transaminase (ALT) (> 5 times normal range): 3 events (1 in
multivitamins group; 2 in placebo group)
Notes Links to other trials (trial ID): Sales 2010
Source of funding: National Institute on Drug Abuse
Conflict of interest: none
Ethics: Florida International University Institutional Review Board, Harvard School of
Public Health IRB, Botswana Health Research Unit of the National Ministry of Health
Trial registration: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A statistician generated block randomiza-
tion in blocks of 20
Allocation concealment (selection bias) Low risk Participants were assigned into one of the
trial groups using the next sequential num-
ber from the randomization list generated
by the data centre. The pharmacist prela-
belled the pills for the entire trial with the
identification number according to the as-
signment list
Blinding (performance bias and detection
bias)
All outcomes
Low risk Pills were indistinguishable in shape, size,
and colour; also the trial authors stated
that trial personnel and participants were
blinded.Outcomemeasures (laboratory as-
says) were unlikely to be affected by detec-
tion bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors reported the number of
participants who withdrew from the trial
due to pregnancy; however, other reasons
for lost-to follow-up were not stated. There
were similar levels of attrition across treat-
ment groups (selenium group: 17% (38/
220); multivitamins plus selenium group:
19% (42/220); placebo group: 15% (21/
219))
For the measures of viral load, the trial au-
thors performed multiple imputation, but
did not provide any details in terms of the
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Baum 2013 BWA (Continued)
proportion of data that was missing
Selective reporting (reporting bias) Unclear risk The trial protocol was unavailable.
Other bias Low risk The trial authors declared no conflicts of
interest. The trial was funded by a non-
conflicting funding source
Burbano 2002 USA
Methods Country: USA
Setting: community-based clinic
Duration of recruitment: 1998 to 2000
Duration of follow-up: 12 months
Design: randomized placebo-controlled trial
Participants Inclusion criteria: confirmed HIV, past or present use of illegal drugs, ≥ 18 years, ade-
quate selenium status (> 85 µg/L)
Exclusion criteria: selenium deficient (< 85 µg/L)
Participants randomized: 259
112 female
Median age = 40 years (range 24 to 54)
Loss to follow-up/withdrawal: 73 at 12 months
Exclusions postrandomization: 0
Interventions 200 microgram selenium or placebo daily for 12 months.
Outcomes Primary outcomes
• Number of hospital admissions
• Type of hospital admissions
• Risk of hospitalization
Secondary outcomes
• CD4 count
• Hospitalization cost
• Plasma selenium
Adverse events None reported
Notes Number of participants on ART:
Selenium group: 64 (76%)
Control group: 60 (53%)
Number, type, and duration of hospital admissions recorded 2 years prior and during
study period. Medical records reviewed by team of physicians
Source of funding: research grant and commercial (materials)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Burbano 2002 USA (Continued)
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe how they
performed sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe how they
performed allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Exclusions from the analysis (73/259
(28%)) not reported by treatment group
Selective reporting (reporting bias) Unclear risk Insufficient information; the trial protocol
was unavailable
Other bias Unclear risk The trial authors did not declare on any
conflicts of interest, if any
Coodley 1993 USA
Methods Country: USA
Setting: hospital outpatient clinics
Duration of recruitment: not stated
Duration of follow-up: 8 weeks
Design: randomized cross-over trial; no washout period
Participants Inclusion criteria: HIV-seropositive
Exclusion criteria: on other forms of vitamin A supplementation; significant hepatic or
renal dysfunction; active opportunistic infection or fever
Participants randomized: 21
20 male and 1 female
Median age: not stated
Loss to follow-up/withdrawal: 4
Exclusions postrandomization: 0
Interventions Intervention: 60 mg beta-carotene
Control: placebo
Duration: 3 times daily for 4 weeks
Outcomes Primary outcomes
• CD4 counts
Secondary outcomes
• White blood cell count
• Lymphocyte count
• B-lymphocytes
• Serum beta-carotene
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Coodley 1993 USA (Continued)
Adverse events No toxicity; skin discolouration in treatment group
Notes CD4 count data reported as means and ranges
16 participants received ART.
Source of funding: Hoffman La Roche Inc.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition at 1 month; the trial authors
provided reasons
Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was unavailable
Other bias Unclear risk The trial authors did not declare on conflict
of interest, if any
Coodley 1996 USA
Methods Country: USA
Setting: hospital outpatient clinic and private practice
Duration of recruitment: not stated
Duration of follow-up: 3 months
Design: randomized controlled trial (RCT)
Participants Inclusion criteria: HIV-seropositive; > 21 years
Exclusion criteria: other forms of vitamin A supplementation 30 days prior to study;
ART 60 days prior to study; significant hepatic or renal dysfunction; CD4 < 50 or > 600
Participants randomized: 72
63 male and 9 female
Median age: not stated
Loss to follow-up/withdrawal: 4 at 1 month; 22 at 3 months
Exclusions postrandomization: 0
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Coodley 1996 USA (Continued)
Interventions Intervention: 60 mg beta-carotene + multivitamins
Control: placebo + multivitamins
Duration: 3 times daily for 3 months
Outcomes Primary outcomes
• CD4 counts
Secondary outcomes
• T-cell counts
• White blood cell counts
• Natural killer cells
• HIV p-24 antigen
• Serum beta-carotene
• Body weight
• Karnofsky scores
Adverse events None reported
Notes Number of participants on ART: treatment group: 10 (28%); control group: 17 (47%)
Source of funding: research grant and commercial (materials)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition at 3 months (22/72 partici-
pants were lost to follow-up); the trial au-
thors did not provide reasons
Selective reporting (reporting bias) Unclear risk Insufficient information; the trial protocol
was unavailable
Other bias Unclear risk The trial authors did not declare on conflict
of interest, if any
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Cárcamo 2006 PER
Methods Country: Peru
Setting: tertiary hospitals
Duration of recruitment: June 1998 to Jan 2000
Duration of follow-up: 2 weeks
Design: randomized placebo-controlled trial
Participants Inclusion criteria:
HIV-seropositive, persistent diarrhoea (≥ 7 days) without prior treatment
Exclusion criteria: none stated
Participants randomized: 159
49 female and 110 male
Median age = 30 years (range 19 to 57) in zinc group
Median age = 31 years (range 19 to 64) in placebo group
Loss to follow-up/withdrawal: 51
Exclusions postrandomization: 0
Interventions Intervention: zinc sulphate (100 mg)
Control: placebo
Duration: daily for 14 days
Outcomes Primary outcomes
• Persistence of diarrhoea
• Time until cessation of diarrhoea
Secondary outcomes:
• Plasma zinc and copper levels
Adverse events Gastrointestinal symptoms attributable to the medication (nausea, vomiting, abdominal
pain) similar in both treatment groups
Notes Sulfamethoxazole-trimethoprim prescribed for participants with enteric bacterial
pathogens (23 in zinc group and 12 in placebo)
Source of funding: Fogarty IARTP grant; University of Washington Center for AIDS
Research; Centers for Disease Control and Prevention (CDC)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used computer-generated
blocked randomization
Allocation concealment (selection bias) Low risk The trial authors stated that the treatment
allocators were unable to access the assign-
ment roll
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
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Cárcamo 2006 PER (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk There were high losses to follow-up in both
groups (34.6% intervention group versus
29.5% control group)
Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was unavailable
Other bias Unclear risk The trial authors did not declare on conflict
of interest, if any
Dougherty 2015 USA
Methods Country: USA
Setting: 2 outpatient clinics, Philadelphia
Design: RCT (safety trial)
Duration of recruitment: January 2010 to January 2011
Duration of follow-up: 12 weeks
Follow-up: participants were followed up at 6 and 12 weeks.
Blood and urine measurements were also performed for vitamin D (25-hydroxy vitamin
D, 1,25-dihydroxy vitamin D), calcium, metabolic parameters, and immunological pa-
rameters
Participants Inclusion criteria: participants with perinatally acquired HIV (PHIV) and behaviorally-
acquired HIV (BHIV)
Exclusion criteria: participation in another study impacting 25(OH) vitaminD, pregnant
or lactating females, and other conditions affecting growth, dietary intake, or nutritional
status. People who were taking supplements that contained vitamin D were not eligible.
Those willing to discontinue supplementation with approval of their medical provider
were eligible after a 2-month washout period
Participants screened: 240
Participants eligible for randomization: 146
Randomization was stratified by HIV acquisition (PHIV/BHIV) and season of the year
Participants randomized: 44
Mean age at randomization: 18.4 ± 4.7 years (4000 IU vitamin D group) and 19.1 ± 5.
0 yrs (7000 IU vitamin D group)
30 male and 14 female
Clinical characteristics, growth status, ART regimen similar at baseline
Interventions Intervention: 7000 IU vitamin D group
One gelatin capsule containing one 2000 IU capsule and one 5000 IU softgel (over-
encapsulated) daily
Control: 4000 IU vitamin D group
One gelatin capsule containing two 2000 IU capsules (over-encapsulated) daily
Duration: 12 weeks
Compliance: residual tablets or volumes recorded at the 12-week visit. Adherence also
assessed by questionnaire at 6,12 weeks and telephonically at weeks 1, 3, 5, 8, and 10.
The trial authors did not report the mean adherence during the trial period
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Dougherty 2015 USA (Continued)
Outcomes Primary outcomes
• Serum 25 (OH) vitamin D and calcium concentrations
Secondary outcomes
• Immunological and virological parameters
Adverse events No evidence of any adverse biochemical, haematological, immunological, or virological
event
Notes Source of funding: National Institutes of Health
Conflict of interest: none
Ethics: Children’s Hospital of Philadelphia IRB
Trial registration: NCT01092338
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It was unclear how the randomization
codes were generated.
Allocation concealment (selection bias) Unclear risk The trial authors did not provide any infor-
mation regarding the method of allocation
concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not specified except for partici-
pants who received a single capsule which
was identical in size, shape, and colour
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was due to migration (n = 1) and
loss to follow-up (n = 1)
Selective reporting (reporting bias) Unclear risk The trial protocol was not available.
Other bias Low risk The trial authors declared no conflicts of
interest. A non-conflicting funding source
funded the trial
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Giacomet 2013 ITA
Methods Country: Italy
Setting: outpatient clinic, Milan
Duration of recruitment: April 2011-
Duration of trial: 15 months
Duration of follow-up: 12 months
Design: randomized placebo-controlled trial
Follow-up: blood samples were taken from each participant (vitamin D, immunological
parameters) at baseline and at 3, 6, 9, 12 months
Participants Inclusion criteria: HIV-positive people aged ≤ 30 years, low blood vitamin D concen-
trations (25(OH)D < 30 ng/mL)
Exclusion criteria: participants of African descent, hyperparathyroidism, vitamin D sup-
plementation during the 12 month period prior to study entry, use of any medication
known to alter vitamin D (excluding ARV) in the previous 6months, concomitant severe
illness
Participants screened: 90
Participants eligible for randomization: 57
Participants randomized: 52
Median age at randomization: vitamin D group: 20 (interquartile range (IQR) 18 to 23)
yrs; placebo group: 18 (15 to 23) years
86% (43/50) of participants on HAART
No reported baseline differences in clinical disease stage, type of antiretroviral therapy
(ART), CD4 cell count, blood vitamin D, calcium, Parathyroid hormone (PTH) con-
centrations. Undetectable viral load (< 37 copies/mL) was recorded for 72% (18/25) and
84% (21/25) of participants in the vitamin D and placebo group, respectively at baseline
Interventions Intervention: single dose of 100,000 IU vitaminD(oral dose in oil suspension) at baseline
and at 3, 6, and 9 months
Control: single dose of placebo (oral dose in oil suspension) at baseline and at 3, 6, and
9 months
Compliance: directly observed
Outcomes Primary outcomes
• Serial mean changes in 25(OH)D; 1,25 (OH)2D concentrations
Secondary outcomes
• Serial mean changes in absolute CD4 cell count, % CD4
Adverse events Reported no adverse events during the trial period
Notes Source of funding: Italian Ministry of Health
Conflict of interest: none
Ethics: Luigi Sacco Hospital Ethical Committee
Trial registered at clinicaltrialsregister.eu (2011-00059354)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Giacomet 2013 ITA (Continued)
Random sequence generation (selection
bias)
Low risk The trial used block randomization in
blocks of 4.
Allocation concealment (selection bias) Unclear risk The trial used matching sealed plastic sy-
ringes labelled with unique identification
numbers, but it is unclear if these numbers
were sequentially labelled or not
Blinding (performance bias and detection
bias)
All outcomes
Low risk All the trial participants, outcome asses-
sors (laboratory technicians and immunol-
ogists) and personnel, except the paediatri-
cian who administered the treatment, were
blinded to it
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors did not provide any rea-
sons for lost to follow-up of 2 participants
in the placebo group at 3 and 6 months.
The trial authors performed ITT analyses
Selective reporting (reporting bias) Low risk The primary and secondary outcomes as
reported are consistent with the trial pro-
tocol from www.clinicaltrialsregister.eu
Other bias Low risk The trial authors declared that they had no
conflicts of interest
Green 2005 SGP
Methods Country: Singapore
Setting: outpatient clinic at national HIV referral centre, Tan Tock Seng Hospital
Duration of trial: January 2003 to July 2003 (7 months)
Duration of follow-up: 28 days
Design: randomized placebo-controlled trial
Follow-up: medical history, physical examination, adverse events at 14 and 28 days.
Bloods taken in fasted state at baseline and after 28 days for immunological parameters
and zinc levels
Participants Inclusion criteria: HIV-positive participants > 18 years with CD4 count < 200 cells/
mm³, no opportunistic infections 6 months prior and stable ART for 3 months prior to
study entry
Exclusion criteria: pregnancy, intravenous drug users, on immunomodulatory therapy,
oral zinc supplementation
Participants screened: 420
Participants eligible for randomization:189
Participants randomized: 66
Mean age at randomization: 40 ± 7.8 yrs (zinc group) versus 40 ± 8.3 yrs (placebo group)
61 male and 5 female
77% of participants were on HAART. Demographic, clinical characteristics, and an-
58Micronutrient supplementation in adults with HIV infection (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Green 2005 SGP (Continued)
tiretroviral drug regimes were similar in both treatment groups at baseline
Interventions Intervention: 220 mg zinc sulphate (50 mg elemental zinc) administered as a capsule
daily along with ART
Control: placebo
Supplement and placebo capsules were identical in appearance
Duration: 28 days
Compliance: adherence was reported as the proportion of participants in each treatment
group who took ≥ 90% of scheduled doses (zinc group: 93.5% (30/32); control group:
94% (32/34))
Outcomes Primary outcome: immune response to tuberculosis
Secondary outcomes: CD4, CD8 cell counts, naive T cells, blood zinc levels
Adverse events Nausea or vomiting (3 participants in both groups), diarrhoea (4 participants in inter-
vention group versus 1 participant in control group)
One participant from the zinc group developed Indinavir-related renal colic on day 7
One participant from the placebo group developed fever on day 28 and was diagnosed
with M. fortuitum infection.
One participant from the placebo group developed a Staphylococcus aureus soft tissue
abscess on day 23.
Notes Conflict of interest: none
Source of funding: National Health Group Singapore
Ethics:Tan Tock Seng Hospital
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used a computer-generated ran-
domization sequence in blocks of 6
Allocation concealment (selection bias) Unclear risk It was unclear how the trial organized the
process of treatment allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not specified, except for par-
ticipants who received identical capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial withdrew one participant due to
an adverse event. This was unlikely to have
influenced the results
Selective reporting (reporting bias) Unclear risk The trial protocol was not available.
Other bias Low risk The trial authors included a statement re-
garding no conflicts of interest
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Grigoletti 2013 BRA
Methods Country: Brazil
Setting: outpatient clinic, Hospital de Clínicas de Porto Alegre, Porto Alegre
Duration of recruitment: August 2009 to September 2011
Duration of trial: 25 months
Duration of follow-up: 4 weeks
Design: randomized placebo-controlled trial
Follow-up: blood samples and vascular measurements taken at baseline and again at 4
weeks
Participants Inclusion criteria: HIV-positive adults on HAART (at least 6 months) with undetectable
HIV viral load (<50 copies/mL) and CD4 count > 200 cells/mm³
Exclusion criteria: diabetes mellitus, active infection, liver or renal disease, history of
cardiovascular disease, uncontrolled hypertension, pregnancy, use of illicit drugs, mental
illness, current tobacco use, women on hormone replacement therapy and current intake
of dietary supplements (such folic acid, antioxidants)
Participants screened: 1332
Participants eligible for randomization: 175
Participants randomized: 30 participants stratified according to sex
Mean age at randomization: 45 ± 2 years
14 male and 16 female
All participants were on HAART. Clinical characteristics and antiretroviral drug regimes
were similar at baseline
Interventions Intervention: 1 capsule containing 5 mg folinic acid daily (in the morning)
Control: 1 placebo capsule, indistinguishable in appearance, daily (in the morning)
Duration: 4 weeks
Compliance: no details provided, but an increase in blood folic acid concentrations was
demonstrated in the intervention group
Outcomes Primary outcome
• Brachial artery vascular response
Secondary outcomes
• CD4 cell counts, blood concentrations of folate, vitamin B12, lipid profiles,
homocysteine
Adverse events No adverse events were reported
Notes Conflict of interest: none
Source of funding: research grants and scholarship (Hospital de Cl nicas de Porto Ale-
gre Fund for Research (FIPE- HCPA), Coordination for the Development of Higher
Education (CAPES), Brazil)
Ethics: Hospital de Clínicas de Porto Alegre Ethics review board
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used computer-generated ran-
domization in blocks of 10
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Grigoletti 2013 BRA (Continued)
Allocation concealment (selection bias) Low risk A person not affiliated to the trial precoded
and sequentially numbered bottles
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors reported blinding of par-
ticipants and investigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up occurred.
Selective reporting (reporting bias) Unclear risk Therewas insufficient information, and the
trial protocol was not available
Other bias Low risk The trial authors declared that they had no
conflicts of interest
Guwatudde 2015 UG
Methods Country: Uganda
Setting: outpatient clinic, Mackerere University College, Kampala
Design: placebo-controlled trial
Duration of recruitment: April 2010 to June 2012
Duration of follow-up: 18 months
Follow-up: at baseline and at 3, 6, 12, and 18 months participants underwent a full
clinical examination. In addition, assessments of the following was performed: complete
blood counts, CD4 cell count, presence of syphilis, malaria, intestinal parasites, and
nutritional status
Participants Inclusion criteria: HIV-positive adults ≥ 18 yrs, initiation of ART at the time of ran-
domization or on HAART for at least 6 months, intention to stay within 20 km of study
site
Exclusion criteria:Pregnancy, participants who were very ill
Participants screened: 1134
Participants eligible for randomization: 421
Participants randomized: 400
Mean age at randomization: 36.9 ± 9.6 years (intervention group) 34.7 ± 8.1 years
(control group)
123 male and 277 female
Clinical characteristics, duration of ART, and multivitamin use similar at baseline
Interventions Intervention (multivitamin group): daily tablet providing the following vitamins at the
RDA level
1.4 mg vitamin B1, 1.4 mg vitamin B2, 1.9 mg vitamin B6, 2.6 µg vitamin B12, 18 mg
niacin, 0.4 mg folic acid, 70 mg vitamin C, 10 mg vitamin E
Control: daily tablet consisting of placebo
Duration: 18 months
Compliance: assessed by research staff everymonth by recording participant self reported
compliance and conductingpill counts. The trial authors did not reportmean compliance
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Guwatudde 2015 UG (Continued)
Outcomes Primary: changes in CD4 cell count and weight, quality of life
Secondary: changes in haemoglobin, bloodALT concentrations, development of a newor
recurrent disease progression event including all-cause mortality, hospitalization events,
changes in ART from first- to second-line therapy
Adverse events A total of 550 adverse events were reported mostly related to nausea and vomiting, with
no differences between treatment arms
The trial authors also reported 1 event of severe anaemia (Hb < 7 g/dL) in the multivi-
tamin group and 3 events of high ALT concentrations (> 200 IU/L) (1 in multivitamin
arm, 2 in placebo arm)
Notes Conflict of interest: none
Source of funding: Eunice Kennedy Shriver National Institute of Child Health and
Human Development of the National Institutes of Health research grant
Ethics: Scientific Review Committee of the Infectious Diseases Institute at Makerere
University College ofHealth Sciences and Institutional ReviewBoards ofHarvard School
of Public Health and Makerere University School of Public Health
Trial registered at clinicaltrials.gov (NCT 1228578)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prior to initiation of the trial, a staff mem-
ber at Harvard School of Public Health
(HSPH) who was not associated with trial
implementation generated serial numbers
from 1 to 400 and randomly assigned par-
ticipants to intervention or placebo groups,
in blocks of 10
Allocation concealment (selection bias) Low risk Trial regimen bottles were labelled with se-
rial numbers only. The trial pharmacist at
the trial site dispensed the assigned regimen
bottles to participants in sequential order
of enrolment. The list that showed the trial
arm linked to each serial number remained
with the trial statistician at HSPH and was
not accessible to trial staff in Uganda
Blinding (performance bias and detection
bias)
All outcomes
Low risk Trial participants, staff, and investigators
were blinded. The size, colouring, and
packaging of the placebo was identical to
the multivitamin tablet
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition was low (8%) and was
due to death (18/400), migration (7/400),
withdrawal of consent (2/400), and loss to
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Guwatudde 2015 UG (Continued)
follow-up (6/400)
Selective reporting (reporting bias) Low risk The primary and secondary outcomes were
as reported, and were consistent with the
trial protocol (Guwatudde 2015 UG).
Other bias Low risk The trial authors declared they had no con-
flicts of interest. A non-conflicting funding
source funded the trial
Humphrey 1999 USA
Methods Country: USA
Setting: HIV clinic
Duration of recruitment: January to July 1996
Duration of follow-up: 8 weeks
Design: randomized placebo-controlled safety trial
Participants Inclusion criteria: 18 to 45 years, CD4 > 200 cells/mm³
Exclusion criteria: pregnant or breastfeeding
Participants randomized: 40 women
Mean age (SD) in years = 36.2 (5.6) in vitamin A group and 33.2 (5.6) in placebo group
Loss to follow-up/withdrawal: 1
Exclusions postrandomization: 0
Interventions Intervention: 300,000 IU vitamin A
Control: placebo
Duration: single dose
Outcomes Primary outcomes
• Viral load
• T-cell subsets (%CD4; % CD8 which are CD38+)
Secondary outcomes:
• Vitamin A status
Adverse events Signs or symptoms of toxicity (headache, nausea, vomiting, diarrhoea, fever) similar in
the intervention and control groups at 24 hours and 1 week after administration
Notes Number of participants on ART
• Vitamin A group: 12 (60%)
• Control group: 7 (35%)
Source of funding: Paediatric AIDS Foundation grant
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Humphrey 1999 USA (Continued)
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
used
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant was lost to follow-up.
Selective reporting (reporting bias) Unclear risk Insufficient information; the trial protocol
was not available
Other bias Unclear risk The trial authors did not declare on con-
flicts of interest, if any
Hurwitz 2007 USA
Methods Country: USA
Setting: university clinic
Duration of recruitment: June 2001 to July 2005
Duration of follow-up: 9 months
Design: randomized placebo controlled trial
Participants Inclusion criteria: aged 18 to 55 years; no history of major systemic disorders related to
HIV; premenopausal and not pregnant
Exclusion criteria: on treatment for chronic conditions; selenium deficient
Participants randomized: 310
Mean age = 40.5 years
179 male and 86 female
Loss to follow-up/withdrawal: 88
Exclusions postrandomization: 48 pretreatment
Interventions Intervention: selenium (200 µg)
Control: placebo
Duration: daily for 9 months
Outcomes Primary outcomes
• Viral load
• CD4 count
• Serum selenium
Adverse events None
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Notes Participants on ART: 105/141 (74%) in selenium group; 87/121 (72%) in placebo group
Preliminary analysis at 9 months of an 18-month trial
Source of funding: National Institutes of Health
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used computerized block random-
ization.
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment used
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were high unexplained losses to
follow-up, which were balanced between
groups. The trial authors performed impu-
tational analyses
Selective reporting (reporting bias) High risk The trial only reported data on main study
outcomes for subgroups of participants (se-
lenium responding versus non-responding
participants)
Other bias Low risk The trial authors declared they had no con-
flicts of interest
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Isanaka 2012 TZA
Methods Country: Tanzania
Setting: outpatient HAART clinics
Duration of recruitment: November 2006 to November 2008
Median duration of follow-up: 15 months (IQR 6 to 19)
Design: RCT
Follow-up: full clinical examination and HIV disease staging (WHO staging criteria) of
participants conducted at baseline and thereaftermonthly by trial physicians.Occurrence
of any illness in the previous month recorded by trial nurses at baseline and thereafter
monthly. They also performed anthropometric measurements (height, weight, waist,
hip, mid-thigh, mid-arm circumference) at baseline and monthly thereafter. Bloods were
taken from participants at baseline and every 4 months for T cell counts, full blood
count, and ALT. HIV viral load was determined at the same time intervals, but was
subject to the availability of reagents. Dietary intake was assessed at baseline and every
12 months
Participants were followed up monthly until the date of death, loss to follow-up, or early
study closure (refer to section on adverse events). Cause of death was determined by the
use of medical records and standard verbal autopsy techniques by 2 HIV clinicians who
had to reach consensus
Participants Inclusion criteria: men and women with HIV-infection initiating ART (WHO Stage 4
HIV disease and CD4 count < 200; WHO Stage HIV infection and CD4 count < 350)
, intention to stay in Dar es Salaam for at least 2 years
Exclusion criteria: pregnant or lactating women
Participants randomized: 3418
Mean age at randomization: 37.8 ± 8.6 years (high-dose group) versus 38.4 ± 8.6 years
(standard-dose group)
1141 female, 569 male (high-dose group) versus 1181 female, 527 male (standard-dose
group)
Interventions Intervention (high-dose group): micronutrient tablet daily containing 8 different mi-
cronutrients at multiple levels of the Recommended Daily Allowance (RDA): thiamine
20 mg, riboflavin 20 mg, vitamin B6 25 mg, niacin 100 mg, vitamin B12 50 µg, folic
acid 0.8 mg, vitamin C 500 mg, vitamin E 30 mg
Control (standard-dose group): micronutrient tablet daily containing 8 different mi-
cronutrients at single level of the RDA: thiamin 1.2 mg, riboflavin 1.2 mg, vitamin B6
1.3 mg, niacin 15 mg, vitamin B12 2.4 µg, folic acid 0.4 mg, vitamin C 80 mg, vitamin
E 15 mg
The intervention and control tablets were indistinguishable in terms of appearance and
taste
Duration: minimum of 24 months
Compliance: determined by the number of tablets absent from the returned bottles every
month divided by the number of the tablets the participant should have taken. Mean
compliance was reported as 90% for both treatment groups (no variance reported)
Co-intervention: cotrimoxazole prophylaxis if CD4 count < 200 in all participants
Outcomes Primary: all-cause mortality, HIV disease progression (new or recurrent episode of HIV
disease according to the WHO Clinical Staging system)
Secondary: AIDS-related mortality (due to Pjiroveci pneumonia, pulmonary tubercu-
losis, extrapulmonary tuberculosis, Kaposi sarcoma, wasting, HIV/AIDS with oppor-
tunistic infection, invasive cervical carcinoma), changes in CD4 count, HIV viral load,
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Isanaka 2012 TZA (Continued)
BMI, haemoglobin
Adverse events Preliminary data analysis after 1 year after the start of the trial (November 2008) in-
dicated an increased mortality risk with high-dose supplementation. Subsequently, all
participants received standard dose supplements up to March 2008 when it was deter-
mined that the increased mortality risk was restricted to severely malnourished partici-
pants (BMI < 16)
These participants were subsequently excluded from enrolment and those who had been
enrolled received standard dose supplementation. Since 612 participants enrolled in this
period did not fulfil the eligibility criteria of the trial protocol, the sample size was
increased
However, the trial was terminated prematurely in March 2009 because of evidence of
increased ALT levels among participants receiving the high-dose supplement
Other adverse events reported include during the trial included fatigue, nausea or vom-
iting, diarrhoea, severe anaemia, peripheral neuropathy, rashes or lesions and genital
discharge or sores
Notes Source of funding: National Institute of Child Health
Conflict of interest: none
Ethics: Harvard School of Public Health, Muhimbili University of Health and Allied
Sciences, Tanzania Food and Drugs Authority, and National Institute of Medical Re-
search
Trial registered at clinicaltrials.gov (NCT00383669)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used a computer-generated ran-
domization sequence in blocks of 20
Allocation concealment (selection bias) Low risk Independent pharmacists performed se-
quential numbering of trial supplements.
At each research site participants were allo-
cated to the next numbered bottle at that
site
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial authors reported the participants
and research staff as blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall loss to follow-up was not reported.
The trial authors only analysed viral load
for a subset (7%) of trial participants and
therefore this outcome was judged to be at
high risk of attrition bias
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Selective reporting (reporting bias) Low risk The primary and secondary outcomes as
reported, as well as the reported changes to
the trial protocol, are consistent with the
trial protocol at www.clinicaltrials.gov.
Other bias High risk Trial was stopped early due to evidence of
increased levels of ALT in the high-dose
group
Jiamton 2003 THA
Methods Country: Thailand
Setting: outpatient clinic
Duration of recruitment: March 2000 to January 2001
Duration of follow-up; 48 weeks
Design: randomized placebo-controlled trial
Participants Inclusion criteria: older than 18 years; 50 < CD4 < 550
Exclusion criteria: taking ARV or micronutrients for during month prior to enrolment
Participants randomized: 481 (stratified according to CD4 cell count < 200 cells/mm³
and ≥ 200 cells/mm³)
189 male and 292 female
Mean age = 32 years
Loss to follow-up/withdrawal: 79 at 48 weeks
Exclusions postrandomization: 0
Interventions Intervention: micronutrient supplement (3000 µg vitamin A, 6 mg beta-carotene, 20
µg vitamin D, 80 mg vitamin E, 180 µg vitamin K, 400 mg vitamin C, 24 mg vitamin
B1, 15 mg vitamin B2, 40 mg vitamin B6, 30 µg vitamin B12, 0.1 mg folic acid, 40 mg
pantothenic acid, 10 mg iron, 200 mg magnesium, 8 mg manganese, 30 mg zinc, 300
µg iodine, 3 mg copper, 400 µg selenium, 150 µg chromium, 60 mg cysteine)
Control: placebo
Duration: twice daily for 48 weeks.
Outcomes Primary outcomes
• Mortality
• Hospital admissions
Secondary outcomes
• CD4 counts
• Viral load
Adverse events A total of 137 minor adverse events such as dizziness, drowsiness, nausea, and rash re-
ported, with more participants in the intervention arm who reported urine discoloura-
tion (P < 0.001)
Notes Source of funding: Nestle Foundation; Vitabiotics
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used centralized random-
ization in blocks of 10
Allocation concealment (selection bias) Low risk Interventions were packaged in identical
coded bottles.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition was low overall (12/242 in the
treatment group and 3/239 in the placebo
group). Similar baseline median CD4 cell
counts among participants fromboth treat-
ment groups who were lost to follow-up.
The trial authors used survival analysis to
address missing outcome data. However,
the trial authors only analysed viral load for
a subset (29%) of trial participants and so
we judged this trials to be at high risk of
attrition bias for this outcome
Selective reporting (reporting bias) Unclear risk Insufficient information; the trial protocol
was not available
Other bias Low risk The trial authors provide a declaration on
no conflicts of interest
Kamwesiga 2015 RWA
Methods Country: Rwanda
Setting: 2 outpatient facilities
Design: placebo-controlled trial
Duration of recruitment: not stated
Duration of follow-up: 24 months
Follow-up: trainednursingpractitionerswill collect clinical, nutritional, andpsychosocial
data at baseline and at 6, 12, 18, and 24 months. Blood samples will also be taken for
CD4 cell count and viral load measurements at these time intervals
Participants Inclusion criteria: HIV-positive adults aged≥ 21 years, ART-naive with CD4 cell counts
400 to 650 cells/mm³, HIV-positive women willing to practice barrier method of birth
control, intention to remain in clinic catchment area for study period
Exclusion criteria: pregnancy
Participants screened: 2680
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Participants eligible for randomization: 300
Participants randomized: 300
Mean age at randomization: 33 years (median) IQR 28 to 39 years (intervention group)
; 35 years (median) IQR 28 to 41 years (control group)
98 male and 202 female
Sociodemographic characteristics, CD4 cell count, HIV viral load, BMI similar at base-
line
Interventions Intervention: 1 tablet containing 200 µg selenium (in the form of selenomethionine)
daily
Control: 1 placebo tablet daily
Duration: 24 months
Compliance: adherence counselling provided at baseline and every month. The trial
authors did not report mean compliance data
Outcomes Primary: composite of the following: reduction in CD4 cell count < 350 cells/mm³ or
start of ART or development of AIDS-defining illness
Secondary: viral load at 6, 12, 18, and 24 months, quality of life, weight gain, presence
of opportunistic infections, mortality
Adverse events Most participants did not report any symptoms. Self-reported symptoms included nau-
sea, vomiting, skin or hair changes or both, and changes in emotional status. Participants
in the selenium group were more likely to report anxiety (41 events versus 16 events
in the placebo group; P = 0.04) and sleep symptoms (36 events versus 15 events in the
placebo group, P = 0.01)
Notes Source of funding: Global Benefit, Canada. Micronutrient supplement supplied by a
nutraceutical company (CanAlt labs and Seroyal)
Conflict of interest: none
Ethics: institutional review boards of the Canadian College of Naturopathic Medicine
and Wilfred Laurier University in Canada, and the National Ethics Committee (NEC)
in Rwanda
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The research department of the manufac-
turing company prepared the randomiza-
tion schedule using a simple randomization
block design, but the trial authors did not
specify the method of sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors stated that each partici-
pant was assigned to a unique study iden-
tification number. Sequential numbering
and allocation was not explicitly stated.
They also stated that an unblinded allo-
cation list was provided to the treatment
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Kamwesiga 2015 RWA (Continued)
provider and an independent statistician
for the purpose of conducting an interim
analyses
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial authors did not specify whether
blinding was performed, except for partic-
ipants who received identical supplements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was 6% in both treatment groups
(9/151 in the selenium group and 9/149
in the placebo group). Reasons for attrition
included death (n = 2), migration (n = 9)
and loss to follow-up (n = 7). The trial au-
thors stated that 10 participants (4 in the
selenium group and 6 in the placebo group)
were not included in their primary analyses
Selective reporting (reporting bias) Low risk Primary and secondary outcomes are con-
sistent with the trial protocol (Kamwesiga
2015 RWA).
Other bias Low risk Although the pharmaceutical industry pro-
vided the trial supplements, the trial au-
thors included a statement of no conflicts
of interest
Kelly 1999 ZMB
Methods Country: Zambia
Setting: home care service of tertiary hospital
Duration of recruitment: not stated
Duration of follow-up: 4 weeks
Design: randomized placebo-controlled trial
Participants Inclusion criteria: adults with persistent diarrhoea for more than 1month
Exclusion criteria: < 18 years, pregnancy, administration of antibiotics in the week prior
to recruitment, Karnofsky scores > 80 or < 50
Participants randomized: 135
79 male and 56 female
Median age = 32.5 years (micronutrient); 34 (placebo)
Loss to follow-up/withdrawal: 29
Exclusions postrandomization: 0
Interventions Intervention: micronutrient supplement (10,500 IU vitamin A, 300 mg vitamin C, 300
mg vitamin E, 150 µg selenium and 200 mg zinc sulphate)
Both treatment groups also received 5 mg folic acid and 800 mg albendazole twice daily
Control: placebo
Duration: daily for 2 weeks
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Outcomes Primary outcomes
• Recovery from diarrhoea
◦ Patient weeks with and without diarrhoea during 12 weeks’ follow-up
◦ Remission at 4 weeks
• All-cause mortality during first 4 weeks
• Change in BMI and mid-upper arm circumference (MUAC)
• Change in Karnofsky score
Secondary outcomes
• Changes in CD4 and CD8 counts at 4 weeks
• Changes in serum vitamin A and E after 4 weeks
Adverse events None
Notes Source of funding: Smithkline Beecham
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
used
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment used
Blinding (performance bias and detection
bias)
All outcomes
High risk Micronutrient and placebo capsules were
not identical; it was unclear whether
providers and assessors were blinded to
treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk 25% of participants were lost to follow-up
due todeath and the tradition of goingback
to the family home when terminally ill
Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was not available
Other bias Unclear risk The trial authors did not provide a decla-
ration on conflicts of interest
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Methods Country: Zambia
Setting: Misisi township, Lusaka, Zambia
Duration of trial: August 2003 to December 2006 (41 months)
Duration of follow-up: 38 months
Design: cluster randomized cross-over trial (cluster randomization by household)
Follow-up: trained nurses recorded episodes of diarrhoea and cough every 2 weeks.
Nutritional status (height, weight, MUAC, body impedance) and household hygiene
(score) were assessed at 6, 14, 22, and 38 months
Participants Inclusion criteria: all adult (≥ 18 years) residents
HIV status: HIV-positive (n = 136); HIV negative (n = 224), and unknown HIV-status
(n = 140)
Interventions Members of the same household received the same treatment allocation
Intervention: multiple micronutrient tablet once daily (β-carotene 4.8 mg; 1.4 mg vi-
tamin B1, 1.4 mg vitamin B2, 1.9 mg vitamin B6, 2.6 µg vitamin B12; 18 mg niacin;
70 mg vitamin C; 10 mg vitamin E; 0.4 mg folic acid; 30 mg iron; 15 mg zinc; 2 mg
copper; 65 µg selenium and 150 µg iodine)
Control: placebo tablet once daily (supplement and placebo tablets identical in appear-
ance and taste
Duration: 1.9 years to trial cross-over; thereafter 1.5 years
Adherence: unused trial supplements were retrieved monthly. Median compliance re-
ported as > 95% (variance not reported) at the crossover point
Outcomes Primary outcome
• Incidence of diarrhoea
Secondary outcomes
• Incidence of severe diarrhoeal episodes
• Incidence of respiratory infection (cough)
• Changes in CD4 count of HIV-positive participants
• Changes in nutritional status
• Mortality
Adverse events Four cases of pellagra occurred in the placebo group; 3 of whom were associated with
high ethanol intakes
Notes Source of funding: Wellcome trust
Ethics: University of Zambia Research Ethics Committee; London School of Hygiene
and Tropical Medicine Research Ethics Committee
Trial registration: ISRCTN 31173864
Conflict of interest: declared no conflict of interest. None of the authors had any financial
interest in manufacturing or licensing of any micronutrient formulation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Kelly 2008 ZMB (Continued)
Random sequence generation (selection
bias)
Low risk The trial statistician generated the ran-
dom number sequence for the selection of
households
Allocation concealment (selection bias) Low risk Only the statistician and manufacturers
had access to the trial code. The supple-
ments were supplied in precoded, sealed
plastic bottles
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, investigators, and assessors
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk There were high rates of attrition (30% be-
fore cross-over; 42% at trial completion);
the trial authors did not state the attrition
rates for each treatment group
Selective reporting (reporting bias) Low risk All the outcomes as reported are con-
sistent with the trial protocol from
www.controlled-trials.com, except for all-
cause mortality.
Other bias Low risk The trial authors declared that they had no
conflicts of interest
Recruitment bias: households were ran-
domized, all participating members of each
household received the same treatment al-
location
Baseline imbalance: randomization was
stratified by household size
Loss of clusters: attrition of clusters was not
reported.
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Lawson 2010 NIG
Methods Country: Nigeria
Setting: 8 district hospitals, Abuja, Nigeria
Duration of recruitment: September 2003 to June 2005
Duration of trial:Not stated
Duration of follow-up: 6 months
Design: randomized placebo-controlled factorial trial with three intervention arms
Follow-up :Blood samples (complete blood count, erythrocyte sedimentation rate (ESR)
and biochemical tests) and three sputum samples and a chest X-ray, were conducted at
enrolment. Sputum specimens were collected weekly for the first 8 weeks of therapy and
again at 12, 16, 20 and 24 weeks. Blood samples and chest X-rays were repeated at 2
and 6 month follow-up
Participants Inclusion criteria: HIV-positive and HIV-negative adults aged > 15 years with sputum
positive pulmonary tuberculosis
Exclusion criteria: previous antituberculous therapy, pregnancy, lactation, use of corti-
costeroids or zinc in the previous month, major surgery in the previous month, diabetes,
severe cardiovascular or hepatic disease, currently taking oral contraceptives, unable to
return
Participants screened: 1321 (399 smear-positive)
Participants eligible for randomization: 350
Participants randomized: 350 (155 HIV-positive participants not stratified)
Mean age at randomization: 29 to 34 years
The mean BMI was greater in the zinc group at baseline:21.3 ± 4.7 versus 19.6 ± 3.5
(zinc and vitamin A group) versus 19.8 ± 3.3 (placebo group)
Interventions Intervention: 90 mg elemental zinc plus retinol (5000 IU) weekly or 90 mg elemental
zinc plus placebo weekly
Control: duel placebo (similar in appearance) weekly
Duration: 6 months
Adherence: all participants received their supplements under direct observation for
the first 2 months together with standard antituberculous treatment (2RHZE/4HE).
Monthly supplies were then given for the following 4 months
Outcomes Primary outcomes: sputum conversion, CXR scores
Secondary outcomes: clinical symptoms, BMI, Karnofsky score, deaths, ESR, haemo-
globin
Adverse events Two major adverse events (participants withdrawn from trial)
Notes Source of funding: none stated
Conflict of interest: no statement included
Ethics: Liverpool School of Tropical Medicine Research Ethics Committee, Zankli Med-
ical Centre Institutional Review Board
Trial registration: ISRCTN36636609
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Lawson 2010 NIG (Continued)
Random sequence generation (selection
bias)
Low risk Treatment allocation into three supple-
ment groups was performed at the Liv-
erpool School of Tropical Medicine using
permuted block randomization with 4 dif-
ferent block sizes. Random numbers gener-
ated by Minitab with block randomization
using 4 different block sizes
Allocation concealment (selection bias) Low risk An investigator who was not on site pre-
pared the allocation sequence. Treatment
assignments were prepared in serially num-
bered sealed envelopes. Sequentially num-
bered packets were assigned consecutively
to participants according to allocation se-
quence
Blinding (performance bias and detection
bias)
All outcomes
Low risk Investigators, participants, and the labora-
tory staff were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up of HIV-positive partic-
ipants at 6 months was not balanced be-
tween treatment groups: zinc group 16 %
(8/56); zinc and vitamin A group 23% (11/
47); and placebo group: 30% (16/52)
Selective reporting (reporting bias) Low risk Primary outcomes reported were con-
sistent with the trial protocol (IS-
RCTN36636609)
Other bias Unclear risk The trial authors did not provide any con-
flict of interest statement
McClelland 2004 KEN
Methods Country: Kenya
Setting: outpatient clinics at Coast Provincial General Hospital, Mombasa
Duration of recruitment: September 1998 to June 2000
Duration of trial: 22 months
Duration of follow-up: 6 weeks
Design: randomized placebo-controlled trial
Follow-up: at the 6 week follow-up visit participants underwent a physical examination
and bloods and genital tract specimens were collected (as before at baseline)
Participants Inclusion criteria: women (18 to 45 years) with HIV-1 infection
Exclusion criteria: women who were pregnant or the use of vitamin supplements or oral
contraceptives during 3-month period before study entry
Participants screened: 2021
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McClelland 2004 KEN (Continued)
Participants eligible for randomization: 650
Number randomized: 400 (plus 200 participants in vitamin A arm)
Mean age: 29 ± 7 years (micronutrient group) versus 29 ± 6 years (placebo group)
Noparticipant receivedART. It is reported thatCD4cell count and vaginalHIV shedding
were higher in the micronutrient group (statistical significance not shown)
Interventions Intervention: micronutrient supplement (20 mg vitamin B1, 20 mg vitamin B2, 25 mg
vitamin B6, 50 µg vitamin B12; 100 mg niacin; 500 mg vitamin C; 30 mg vitamin E;
0.8 mg folic acid; 200 µg selenium) administered as a hard gel capsule daily
Control: placebo (supplement and placebo capsules identical in appearance)
Duration: daily for 6 weeks
Compliance: reported as the proportion of participants in each treatment group who
took 95% of scheduled doses (micronutrient group: 93.7% (168/179); control group:
92.1% (164/178). Supplements were dispensed with an electronic alarm vial
Outcomes Primary outcomes: vaginal and cervical HIV-1 shedding
Secondary outcomes: CD4, CD8 cell count, viral load
Adverse events Multivitamin supplementation increased cervical and vaginal shedding of HIV-positive
cells
Notes Source of funding: National Institutes of Health and University of Washington Clinical
Nutrition Research Unit
Conflict of interest: statement not included
Ethics: University of Nairobi, University of Washington
Trial registration: not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used computer-generated ran-
domization sequence in blocks
Allocation concealment (selection bias) Unclear risk It was unclear who was responsible for the
allocation of treatment (sequential num-
bering of medication bottles not specified)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding was not specified except for par-
ticipants who received identical capsules
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Twenty-one(10.5%) and 22(11%) partici-
pants were lost to follow-up from the mul-
tivitamin and placebo groups respectively.
However, the trial authors did not state the
reasons for loss to follow-up. Participants
who were lost to follow-up had lower CD4
cell counts compared to those who com-
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McClelland 2004 KEN (Continued)
pleted the trial, but cell counts were not re-
ported for each treatment group
Selective reporting (reporting bias) Unclear risk The trial protocol was not available
Other bias Unclear risk The trial authors did not provide any state-
ment regarding conflicts of interest
Overton 2015 USA
Methods Country: USA
Setting:39 AIDS Clinical trials network research units
Duration of recruitment: September 2011 to February 2012
Duration of trial: 48 weeks
Duration of follow-up: 48 weeks
Design: randomized placebo-controlled trial
Follow-up: blood samples at enrolment, 24 and 48 weeks; DXA scan at enrolment and
again at 48 weeks
Participants Inclusion criteria: HIV-positive people who were not on ART with viral load > 1000
copies/mLandblood25 (OH) vitaminD level≥ 10 and<75ng/mL, creatinine clearance
≥ 60 mL/min and serum calcium < 10.5 mg/dL
Exclusion criteria: participants taking daily supplements containing calcium and vita-
min D exceeding 500 mg and 800 IU respectively, any biphosphonate therapy, recent
steroid or chemotherapy treatment, thyroid disease, substance or alcohol abuse, a history
of fragility fracture, osteoporosis or nephrolithiasis or weight > 300 lb. Pregnant and
lactating women were also excluded
Participants screened: 218
Participants eligible for randomization: 183
Number randomized: 167
Mean age: 36 years (IQR 28 to 47) (vitamin D/calcium group) versus 31 years (IQR 25
to 44) (placebo group)
Two participants from the vitamin D/calcium group had protocol violations due to the
incorrect screening vitamin D assay being performed. The trial authors did not include
this data in the analyses
Interventions Intervention: 4000 IU vitamin D3 daily plus 500 mg calcium carbonate twice daily with
food
Control: placebo daily plus placebo twice daily with food (identical in appearance)
Duration: daily for 48 weeks
Compliance: all participants were initiated on first line ART (EFV/FTC/TDF)
Outcomes Primary: change in total hip bone mineral density (BMD)
Secondary: changes in lumbar spine BMD, 25(OH) vitamin D levels, parathyroid hor-
mone (PTH), markers of bone turnover, and other inflammatory biomarkers and CD4
cell counts at 24 and 48 weeks
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Overton 2015 USA (Continued)
Adverse events No differences were observed between the treatment groups in terms of reported adverse
events during the study period. Vitamin D/calcium group (33 Grade 1-2 events, 15
Grade 3 events, and 2 Grade 4 events) and placebo group (33 Grade 1-2 events, 15
Grade 3 events, and 5 Grade 4 events). No cases of hypercalcaemia were reported. One
death in the Vitamin D/calcium group was reported in the context of rapid HIV disease
progression
Notes Source of funding: National Institute of Allergy and Infectious Diseases. The pharma-
ceutical industry provided supplements and placebos
Conflict of interest: none
Ethics: Institutional Review Boards of all participating research sites
Trial registration: NCT 01403051
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors reported block random-
ization stratified for baseline 25(OH) vita-
min D levels (≤ 20 and > 20 ng/mL), but
the trial authors did not specify themethod
of generation randomization sequence
Allocation concealment (selection bias) Unclear risk The trial authors did not report the details
regarding the allocation of study supple-
ments
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not specified except for partici-
pants who received identical supplements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attritionwas 9%(15/167). Reasons
for attrition include death (n = 1), non-
adherence to treatment/study visits (n = 2),
withdrew consent (n = 1), or lost to follow-
up (n = 11)
Selective reporting (reporting bias) Low risk Primary and secondary outcomes reported
were consistent with trial protocol (NCT
01403051)
Other bias High risk The pharmaceutical industry sponsored
ARTs and supplements, industry represen-
tatives served on the study team and re-
viewed manuscript prior to publication,
thus there was a potential conflict of inter-
est
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Range 2006 TZA
Methods Country: Tanzania
Setting: 5 district health facilities
Duration of recruitment: August 2001 to July 2002
Design: placebo-controlled 2 x 2 factorial trial
Participants Inclusion criteria: HIV-positive and HIV-negative people aged≥15 years with sputum-
positive pulmonary tuberculosis (new or relapsed cases)
Exclusion criteria: participants who defaulted tuberculosis chemotherapy or those who
remained smear-positive on chemotherapy (failure cases) and those with serious tuber-
culosis or other disease unlikely to survive; pregnant and lactating women
Participants randomized: 530
213 HIV-positive
325 male and 205 female
Mean age = 35.4 years
Participants analysed: 499
Loss to follow-up/withdrawal: 77 within 244 days post-treatment
Exclusions postrandomization: 31
Interventions InterventionS: micronutrient supplement contained vitamin A (1.5mg), vitamin B1 (20
mg), vitamin B2 (20 mg), vitamin B6 (25 mg), vitamin B12 (50mg), folic acid (0·8 mg)
, niacin (40 mg), vitamin C (200 mg), vitamin E (60 mg), vitamin D3 (5 mg), selenium
(0·2 mg) and copper (5 mg), and zinc tablets contained 45 mg elementary zinc
Control: placebo (2 x 2 factorial)
Duration: daily for 8 months.
All participants received a standard 8 month tuberculosis chemotherapy regimen
Outcomes Primary outcomes
• All-cause mortality at 8 months
Secondary outcomes
• Viral load
• CD4 counts
• Weight gain
Adverse events None reported
Notes Source of funding: Danish International Development Assistance
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerized randomization.
Allocation concealment (selection bias) Low risk Sealed envelopes, codes unbroken until
post-analysis
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Range 2006 TZA (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigators were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Differential attrition rates between treat-
ment groups > 10% [Zinc group: 10.3%
(6/58); Multivitamin/mineral group: 23.
7% (14/59); Multivitamin/mineral plus
zinc group: 12.5 % (6/48) Placebo group:
12.5% (6/48)]
Selective reporting (reporting bias) Unclear risk Insufficient information; study protocol
not available
Other bias Unclear risk Randomization was not stratified by HIV-
status of participants. Declared no conflict
of interest
Semba 1998 USA
Methods Country: USA
Setting: community-based clinic
Duration of recruitment: not stated
Duration of follow-up: 4 weeks
Design: randomized placebo-controlled trial
Participants Inclusion criteria: HIV-positive intravenous drug users participating in ALIVE (AIDS
Linked to Intravenous Experiences) Cohort (N = 630); ≥ 18 years; not taking vitamin
A supplements
Exclusion criteria: CD4 > 500 cells/mm³; pregnancy.
Participants randomized: 120
89 male and 31 female
Mean age = 38.2 years
50% treatment group versus 43% placebo group on ART
Loss to follow-up/withdrawal: 8.3% at 4 weeks
Exclusions postrandomization: 0
Interventions Intervention: single dose of 200 000 IU vitamin A
Control: placebo
Outcomes Primary outcomes
• Viral load
• CD4 count
Secondary outcomes
• Serum vitamin A
Adverse events None reported
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Notes Source of funding: USAID
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used a random number table in
blocks of 10.
Allocation concealment (selection bias) Low risk The trial used sequentially numbered en-
velopes to conceal allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data were balanced across
groups.
Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was not available
Other bias Unclear risk The trial authors did not provide any dec-
laration regarding conflicts of interest
Semba 2007 MWI
Methods Country: Malawi
Setting: 8 community health centres
Duration of recruitment: July 1999 to October 2004
Design: placebo-controlled
Participants Inclusion criteria:HIV-positive andHIV-negative adults with smear-positive pulmonary
tuberculosis (new cases)
Exclusion criteria: prior or current tuberculosis chemotherapy, prior vitamin supplements
Participants randomized: 1148
829 HIV-positive
336 male and 493 female
Mean age = 34 years
Participants analysed: 1148
Loss to follow-up: 103 in HIV-positive group (50 and 53 in micronutrient and placebo
groups, respectively)
Exclusions postrandomization: 0
Interventions Intervention: micronutrient supplement (vitamin A, C, D, E, B6, B12, riboflavin, thi-
amine, niacin, folate, zinc, iodine, selenium)
Control: placebo
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Semba 2007 MWI (Continued)
Duration: daily for 24 months.
All participants received a standard 8-month tuberculosis chemotherapy regimen
Outcomes Primary outcomes
• All-cause mortality
Secondary outcomes
• Serum vitamin A, vitamin E, and selenium
Adverse events Not reported
Notes Source of funding: National Institutes of Health and the Fogarty International Centre
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used blocked randomization.
Allocation concealment (selection bias) Low risk The trial used prepacked sequentially num-
bered supplements.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk The attrition rates were greater than 10%
and the trial authors did not report the
reasons for loss to follow-up (supplement
group 12.3%; placebo group 12.5%)
Selective reporting (reporting bias) Low risk The trial protocol was available; the trial
authors reported on all outcomes of interest
Other bias Unclear risk The trial authors did not stratify random-
ization by HIV status of participants. The
trial authors did not declare their conflicts
of interest, if any
Semba 2007 USA
Methods Country: USA
Setting: study clinic
Duration of recruitment: September 2002 to August 2005
Design: controlled trial
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Participants Inclusion criteria: women ≥ 18 years; history of injection drug use (IDU) within past
10 years; hepatitis C (HCV) antibody-positive; Karnofsky status > 80%; serum ferritin
< 200 ng/mL
Exclusion criteria: pregnant; history of liver failure, renal disease, interferon therapy for
HCV; haemochromatosis; blood disorders
Participants randomized: 458
Mean age = 40 years
138 (30.1%) HIV-positive
Participants analysed: 115 at 12 months
Loss to follow-up/withdrawal:151 (33%)
Exclusions postrandomization: 0
Interventions Intervention: micronutrients with iron (18 mg)
Control: micronutrients only
Duration: daily for 12 months
Outcomes Primary outcomes
• Haemoglobin
• Iron status
• Plasma HCV
• Viral load
• Liver enzymes
Adverse events Not reported
Notes On HAART: 27/69 (intervention) and 23/69 (control)
Trial stopped early due to slow recruitment.
Source of funding: National Institute on Drug Abuse; National Institute on Nursing
Research
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used computerized randomiza-
tion.
Allocation concealment (selection bias) Low risk The trial used prepacked sequentially num-
bered study supplements
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk There was high loss to follow-up (27.7%)
in both groups, and the trial authors did
not report this information by HIV status
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Selective reporting (reporting bias) Unclear risk There was insufficient information; the
trial protocol was not available
Other bias Unclear risk The trial authors did not provide a decla-
ration on conflicts of interest
Stallings 2014 USA
Methods Country: USA
Setting: Children’s Hospital of Philadelphia, Philadelphia
Duration of recruitment: July 2011 to June 2013
Duration of follow-up: 12 months
Design: randomized placebo-controlled trial
Follow-up: participants were followed up at 3, 6, and 12 months. At each visit adverse
events and compliance were recorded. Blood and urine measurements were also per-
formed for vitamin D (25-Hydroxy vitamin D, 1,25 Dihydroxy vitamin D), calcium,
metabolic parameters, and immunological parameters
Participants Inclusion criteria: perinatally acquired HIV infection (PHIV), 5.0 to 24.9 year or behav-
iorally-acquired HIV infection (BHIV), 15.0 to 24.9 years; usual state of good health 2
weeks before study entry
Exclusion criteria: other adverse growth, dietary intake, or nutritional status conditions,
pregnancy, lactation, and use of vitamin D3 supplements. If Vitamin D3 supplements
were discontinued, participants underwent a 2-week wash-out period before trial entry
Participants screened: 121
Participants eligible for randomization: 58
Participants randomized: 58 (stratified by PHIV/BHIV)
Mean age at randomization: 20.7 ± 3.7 years
76% of participants on HAART (vitamin D group:23/30 (77%); placebo group 21/28
(75%))
The trial authors reported no statistically differences in baseline disease characteristics,
vitamin D status, dietary intake, or metabolic parameters
Interventions Intervention: 7000 IU vitamin D3 daily (those unable to swallow capsules took 0.49
mL daily of 400 IU vitamin D3 drops)
Control: placebo capsules (those unable to swallow capsules took 0.49 mL daily of
placebo drops)
Duration: 12 months
Compliance: residual capsules or volume (in the case of drops) were recorded at follow-
up visits. Mean adherence was 92 ± 8% over 12 months with no differences between
groups
Outcomes Primary: blood 25-Dehydroxy vitamin D levels
Secondary: HIV load (among participants with a detectable viral load), CD4%
Adverse events Four participants in the placebo group were withdrawn from the study after 6 months
according to prespecified criteria (3 consecutive 25 (OH) vitamin D values < 11 ng/mL)
. No participant experienced the predefined serious adverse event of 25 (OH) vitamin
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Stallings 2014 USA (Continued)
D levels > 80 ng/mL at any time during the follow-up period. Serum calcium levels
increased from 9.5 ± 0.4 to 9.6 ± 0.4 mg/dL after 12 months in the vitamin D group
Notes Source of funding: NIH/National Center for Complementary and AlternativeMedicine,
National Center for Research Resources, National Center for Advancing Translational
Sciences
Conflict of interest: the trial authors declared no conflict of interest
Ethics: Children’s Hospital of Philadelphia Institutional Review Board
Trial registration: clinicaltrials.gov (NCT 01475890)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors stated that participants
were randomized in parallel (1:1 ratio) to
receive the intervention of the placebo
Allocation concealment (selection bias) Unclear risk The trial authors did not provide any in-
formation in terms of how study supple-
ments were numbered and allocated to par-
ticipants
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial authors referred to a “double
blind” study but it was unclear who was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were 10% (3/30) in vita-
min D group versus 17% (5/28) in placebo
group. Three participants were lost to fol-
low-up (without reasons) in the vitamin
D group and 1 participant in the placebo
group. Four participants from the placebo
group were withdrawn from study (accord-
ing to prespecified withdrawal rules)
Selective reporting (reporting bias) Low risk The primary outcomes as reported were
consistent with the trial protocol from
www.clinicaltrials.gov.
Other bias Low risk The trial authors declared no conflicts of
interest.
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Villamor 2008 TZA
Methods Country: Tanzania
Setting: 5 outpatient tuberculosis clinics
Duration of recruitment: April 2000 to April 2005
Median duration of follow-up: 30 months (IQR 15 to 41)
Design: randomized placebo-controlled trial
Participants Inclusion criteria: HIV-positive and HIV-negative adults aged 18 to 65 years with posi-
tive sputum smears for acid-fast bacilli who planned to stay in Dar es Salaam for 2 years
Exclusion criteria: pregnancy, antituberculosis treatment for > 4 weeks in previous year,
Karnofsky score < 40%
HIV-positive participants randomized: 471
273 male and 198 female
Mean age = 34 years
Loss to follow-up: 67 in HIV-positive group (33 and 34 in micronutrient and placebo
groups, respectively)
Exclusions postrandomization: 0
Interventions Intervention: micronutrient supplement (retinol; vitamins B1, B2, B6, B12; niacin;
vitamin C; vitamin E; folic acid; selenium)
Control: placebo
Duration: daily for 24 months.
All participants received DOTS antituberculosis chemotherapy
Outcomes Primary outcomes
• Culture negativity at 1 month after initiation of treatment; mortality during at
least 24 months of follow-up; tuberculosis recurrences.
Secondary outcomes
• Changes from baseline in viral load, CD4 cell counts, and body weight.
Adverse events None reported
Notes Source of funding: National Institute of Allergy and Infectious Diseases; USDepartment
of Agriculture
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors used computer-generated
permuted blocks of 20.Randomizationwas
stratified by HIV status of participants
Allocation concealment (selection bias) Unclear risk All clinical and research staff were unaware
of the participants’ treatment assignment,
but the trial authors provided insufficient
information
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Villamor 2008 TZA (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors did not provide reasons
for losses to follow-up, although they used
appropriate statistical analyses
Selective reporting (reporting bias) Unclear risk Insufficient information; the trial protocol
was not available
Other bias Low risk The trial authors declared that they had no
conflicts of interest
Wejse 2009 GNB
Methods Country: Guinea-Bissau
Setting: tuberculosis clinics in urban disease surveillance site
Duration of recruitment: November 2003 to December 2005
Duration of follow-up: 12 months
Design: placebo-controlled, parallel group
Participants Inclusion criteria: tuberculosis participants starting antituberculosis treatment, ≥ 15
years
Exclusion criteria: none
Participants randomized: 222 male and 143 female;mean age 37.5 yrs; 131 HIV-positive
Participants analysed: 365
Loss to follow-up/withdrawal: 84
Exclusions postrandomization: 2
Interventions Intervention: 100,000 IU cholecalciferol (vitamin D)
Control: placebo
Duration: at inclusion; 5 and 8 months after inclusion
Outcomes Primary outcomes:
Reduction in a clinical severity score (tuberculosis score)
Secondary outcomes:
12-month mortality
Adverse events Minor adverse events reported; no difference between groups. There were no reported
cases of hypercalcaemia
Notes Source of funding: Aarhus University Hospital; Danish Research Council for Develop-
mental Research
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Wejse 2009 GNB (Continued)
Random sequence generation (selection
bias)
Low risk The trial authors used a computer-gener-
ated sequence when performing random-
ization
Allocation concealment (selection bias) Low risk The trial used identical, sequentially num-
bered containers to perform allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, staff, and researchers were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up was unknown in the
HIV-positive subgroup.
Selective reporting (reporting bias) Low risk The trial protocol was available; the trial
authors reported on all outcomes of interest
Other bias Low risk The trial authors did not prespecify the
HIV subgroup analyses but proportions
were equally distributed; the trial funder
and provider had no role in trial design
Zhao 2010 CHN
Methods Country:China
Setting: village in Huaiyang county, Henan province
Design: randomized placebo-controlled trial
Duration of recruitment: June 2008 to November 2008
Duration of follow-up: 6 months
Participants Inclusion criteria: HIV-positive people aged 25 to 49 years with BMI 18-25kg/m2 and
CD4 count > 200 with no clinical symptoms of AIDS
Exclusion criteria: not stated
Number randomized: 102
Mean age at randomization: micronutrient group:37.8 ± 2.9 years; placebo group: 37.3
± 2.3 years
50 male and 49 female
No baseline differences between treatment groups in terms of gender, weight, height
Interventions Intervention: tablet containing: vitamin A 200 µg, β-carotene 200 µg, vitamin D 5 µg,
thiamin 1 mg, riboflavin 1 mg, vitamin B6 1 mg, folic acid 0.15 mg, vitamin C 100 mg,
vitamin E 15 mg, iron 6 mg, zinc 5 mg, selenium 30 µg, calcium 400 mg
Control: identical placebo daily
Duration: 6 months
Compliance: not reported
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Zhao 2010 CHN (Continued)
Outcomes Primary: change in absolute CD3, CD4, and CD8 counts and of markers of humoral
immunity (IgA, IgG, IgM, and C3)
Adverse events Not reported
Notes Source of funding: not specified
Conflict of interest: not specified
Ethics: review board not specified
Trial registration: not specified
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk There was no information from the trial
authors on blinding of participants, inves-
tigators, or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three participants, out of a total number
of 102 randomized, were lost to follow-up
Selective reporting (reporting bias) Unclear risk The trial protocol was not available.
Other bias Unclear risk The study authors did not provide conflict
of interest statements
Abbreviations: ALT: alanine aminotransferase; ALP: alkaline phosphate; ART: antiretroviral therapy; AST: aspartate aminotransferase;
BMI: Body Mass Index; CXR: Chest X-Ray; ESR: erythrocyte sedimentation rate ; GFR: glomerular filtration rate; HAART: highly
active antiretroviral therapy; IDU: injection drug user; HCV: Hepatitis C; INH: isoniazid; IQR: interquartile range; MUAC: mid-
upper arm circumference; NSAIDS: non-steroidal anti-inflammatory drugs; PTH:Parathyroid hormone; SD: standard deviation.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aghdassi 2010 Trial participants had highly active antiretroviral therapy (HAART)-related co-morbidity
AIDS Policy Law 2012 Not a randomized controlled trial (RCT)
Arpadi 2012 Most trial participants were under 15 years of age
Austin 2006 The trial intervention was irrelevant to this review
Balasubramanyam 2011 Co-intervention present
Balfour 2014 The trial intervention was irrelevant to this review
Brown 2015 This study did not report any relevant outcomes
Chow 2010 Trial participants had HAART-related co-morbidity
Coelho 2015 Not a RCT
Currier 2010 Not a RCT
Daneshpajouhnejad 2011 This study did not report any relevant trial outcomes
Etminani-Esfahani 2012 Not a RCT
Gharakhanian 2011 Not a RCT
Groleau 2013 This study did not report any relevant trial outcomes
Havens 2012a This study did not report any relevant trial outcomes
Havens 2012b This study did not report any relevant trial outcomes
Havens 2012c This study did not report any relevant trial outcomes
Havens 2012d This study did not report any relevant trial outcomes
Hemsworth 2012 The trial intervention was irrelevant to this review
Hummelen 2011 The trial intervention was irrelevant to this review
Kaiser 2006 The trial intervention was irrelevant to this review
Kakalia 2011a Most trial participants were less than 15 years of age
Kakalia 2011b Most trial participants were less than 15 years of age
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(Continued)
Lachmann 2014 Not a RCT
Ladep 2010 Co-intervention present
Lange 2009 The trial intervention was irrelevant to this review
Lange 2011 The trial intervention was irrelevant to this review
Lescoat 2012 Not a RCT
Lin 2013 Trial participants had HAART-related co-morbidity
Longenecker 2011 This study did not report any relevant trial outcomes
Madrid 2012 Not a RCT
Mandal 2011 This study did not report any relevant trial outcomes
Martineau 2013 Not a RCT
Mascitelli 2011 Not a RCT
Mburu 2010 The trial intervention was irrelevant to this review
Mehta 2010 Not a RCT
Morgan 2010 Co-intervention present
Motswagole 2013 The trial intervention was irrelevant to this review
Pasquet 2011 Not a RCT
PrayGod 2011 The trial intervention was irrelevant to this review
Schall 2016 The study did not report any relevant outcomes
Scrimgeour 2010 The study did not report any relevant outcomes
Singhal 2010 The trial intervention was irrelevant to this review
Steenhoff 2015 More than 20% of the trial participants were less than 15 years of age
Stewart 2011 Co-intervention present
Sudarsanam 2011 The trial intervention was irrelevant to this review
Visser 2011 The study did not report any relevant trial outcomes
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(Continued)
Welz 2011 Not a RCT
Abbreviations: HAART: highly active antiretroviral therapy; RCT: randomized controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Odunukwe 2016
Methods Country: Nigeria
Setting: HIV treatment centre, Lagos
Participants Inclusion criteria: HIV-positive men and women who were eligible for highly active antiretroviral therapy (HAART)
and who were HBsAg positive (Hepatitis B virus or HBV)
Interventions Intervention: 200 µg selenium daily plus HAART
Control: HAART
Duration: 18 months
Outcomes Changes in HBV load, HIV load, CD4 cell count, and alanine transaminase (ALT)
Notes
Abbreviations: HAART: highly active antiretroviral therapy; HBV: hepatitis B.
Characteristics of ongoing studies [ordered by study ID]
Lebouché 2014
Trial name or title The role of extended-release niacin on immune activation and neurocognition inHIV-positive patients treated
with antiretroviral therapy (CTN PT006)
Methods Country: Canada
Setting: Chronic Viral Illness Service, Montreal Chest Institute of the McGill University Health Centre
(MUHC), and the Cliniquemédicale l’Actuel, Montreal
Design: randomized cross-over trial
Participants Inclusion criteria: 21 years or older, viral load < 50 copies/mL for the last 3 months, CD4+ T-cell count ≤
350 cells/µL; and on stable ART (ART unchanged for treatment failure (rebound in viral load)) for more
than 12 months
Exclusion criteria: prior history of hypersensitivity reaction to niacin or any other component of the study
drug; prior history of flushing; liver disease (including coinfection with hepatitis B or C virus) or unexplained
persistent elevations of serum transaminases; alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) or alkaline phosphatase > 2.5 times the upper limit of normal ; active duodenal or gastric peptic ulcer;
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Lebouché 2014 (Continued)
active bleeding disorders; history of gout; active AIDS events in the last 3 months as determined by the
treating physician; unstable angina or acute phase myocardial infarction; diabetic or potentially diabetic with
hypercholesterolaemia; renal dysfunction; co-enrolment in another study involving neurocognitive evaluation;
or pregnant or nursing or planning to become pregnant
Interventions Immediate versus deferred use of ER niacin for 24 weeks. The administration of ER niacin will be titrated
(weeks 0 to 4: 500 mg, weeks 5 to 12: 1000 mg, weeks 12 to 24: 2000 mg). All participants will receive ART
Outcomes Primary outcome: T cell activation (change in percentage of CD8+ CD38+ HLA-DR+ T-cells)
Secondary outcomes: change in total CD4 cell count
Starting date February 2012
Contact information bertrand.lebouche@mcgill.ca
Notes
NCT 01295034
Trial name or title Vitamin D supplements for HIV-positive patients on cART (NCT01295034)
Methods Country: USA
Setting: Mount Sinai Medical Center, New York
Design: controlled trial
Participants Inclusion criteria: HIV-positive adults ≥ 18 to 70 yrs, stable highly active antiretroviral therapy (HAART)
regimen (at least 12 months) with undetectable viral load (at least 6 months), not consuming more than 2 g
calcium and 800 IU vitamin D daily
Exclusion criteria: receiving vitamin D, current treatment for bone disease, receiving medications known to
affect bone mineralization, medical conditions known to affect vitamin D, calcium and phosphate levels,
kidney disease, unstable medical condition likely to preclude participation in a 12-month trial, pregnancy
Interventions Intervention: oral dose of 50,000 IU vitamin D2 weekly for 8 weeks, thereafter 1000 IU vitamin D2 daily
for 48 weeks
Control: oral dose of 2000 to 4000 IU vitamin D3 daily for 12 months, with dose titration as necessary
Duration: 12 months
Outcomes Primary: 25 (OH) vitamin D levels (% of participants who have levels in the range of 30 to 60 ng/mL)
Secondary: change in CD4 cell count
Starting date March 2011
Contact information andrea.branch@mssm.edu
Notes
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NCT 01798680
Trial name or title Trial of Vitamin D in HIV progression (TOV4)
Methods Country: Tanzania
Setting: Dar es Salaam
Design: placebo-controlled trial
Participants Inclusion criteria: HIV-positive adults≥ 18 yrs, initiation of HAART at the time of randomization, 25(OH)
vitamin D concentration < 30 ng/mL
Exclusion criteria:pregnancy, participation in another micronutrient trial
Interventions Intervention: oral dose of 50000 IU vitamin D3 weekly for 4 weeks, thereafter 2000 IU vitamin D3 daily up
to 12 months
Control: oral dose of placebo weekly for 4 weeks, thereafter 2000 IU vitamin D3 daily up to 12 months
Duration: 12 months
Outcomes Primary: All-cause death, pulmonary tuberculosis within 12 months of randomization
Secondary: CD4 cell count, clinical diagnosis of co-morbidities, weight, calcium, Parathyroid hormone (PTH)
and alkaline phosphate (ALP) concentrations
Starting date February 2014
Contact information mina@hsph.harvard.edu
fmugusi@muhas.ac.tz
Notes
NCT 02810275
Trial name or title Folinic Acid: Supplementation and Therapy (NCT02810275)
Methods Country: Brazil
Setting: Hospital de Clinicas de Porto Alegre
Participants Inclusion criteria: HIV infected and HIV-HCV co-infected men and women aged 18 to 50 years receiving
HAART with undetectable viral load for more than 6 months
Exclusion criteria: diabetesmellitus, previousCVD: acutemyocardial infarction,myocardial revascularization,
or stroke,creatinine > 1.5 mg/dL,clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of
liver cirrhosis, on treatment with: statins, fibrates, hormone replacement therapy, sulfonamides, vitamin
supplements, or folinic acid in the last 30 days and pregnant women
Interventions Intervention: 5 mg folinic acid daily
Control: placebo daily
Duration: 4 weeks
Outcomes Changes in flow mediated dilatation. serum homocysteine levels
Starting date October 2012
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NCT 02810275 (Continued)
Contact information Sandra Costa Fuchs, Hospital de Clinicas de Porto Alegre
Notes
NCT 02827643
Trial name or title VitaminDandCalciumSupplement Attenuate Bone Loss AmongHIV- Infected Patients ReceivingTenofovir
Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz (NCT02827643)
Methods Country: Thailand
Setting: Ramathibodi Hospital, Mahidol University, Bangkok
Participants Inclusion criteria: HIV-1-infected patients aged 18 to 50 years who start 3TC or FTC, TDF, and EFV within
3 months before enrolment
Exclusion criteria: CrCl < 60 mL/min/1.73 m2, CaCO3 supplement > 500 mg/day or vitamin D supplement
> 800 IU/day, steroid use (equivalent to prednisolone> 5 mg/day more than 3 months), osteoporosis treat-
ment, serum calcium > 10.5 g/dL clinical history of fragility fracture, pregnancy, or breastfeeding, secondary
amenorrhoea, hyperthyroidism, history of kidney stone or current active opportunistic infection
Interventions Intervention: once daily calcium carbonate 1,250 mg (600 mg elemental calcium) and weekly vitamin D2
(20,000 IU) plus TDF/3TC or FTC/EFV therapy
Control: TDF/3TC or FTC/EFV therapy
Duration: 24 weeks
Outcomes Changes in bone mineral density, 1,25 (OH) vitamin D concentrations
Starting date June 2016
Contact information pataweeb44@gmail.com
Notes
NCT 02856269
Trial name or title Zinc Supplementation and Cardiovascular Risk in HIV (NCT02856269)
Methods Country: USA
Setting: University Hospitals Cleveland Medical Center
Participants Inclusion criteria: HIV-1 infected adults aged≥ 18 years with blood zinc level≤ 0.75 mg/L that are receiving
a stable antiretroviral regimen with no plans to change during study with HIV-1 RNA level of ≤ 400 copies/
mL and no diarrhoea or nausea/vomiting for the last month
Exclusion criteria: pregnancy/lactation,presence of inflammatory condition, regular use of agents that may
affect inflammation in the last 3 months. regular use of NSAIDS, aspirin, or statins will be allowed as long
as dose has been stable for the last 3 months and is not expected to change during the study
Presence of active neoplastic diseases requiring chemotherapy and use of immunosuppressive drugs, known
cardiovascular disease, uncontrolled diabetes, allergy or intolerance to zinc sulfate. AST, and ALT > 2.5 x
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NCT 02856269 (Continued)
upper normal limit, haemoglobin < 9.0 g/dLor GFR < 50 mL/min
Interventions Intervention: 45 mg zinc gluconate daily
Control: 90 mg zinc gluconate daily
Duration: 12 weeks
Outcomes Changes in blood zinc concentrations
Starting date September 2016
Contact information mccomsey.grace@clevelandactu.org
Notes
Abbreviations: ALT: alanine aminotransferase; ALP: alkaline phosphate; ART: antiretroviral therapy; AST: aspartate aminotransferase;
GFR: glomerular filtration rate; HAART: highly active antiretroviral therapy; NSAIDS: non-steroidal anti-inflammatory drugs;
PTH: parathyroid hormone.
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D A T A A N D A N A L Y S E S
Comparison 1. Multiple micronutrients versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 7 2897 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.72, 1.15]
1.1 People with HIV not on
ART
3 1068 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.31, 1.15]
1.2 People with HIV on ART
or initiating ART
1 400 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.50, 3.10]
1.3 People with HIV not on
ART and on treatment for
active tuberculosis
3 1429 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.69, 1.23]
2 Hospital admissions 2 881 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.61, 1.22]
2.1 People with HIV not on
ART
1 481 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.42, 1.49]
2.2 People with HIV on ART 1 400 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.59, 1.36]
3 Clinical disease progression 1 Hazard Ratio (Random, 95% CI) 1.08 [0.72, 1.62]
3.1 People with HIV not on
ART and on treatment for
active tuberculosis
1 Hazard Ratio (Random, 95% CI) 1.08 [0.72, 1.62]
4 CD4+ cell count 6 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 At baseline 5 1209 Mean Difference (IV, Random, 95% CI) -18.27 [-55.97, 19.
42]
4.2 At longest follow-up 6 1533 Mean Difference (IV, Random, 95% CI) 26.40 [-22.91, 75.
70]
5 CD4+ cell count at longest
follow-up; subgrouped by
participant characteristics
6 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 People with HIV not on
ART
2 441 Mean Difference (IV, Random, 95% CI) 30.36 [-7.13, 67.84]
5.2 People with HIV on ART
or initiating ART
1 367 Mean Difference (IV, Random, 95% CI) -6.0 [-35.87, 23.87]
5.3 People with HIV not on
ART and on treatment for
active tuberculosis
2 626 Mean Difference (IV, Random, 95% CI) -5.77 [-55.80, 44.
25]
5.4 People with HIV - Not
stated if they are taking ART
1 99 Mean Difference (IV, Random, 95% CI) 106.0 [77.23, 134.
77]
6 Viral load 4 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 At baseline 4 1166 Mean Difference (IV, Random, 95% CI) -0.05 [-0.16, 0.07]
6.2 At longest follow-up 4 792 Mean Difference (IV, Random, 95% CI) -0.10 [-0.26, 0.06]
7 Viral load at longest follow-up;
sub-grouped by participant
characteristics
4 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 People with HIV not on
ART
2 497 Mean Difference (IV, Random, 95% CI) -0.10 [-0.27, 0.07]
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7.2 People with HIV not on
ART but in treatment for active
tuberculosis
2 295 Mean Difference (IV, Random, 95% CI) -0.09 [-0.45, 0.26]
Comparison 2. High dose multivitamins versus standard dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 3418 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.89, 1.26]
1.1 People with HIV on ART
or initiating ART
1 3418 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.89, 1.26]
2 CD4+ cell count 1 6186 Mean Difference (IV, Fixed, 95% CI) -8.20 [-14.08, -2.32]
2.1 At baseline 1 3418 Mean Difference (IV, Fixed, 95% CI) -7.0 [-13.74, -0.26]
2.2 At follow-up 1 2768 Mean Difference (IV, Fixed, 95% CI) -12.0 [-22.00, -0.00]
3 Viral load 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Baseline 1 3418 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.05, 0.05]
3.2 At follow-up 1 236 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.51, 0.11]
Comparison 3. Vitamin D versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 People with HIV not on
ART and on treatment for
active tuberculosis
1 131 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.65, 2.02]
Comparison 4. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 3 433 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.53, 2.86]
1.1 People with HIV on ART 1 231 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.58, 3.32]
1.2 People with HIV not on
ART and on treatment for
active tuberculosis
2 202 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.22, 11.89]
2 Persistence of diarrhoea 1 104 Hazard Ratio (Random, 95% CI) 0.91 [0.50, 1.66]
2.1 People with HIV not on
ART
1 104 Hazard Ratio (Random, 95% CI) 0.91 [0.50, 1.66]
3 Rate of diarrhoea 1 231 Odds Ratio (Random, 95% CI) 0.40 [0.18, 0.87]
3.1 People with HIV on ART 1 231 Odds Ratio (Random, 95% CI) 0.40 [0.18, 0.87]
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Comparison 5. Selenium versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital admissions 1 186 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.21, 0.75]
1.1 People with HIV on ART 1 186 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.21, 0.75]
A D D I T I O N A L T A B L E S
Table 1. Optimal information size calculations (dichotomous outcomes)
Outcome Power Two-sided signifi-
cance level
Risk in control
group
Relative risk re-
duction
Risk in interven-
tion group
Sample size (to-
tal)
Death 80% 95% 15.5%1 25% 11.6% 2412
Death 80% 95% 8.3%2 25% 6.2% 4782
Death 80% 95% 5.5%3 25% 4.1% 7314
CD4 cell count
≤ 350 cells/mm
34
80% 95% 10% 60% 55% 2312
CD4 cell count
≤ 350 cells/mm
34
80% 95% 25% 60% 44% 314
CD4 cell count
≤ 350 cells/mm
34
80% 95% 50% 60% 29% 76
1Estimated annual risk of death of antiretroviral naive HIV-infected persons (≥10 years after seroconversion) (Collaborative Group on
AIDS Incubation 2000).
2Estimated annual risk of death of antiretroviral naive HIV-infected persons (5 to 9 years after seroconversion) (Collaborative Group
on AIDS Incubation 2000).
3Estimated risk of death of HIV-infected persons after receiving first-line antiretroviral therapy regimens for 12 months (Mbuagbaw
2010).
4Antiretroviral naive HIV-infected participants who experience a decline in CD4 count (Kamwesiga 2011a, which is under Kamwesiga
2015 RWA).
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Table 2. Optimal information size calculations (continuous outcomes)
Outcome Power Two-sided
signifi-
cance level
Ratio
of group 1:
group 2
Mean
in control
group
SD Mean in
supplement
group
SD Mean difference Sample size (to-
tal)
Mean
blood 25
(OH) vita-
min D
level at 12
months1
80% 95% 1 17 ng/ml 9 28 ng/ml 9 11.5 22
Mean
blood 25
(OH) vita-
min D
level at 12
months1
80% 95% 1 17 ng/ml 20 28 ng/ml 20 11.5 104
Mean BMI
at 24
months3
80% 95% 1 21 kg/m2 3 22 kg/m2 3 1 kg/m2 284
Mean BMI
at 24
months4
80% 95% 1 21 kg/m2 3 23 kg/m2 3 2 kg/m2 72
Abbreviations: BMI: body mass index; SD: standard deviation.
1This example is based on data from Stallings 2014 USA. This example uses the SD from the control group.
2This example is based on data from Stallings 2014 USA. This example uses the SD from the supplemented group.
3This example uses the SD from Villamor 2008 TZA, but uses a 1 kg/m2 mean difference for illustrative purposes.
4This example uses the SD from Villamor 2008 TZA, but uses a 2 kg/m2 mean difference for illustrative purposes.
Table 3. Characteristics of trials evaluating multiple micronutrients versus placebo
Trial ID Country Participants Baseline
HAART use
(%)
Mean baseline
CD4+ cell
count (cells/
mm3)
Mean baseline
viral load
(copies/ml or
log10 copies/
mL)
MMN dose1 Dura-
tion of supple-
mentation
Baum 2013
BWA
Botswana HIV-positive 0 423 (median) 11,800
(median)
High 24 months
Guwatudde
2015 UG
Uganda HIV-positive 49.82 145 (median)
137 (median)
N/A Standard 18 months
Jiamton 2003
THA
Thailand HIV-positive 0 244 (median) 3.9 (1.0) High 48 weeks
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Table 3. Characteristics of trials evaluating multiple micronutrients versus placebo (Continued)
Kelly 1999
ZMB
Zambia HIV-positive
plus chronic
diarrhoea
0 291 (median) N/A High 2 weeks
Kelly 2008
ZMB
Zambia HIV-positive 03 N/A N/A Standard 1.9 years4
McClelland
2004 KEN
Kenya HIV-positive 0 294 (209) 5.3 (0.9) High 6 weeks
Zhao 2010
CHN
China HIV-positive Not stated 417 (69) Not stated Standard 6 months
Range 2006
TZA
Tanzania HIV-positive
plus active TB
0 363 (275) 4.02 (0.98) High 8 months
Semba 2007
MWI
Malawi HIV-positive
plus active TB
0 Not stated 5.4 (median) Standard 24 months5
Villamor
2008 TZA
Tanzania HIV-positive
plus active TB
0 305 (227) 4.6 (1.0) High 24 months
Abbreviations: HAART: highly active antiretroviral therapy; MMN: multiple micronutrient; TB: Tuberculosis
1Standard dose supplements provided most of the micronutrients at the level of the Dietary Recommended Intake (DRI). High-dose
supplements provided most of the micronutrients in multiples of the DRI.
2Guwatudde 2015 UG: participants who received ART for no longer than 6 months. The rest of the trial participants were initiated
on ART at baseline.
3Kelly 2008 ZMB: we excluded participants taking HAART from the analysis of CD4 and viral load.
4Kelly 2008 ZMB was a cross-over trial, with cross-over at the end of 1.9 years. We did not include the outcome data for the period
after cross-over.
5Semba 2007 MWI: the median duration of follow-up was 12.5 months, due to the introduction of ART programme.
Table 4. Composition of multiple micronutrient supplements
Mi-
cronu-
trient
RDA
male
aged
19 to
70
years
Standard doses1 High doses2 Stan-
dard
dose
High
dose
Kelly
2008
ZMB
Zhao
2010
CHN
Semba
2007
MWI
Guwatudde
2015
UG
Baum
2013
BWA
Kelly
1999
ZMB
Ji-
amton
2003
THA
Mc-
Clel-
land
2004
KEN
Range
2006
TZA
Vil-
lamor
2008
TZA
Isanaka 2012
TZA
Vita-
min A
900 µg
(3000
IU)
- 200 µg
(660
IU)
2424µg
(8000
- - 3182
µg
(10500
3027
µg
(9990
- 1500
µg
(5000
1515
µg
(5000
- -
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Table 4. Composition of multiple micronutrient supplements (Continued)
IU) IU) IU) IU) IU)
B-
carotene
- 4.8 mg - - - - - 6 mg - - - - -
Vita-
min
B1
(Thi-
amine)
1.2 mg 1.4 mg 1 mg 1.5 mg 1.4 mg 20 mg - 24 mg 20 mg 20 mg 20 mg 1.2 mg 20 mg
Vita-
min
B2 (ri-
boflavin)
1.3 mg 1.4 mg 1 mg 1.7 mg 1.4 mg 20mg - 15 mg 20 mg 20 mg 20 mg 1.2 mg 20 mg
Vita-
min
B3
(niacin)
16 mg 18 mg - 20 mg 18 mg 100
mg
- 54 mg 100mg 40 mg 100
mg
15 mg 100
mg
Vita-
min
B6
(pyri-
dox-
ine)
1.3 to
1.7 mg
1.9 mg 1 mg 2 mg 1.9 mg 25 mg - 40mg 25 mg 25 mg 25 mg 1.3mg 25 mg
Vita-
min
B9
(folinic
acid)
400 µg 400 µg 150 µg 400 µg 400 µg 800 µg 5000
µg
100 µg 800 µg 800 µg 800 µg 400 µg 800 µg
Vita-
min
B12
2.4 µg 2.6 µg 6 µg 2.6 µg 50 µg - 30µg 50 µg 50 µg 50 µg 2.4 µg 50 µg
Pan-
thothenic
acid
5 mg - - - - - - 40 mg - - - - -
Vita-
min E
15 mg 10 mg 15 mg 133
mg
10 mg 30 mg 300
mg
80 mg 30 mg 60 mg 200
mg
15 mg 30 mg
Vita-
min D
5 to 15
µg
(200 to
600
5 µg
(200
IU)
5 µg
(200
IU)
10 µg
(400
IU)
- - - 20 µg
(800
IU)
- 5 µg
(200
IU)
- - -
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Table 4. Composition of multiple micronutrient supplements (Continued)
IU)
Vita-
min K
120 µg - - - - - - 180 µg - - - - -
Vita-
min C
90 mg 70 mg 100
mg
500
mg
70 mg 500
mg
300
mg
400
mg
500
mg
200
mg
500
mg
80 mg 500
mg
Sele-
nium
55 µg 65 µg 30 µg 65 µg - 200 µg 150 µg 400 µg 200 µg 200 µg 100 µg - -
Iron 8 mg 6 mg - - - - 10 mg - - - - -
Zinc 11 mg 15 mg 5 mg 10 mg - - 200
mg
30 mg - 45 mg - - -
Cop-
per
0.9 mg - - - - - - 3 mg - 5 mg - - -
Iodine 150 µg - - 175 µg - - - 300 µg - - - - -
Chromium
35 µg - - - - - - 150 µg - - - - -
Man-
ganese
2.3 mg - - - - - - 8 mg - - - - -
Cal-
cium
1000
mg
- 400
mg
- - - - - - - - - -
Abbreviations: IU: International units; RDA:Recommended Daily Allowance
1Standard dose supplements provided most of the micronutrients at the level of the RDA.
2High-dose supplements provided most of the micronutrients in multiples of the RDA.
Table 5. Change in CD4 cell count (cells/mm3): multiple micronutrients versus placebo
Trial ID Statistical
measure
Intervention Control Timing of end-
point
Difference be-
tween groups
at endpoint (as
reported by
trial authors)Baseline Endpoint N
1 Baseline Endpoint N1
Guwatudde
2015 UG
Median
(IQR)
145 (86 to
215)
Not
reported
200 137 (68 to
192)
Not
reported
200 18 months MD -
6.17 (95% CI -
29.3 to 16.9)2
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Table 5. Change in CD4 cell count (cells/mm3): multiple micronutrients versus placebo (Continued)
Jiamton
2003 THA
Median
(IQR)
244 (52 to
544)
200 (66 to
358)
192 261 (50 to
550)
232 (73 to
377)
184 48 weeks “Did not differ”
Kelly 1999
ZMB
Median
(IQR)
292 Not
reported
66 282 Not
reported
69 4 weeks “Not different”3
Kelly 2008
ZMB
Mean (SD) 370 (190) 415 (242) 41 365 (212) 409 (192) 43 1.9 years3 P = 0.55
McClel-
land
2004 KEN
Mean (SD) 294 (209) 300 (205) 179 262 (202) 265 (189) 178 6 weeks Adjusted regres-
sion co-efficient
23 (95% CI 3 to
43); P = 0.03
Zhao 2010
CHN
Mean (SD) 417 (69) 589 (85) 50 466 (72) 483 (59) 49 6 months P < 0.05
Range
2006 TZA
Mean (SD) 460 (391) 423 (373) 48 460 (385) 403 (460) 48 8 weeks P = 0.18
Villamor
2008 TZA
Mean (SD) 305 (277) Not
reported
200 339 (256) 340 (240) 204 2 years5 MD -5 (−37 to
26); P = 0.74
Baum
2013 BWA
Median
(IQR)
428 (336
to 555)
Not
reported
220 411 (327 to
545)
Not
reported
217 2 years Not reported7
Abbreviations: IQR: Interquartile range; MD: Mean difference; SD: Standard deviation
1The number of participants stated is the number assessed for end-point data.
2Guwatudde 2015 UG: the trial authors reported a mean difference which is different to our calculation. The reasons for this are
unclear.
3Kelly 1999 ZMB: the trial authors did not report data that we could include in a meta-analysis.
4Kelly 2008 ZMB was a cross-over trial, with cross-over at the end of 1.9 years. CD4+ counts were recorded during the second year of
follow-up. The data for the period after cross-over is not included in this table.
5Range 2006 TZA: data shownare formultiplemicronutrients plus zinc versus placebo.Therewere also no differences formicronutrients
without zinc versus placebo.
6Villamor 2008 TZA also reported outcomes at 8 months, with no significant difference between groups.
7Baum 2013 BWA: data shown are for multivitamins plus selenium versus placebo. The trial authors reported reductions in the
risk of CD4+ falling to < 250 cells/µL for multivitamins plus selenium versus placebo (HR 0.48, 95% CI 0.26 to 0.88 ) and for
multivitamins alone versus placebo (HR 0.54, 95% CI 0.3 to 0.98). Multivariate analysis showed that this effect was only apparent
with supplementation of both multivitamins and selenium (HR 0.46, 95% CI 0.25 to 0.85).
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Table 6. Change in viral load (log10 copies/mL): multiple micronutrients versus placebo
Trial ID Statistical
measure
Intervention Control Timing of end-
point
Difference be-
tween groups
at endpoint (as
reported by
trial authors)Baseline Endpoint N
1 Baseline Endpoint N1
Baum
2013 BWA
Median
(IQR)
4.0 (3.3-4.
7)
Not
reported2
220 4.3 (3.6 to
4.8)
Not
reported2
217 24 months P = 0.43
Jiamton
2003 THA
Mean (SD) 3.9 4.4 (1.4) 714 4.2 4.5 (1.54) 69 48 weeks P = 0.4
McClel-
land
2004 KEN
Mean (SD) 5.3 (0.9) 5.3 (0.9) 179 5.4 (0.9) 5.4 (0.9) 178 6 weeks P = 0.4
Range
2006 TZA
Mean (SD) 3.72 (1.
18)
3.85 (1.4) 48 3.9 (1.33) 4.1 (1.54) 48 8 weeks “Not
significant”5
Villamor
2008 TZA
Mean (SD) 4.6 (1.0) Not
reported
71 4.6 (0.9) 4.74 (1.54) 69 2 years6 MD −0.08
(−0.22 to 0.05)
; P = 0.23
Abbreviations: CI: Confidence interval; IQR: Interquartile range; MD: Mean difference; SD: Standard deviation
1The number of participants stated is the number assessed for end-point data.
2Baum 2013 BWA: multiple imputation of viral load data was performed. The trial authors did not provide details.
3Baum 2013 BWA: data shown are for multivitamins plus selenium versus placebo. There were also no differences for multivitamins
without selenium versus placebo.
4Jiamton 2003 THA: viral load analyses was conducted on the first 140 consecutive participants (29% of participants).
5Range 2006 TZA: data shownare formultiplemicronutrients plus zinc versus placebo.Therewere also no differences formicronutrients
without zinc versus placebo.
6Villamor 2008 TZA also reported outcomes at 8 months, with no significant difference between groups.
Table 7. Change in nutritional status parameters: multiple micronutrients versus placebo
Trial ID Nutri-
tional
parame-
ter
Statisti-
cal mea-
sure
Intervention Control Timing
of
endpoint
Differ-
ence be-
tween
groups
at
endpoint
(as
reported
by trial
authors)
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Table 7. Change in nutritional status parameters: multiple micronutrients versus placebo (Continued)
Baseline End-
point
N1 Baseline End-
point
N1
Villamor
2008
TZA
BMI (kg/
m2)
Mean
(SD)
19.3 (2.8) Not
reported
233 19.6 (2.9) 21.2
(3.3)
238 2 years2 MD -0.1
(−0.4 to
0.2); P =
0.37
Guwatudde
2015 UG
Weight
(kg)
Haemo-
globin (g/
dL)
Not
reported
Median
(IQR)
Not
reported
12.2 (11.
2 to 13.2)
Not
reported
Not
reported
200
200
Not
reported
12.3 (11.
3 to 13.5)
Not
reported
Not
reported
200
200
18
months
18
months
MD 0.54
(−0.40 to
1.48); P =
0.691
MD 0.16
(−0.21 to
0.16);
P = 0.977
Jiamton
2003 12
Blood vi-
tamin
E (µmol/
L)3
Mean
(SD)
22 (9) Not
reported
Not
reported
19 (7) Not
reported
Not
reported
48 weeks MD 10.
7 (7.0 to
14.3)4; P
< 0.001
Blood se-
lenium
(µmol/L)
5
Mean
(SD)
1.6 (0.2) Not
reported
Not
reported
1.6 (0.2) Not
reported
Not
reported
48 weeks MD 0.16
(0.0 to 0.
34)6; P =
0.04
Kelly
1999
ZMB12
Blood vi-
tamin
A (µmol/
L)7,8
Mean 0.63 Not
reported
66 0.65 Not
reported
69 4 weeks P = 0.21
Blood vi-
tamin
E (µmol/
L)3,8
Mean 11.4 Not
reported
66 11.7 Not
reported
69 4 weeks “No dif-
ference”
Kelly
2008
ZMB
BMI (kg/
m2)
MUAC
(cm)
Fat mass
(kg)
Lean
body
mass (kg)
Grip
strength
(kg)
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
1.9 years
9
“No sig-
nificant
differ-
ences at
any time
point”
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Table 7. Change in nutritional status parameters: multiple micronutrients versus placebo (Continued)
Semba
2007
MWI12
Blood vi-
tamin
A (µmol/
L)7,11
Geomet-
ric mean
0.59 Reported
in a graph
383 0.59 Reported
in a graph
397 8 months “Signifi-
cantly
higher”
Blood se-
lenium
(µmol/L)
10,11
Geomet-
ric mean
0.66 Reported
in a graph
392 0.64 Reported
in graph
405 8 months
Abbreviations: BMI: Body Mass Index; IQR: Interquartile range; MUAC: Mid-upper arm circumference; MD: Mean difference; SD:
Standard deviation
1The number of participants stated is the number assessed for endpoint data.
2Villamor 2008 TZA also reported outcomes at 8 months, with no significant difference between groups (MD 0, 95% CI−0.2 to 0.3;
P = 0.74).
3Reference value for vitamin E sufficiency ≥ 11.6 µmol/L.
4Jiamton 2003 THA: the trial authors reported endpoint data on a subset of 44 participants. The trial authors did not state the number
of participants for each treatment group. Baseline vitamin E levels (µmol/L) reported for 112 participants.
5Reference value for selenium sufficiency: ≥ 0.95 µmol/L.
6Jiamton 2003 THA: the trial authors reported endpoint data on a subset of 54 participants. The number of participants for each
treatment group is not stated. Baseline selenium levels (µmol/L) reported for 129 participants.
7Reference value for vitamin A deficiency: < 0.7 µmol/L.
8Kelly 1999 ZMB: the trial authors reported that 67% and 55% of participants were deficient in vitamins A and E, respectively, at
baseline.
9Kelly 2008 ZMB was a cross-over trial, with cross-over at the end of 1.9 years.
10Reference value for selenium sufficiency: ≥ 0.75 µmol/L.
11Semba 2007MWI: the trial authors reported that 60% and 75% of participants were deficient in vitamin A and selenium respectively,
at baseline.
12Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.
Table 8. Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART
Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART Multiple micronutrients
currently taking
Participant or population: adults with HIV infection not currently taking ART
Settings: all settings
Intervention: multiple micronutrient supplementation (standard or high dose daily)
Comparison: placebo
Participant or population:
Settings: all settings
Intervention: multiple
Comparison: placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(trials)
Certainty of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
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Table 8. Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART (Continued)
Placebo Micronutrients
Mortality
Follow-up: 12 to
24 months
45 per 1000 26 per 1000
(14 to 52)
RR 0.60
(0.31 to 1.15)
1068
(3 trials)
⊕⊕©©
low1,2,3,4
due to indirect-
ness and impre-
cision
Multiple mi-
cronutrientsmay
reduce mortality
Hospital admis-
sions
Follow-up: 48
weeks
84 per 1000 66 per 1000
(35 to 125)
RR 0.79
(0.42 to 1.49)
481
(1 trial)
⊕©©©
very low1,4,5
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on hospital
admissions
CD4 cell count
Follow-up: 6
weeks to 2 years
The mean in the
placebo groups
ranged from
265 to 409
cells/mm³
The mean in the
mul-
tiple micronutri-
ent group was
30.36 cells/
mm³ higher
(7.13 lower to
67.84 higher)
- 441
(2 trials)
⊕⊕©©
low1,6,7
due to indirect-
ness and incon-
sistency
Mul-
tiple micronutri-
entsmay have lit-
tle or no effect on
CD4+ cell count
Viral load
Follow-up: 6 to
48 weeks
The mean in the
placebo groups
ranged from
4.4 to 5.3
log10copies/mL
The mean in the
mul-
tiple micronutri-
ent groups was
0.
10 log10copies/
mL lower
(0.27 lower to 0.
07 higher)
- 497
(2 trials)
⊕⊕⊕©
moderate1,8
due to indirect-
ness
Mul-
tiple micronutri-
ents proba-
bly have little or
no effect on viral
load
BMI (kg/m²)
Follow-up: 1.9
years
- - - 84
(1 trial)
⊕©©©
very low1,9,10
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on BMI
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; MUAC: mid-upper arm circumference;
RR: risk ratio
The basis for the
corresponding risk
group and the relative
Abbreviations: AR
interval; MUAC:
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
GRADE Working
High certainty: fur
in the estimate of
Moderate certainty:
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Table 8. Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART (Continued)
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low certainty: we are very uncertain about the estimate.
on our confidence
Low certainty: fur
our confidence in
Very low certainty:
1No serious risk of bias: all trials were at low risk of selection bias. Appropriate methods of blinding were used.
2No serious heterogeneity: none of the trials found statistically significant effects.
3Downgraded by 1 for serious indirectness: the three trials were conducted in Botswana (Baum 2013 BWA), Zambia (Kelly 2008
ZMB) and Thailand (Jiamton 2003 THA).The finding of no effect may not apply to all populations.
4Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall
meta-analysis is substantially underpowered to confidently exclude effects.
5Downgraded by 2 for very serious indirectness: only a single trial is available from Thailand (Jiamton 2003 THA). The finding of no
effect is not easily generalized to other settings.
6Downgraded by 1 for serious inconsistency: One trial in Botswana among ART-naive adults (not included in the meta-analysis)
reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This
finding is inconsistent with other trials that used similar combinations of micronutrients and selenium.
7Downgraded by 1 for serious indirectness: these two trials both used high-dose multiple micronutrients and were conducted in Kenya
(with 6 weeks follow-up) and Zambia (with 1.9 years follow-up). TThe finding of no effect may not apply to people on ART or other
populations and settings.
8Downgraded by 1 for serious indirectness: these two studies both used high dose multiple micronutrients and were conducted in
Kenya (with 6 weeks follow-up) and Thailand (with 48 weeks follow-up). The finding of no effect may not apply to people on ART
or other populations and settings.
9Downgraded by 2 for very serious indirectness: only a single trial from Zambia (Kelly 2008 ZMB) reports measures of nutritional
status. This does not exclude the possibility of effects in some populations.
10Downgraded by 1 for serious imprecision: this trial is underpowered to detect or exclude clinically important differences. The trial
reported no difference in BMI, mid-upper arm circumference (MUAC), lean body mass or fat mass but did not present data.
Table 9. Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART
Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART Multiple micronutrients
rently taking AR
Participant or population: adults with HIV infection currently taking ART
Settings: any setting
Intervention: multiple micronutrient supplementation (standard dose daily)
Comparison: placebo
Participant or population:
Settings: any setting
Intervention: multiple
Comparison: placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(trials)
Certainty of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Placebo Micronutrients
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Table 9. Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART (Continued)
Mortality
Follow-up: 12 to
24 months
40 per 1000 50 per 1000
(20 to 124)
RR 1,25
(0.50 to 3.10)
400
(1 trial)
⊕©©©
very low1,2,3
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on mortality
Hospital admis-
sions
Follow-up: 48
weeks
195 per 1000 176 per 1000
(115 to 265)
RR 0.90
(0.59 to 1.36)
400
(1 trial)
⊕©©©
very low1,2,3
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on mortality
CD4 cell count
Follow-up: 18
months
The
mean change in
the placebo
group was 147
cells/mm³
The
mean change in
the multiple mi-
cronutrient
group was 6.17
cells/mm³lower
(29.3 lower to
16.9 higher)
367
(1 trial)
⊕©©©
very low1,2,4
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on CD4 cell
count
Viral load - - - - - -
Weight (kg)
Follow-up: 18
months
The
mean change in
the placebo
groupwas 3.3 kg
The
mean change in
the mul-
tiple micronutri-
ent group was 0.
54 kg higher
(0.40 lower to 1.
48 higher)
400
(1 trial)
⊕©©©
very low1,2,4
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on weight
*The basis for the assumed risk (for example, themedian control group risk across studies) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
Abbreviations: CI: confidence interval; HR: hazard ratio; RR: risk ratio.
*The basis for the
studies) is provided
the assumed risk
(and its 95% CI).
Abbreviations: CI:
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low certainty: we are very uncertain about the estimate.
GRADE Working
High certainty: fur
in the estimate of
Moderate certainty:
on our confidence
Low certainty: fur
our confidence in
Very low certainty:
1No serious risk of bias: this trial was at low risk of selection bias. The trial authors used appropriate methods of blinding.
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2Downgraded by 2 for serious indirectness: this single trial was conducted in Uganda and administered standard dose multiple
micronutrients for two years. The finding of no effect may not be applicable to higher dose or the populations or settings.
3Downgraded by 2 for serious imprecision: this single trial is significantly underpowered to confidently detect or exclude effects.
4Downgraded by 1 for serious imprecision: the 95% CI is wide and includes what may be clinically important effects and no effect.
Table 10. Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis
Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis not currently
taking ART
Multiple micronutrients
concurrent activ
Participant or population: adults with HIV infection and concurrent active tuberculosis not currently taking ART
Settings: any setting
Intervention: multiple micronutrient supplementation (standard or high dose daily)
Comparison: placebo
Participant or population:
currently taking AR
Settings: any setting
Intervention: multiple
Comparison: placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(trials)
Certainty of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Placebo Micronutrients
Mortality
Follow-up: 8 to
24 months
357 per 1000 328 per 1000
(246 to 439)
RR 0.92
(0.69 to 1.23)
1429
(3 trials)
⊕⊕©©
low1,2.3,4
due to indirect-
ness and impre-
cision
Multiple mi-
cronutrientsmay
have little or no
effect on mortal-
ity
Clinical
disease progres-
sion from stage
3 to stage 4
Follow-up: 24
months
- - HR 1.08 (0.72
to 1.62
313
(1 trial)
⊕©©©
very low1,4,5
due to indirect-
ness and impre-
cision
We don’t know
if multiple mi-
cronutrients
have any effect
on clinical dis-
ease progression
CD4 cell count
Follow-up: 2 to
24 months
The mean in the
placebo groups
ranged from
340 to 403
cells/mm³
The mean in the
mul-
tiple micronutri-
ent group was
5.77 cells/mm³
lower
(55.8 lower to
44.25 higher)
- 674
(2 trials)
⊕⊕©©
low1,3,4
due to indirect-
ness and impre-
cision
Multiple mi-
cronutrientsmay
have no effect on
CD4 cell count
Viral load
Follow-up: 2 to
24 months
The mean in the
placebo groups
ranged from
The mean in the
mul-
tiple micronutri-
- 343
(2 trials)
⊕⊕©©
low1,3,4
due to indirect-
Multiple mi-
cronutrientsmay
have no effect on
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Table 10. Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis
(Continued)
4.1 to 4.7
log10copies/mL
ent groups was
0.
09 log10copies/
mL lower
(0.45 lower to 0.
26 higher)
ness and impre-
cision
viral load
BMI
Follow-up: 24
months
The mean BMI
in the placebo
group was 21.2
kg/m2
The mean BMI
in the micronu-
trient group was
0.1 lower
(0.4 lower to 0.2
higher)
- 471
(1 trial)
⊕©©©
very low1,4,5
due to indirect-
ness and impre-
cision
We don’t know if
mul-
tiple micronutri-
ents have any ef-
fect on BMI
*The basis for the assumed risk (for example, themedian control group risk across studies) is provided in footnotes. The corresponding
risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
Abbreviations: ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; RR: risk ratio
*The basis for the
studies) is provided
the assumed risk
(and its 95% CI).
Abbreviations: AR
RR: risk ratio
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low certainty: we are very uncertain about the estimate.
GRADE Working
High certainty: fur
in the estimate of
Moderate certainty:
on our confidence
Low certainty: fur
our confidence in
Very low certainty:
1No serious risk of bias: the trials were at low risk of selection bias, except for two trials that recruited both HIV-positive and HIV-
negative participants and did not stratify the randomization (Range 2006 TZA; Semba 2007 MWI). The trials used appropriate
methods of blinding.
2No serious heterogeneity: one small subgroup of a trial in Tanzania did find a statistically significant difference (Range 2006 TZA),
but larger trials did not.
3Downgraded by 1 for serious indirectness: the three trials were conducted in Tanzania and Malawi and most patients were not taking
ART. The finding of no effect may not apply to people on ART or other populations and settings.
4Downgraded by 1 for serious imprecision: the 95% CI is wide and includes clinically important effects and no effect.
5Downgraded by 2 for serious indirectness: data is provided by a single trial from Tanzania and participants were not on antiretroviral
therapy (ART).
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Table 11. Characteristics of trials evaluating vitamin A supplements versus placebo
Trial ID Country Participants Baseline
ART use
Mean base-
line
blood vita-
min A con-
centration
(µmol/L)1
Mean base-
line CD4+
cell count
(cells/mm3)
Mean base-
line viral
load (log10
copies/mL)
Dose2 Duration of
supplemen-
tation
Baeten 2002
KEN
Kenia HIV-posi-
tive women
0% 0.097 (me-
dian)
0.095 (me-
dian)
240
(median)
203
(median)
5.34
(median)
5.54
(median)
10,000 IU
retinol daily
6 weeks
Humphrey
1999 USA
USA HIV-posi-
tive women
49% 1.52 (0.42)
1.41 (0.31)
Not reported Not reported 300,000 IU
retinol
Single dose
Semba 2007
USA
USA HIV-posi-
tive IDUs
46% 1.61
1.37
296
(median)
259
(median)
9.49
(median)
9.67
(median)
200,000 IU
retinol
Single dose
Coodley
1993 USA3
USA HIV-
positive
94% - - - 180 mg β-
carotene
4 weeks
Abbreviations: IDUs: Injection drug users; IU: International units; RDA: Recommended Daily Allowance
1Reference value for vitamin A sufficiency: > 1.05 µmol/L.
2RDA for a male aged 19 to 70 years is 900 µg (3000 IU) daily.
3Coodley 1993 USA was a cross-over trial, with cross-over at the end of 4 weeks. The baseline and outcome data is not reported for
the period before cross-over and therefore we could not include it.
Table 12. Change in CD4 cell count (cells/mm3): vitamin A versus placebo
Trial ID Statistical
measure
Intervention Control Timing of
end-point
Difference
between
groups
at end-
point (as
reported
by trial au-
thors)Baseline End-point N
1 Baseline End-point N1
Semba
1998 USA
Median 296 Reported
in a graph
Not
reported2
259 Reported
in a graph
Not
reported2
4 weeks P = 0.17
Baeten
2002 KEN
Median 240 272 176 203 225 178 6 weeks P = 0.04
Adjusted
regres-
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Table 12. Change in CD4 cell count (cells/mm3): vitamin A versus placebo (Continued)
sion coeffi-
cient 0.34
−0.22 to 0.
90); P = 0.
90
1The number of participants stated is the number assessed for endpoint data.
2Semba 1998 USA: the trial authors reported that 110 particpants completed the trial, but did not report the number of participants
for each treatment group.
Table 13. Change in viral load (log10 copies/mL) : Vitamin A versus placebo
Trial ID Statistical
measure
Intervention Control Timing of
endpoint
Difference
between
groups
at end-
point (as
reported
by trial
authors)Baseline Endpoint N
1 Baseline Endpoint N1
Semba
1998 USA
Median 9.49 Reported
in a graph
Not
reported2
9.67 Not
reported
Not
reported2
4 weeks P = 0.17
Humphrey
1999 USA
Geometric
mean
Reported
in a graph
Reported
in a graph
19 Reported
in a graph
Reported
in a graph
12 8 weeks P = 0.56
Baeten
2002 KEN
Median 5.34 5.34 176 5.54 5.49 178 6 weeks P = 0.1
1The number of participants stated is the number assessed for endpoint data.
2Semba 1998 USA: the trial authors reported that 110 particpants completed the trial, but do not report the number of participants
for each treatment group.
Table 14. Change in nutritional status parameters: vitamin A versus placebo
Trial ID Nutri-
tional
parame-
ter
Statisti-
cal Mea-
sure
Intervention Control Timing
of
endpoint
Differ-
ence be-
tween
groups
at end-
point (as
reported
by trial
authors)
Baseline End-
point
N1 Baseline End-
point
N1
Baeten
2002
KEN3
Vitamin
A (µmol/
L)2
Median 0.97 1.03 Not
reported
0.95 0.94 Not
reported
6 weeks P =
0.03. “No
effect” re-
ported for
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Table 14. Change in nutritional status parameters: vitamin A versus placebo (Continued)
those who
were
severely
de-
ficient at
baselineSemba
1998
USA3
Vitamin
A (µmol/
L)3
Median 1.61 Presented
in a graph
Not
reported
1.37 Presented
in a graph
Not
reported
4 weeks “Not dif-
ferent”
Humphrey
1999
USA3
Vitamin
A (µmol/
L)3
Median 1.56 1.54 20 1.37 1.30 15 4 weeks “No
change”
1The number of participants stated is the number assessed for endpoint data.
2Baeten 2002 KEN: Data converted from µg/dL to µmol/L.
3Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.
Table 15. Characteristics of trials evaluating Vitamin D supplements versus placebo
Trial ID Country Partici-
pants
Baseline
ART use
Mean base-
line blood
25(OH)
2 vitamin D
concen-
tration (ng/
mL)1
Mean base-
line CD4+
cell count
(cells/mm3)
Mean base-
line viral
load (log10
copies/mL)
Dose2 Duration of
supplemen-
tation
Bang 2012
DEN
Denmark HIV-
positive men
100% 27.2 (11.5)
29.2 (12.4)
507 (268)
463 (197)
Not
reported
100,
000 IU then
1200 IU
Single dose
at baseline
then daily
for 16 weeks
(plus 1200
mg calcium
daily)
Giacomet
2013 ITA
Italy HIV-pos-
itive; ≤ 30
years
86% 15 (median)
3
663
(median)
673
(median)
Not
reported
100,000 IU Single
dose at base-
line and at
3, 6, and 9
months
Overton
2015 USA
USA HIV-
positive men
and women
0%4 26.7
(median)
25.1
(median)
346
(median)
337
(median)
4.5 4000 IU Daily for 48
weeks (plus
100 mg cal-
cium)
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Table 15. Characteristics of trials evaluating Vitamin D supplements versus placebo (Continued)
Stallings
2014 USA
USA HIV-pos-
itive; ≤ 25
years
76% 18.2 (8.4)
17.7 (9)
Not
reported5
3.17 (0.96)6 7000 IU Daily for 12
months
Wejse 2009
GNB
Guinea-
Bissau
HIV-
positive plus
active TB
0% Not
reported for
HIV-
positive par-
ticipants
Not
reported for
HIV-
positive par-
ticipants
Not
reported
100,000 IU Single dose
at baseline,
5, 8 months
Abbreviations: ART: antiretroviral therapy; IU: International units; TB: Tuberculosis
1Reference value for vitamin D sufficiency: 25 (OH) vitamin D ≥ 30 ng/mL.
2RDA for a male aged 19 to 70 years ranges between 5 to 15 µg (200 to 600 IU) daily.
3Giacomet 2013 ITA: only participants with low blood vitamin D concentrations were included in the trial (25(OH)D < 30 ng/mL).
4Overton 2015 USA: all trial participants were intiated on ART at baseline.
5Stallings 2014 USA: 62% of partcipants had a CD4 cell count > 500 cells/mm3.
6Stallings 2014 USA: 44% of trial participants presented with a detectable viral load at baseline (vitamin D group:13, placebo group:
11).
Table 16. Change in CD4 cell count (cells/mm3): vitamin D versus placebo
Trial ID Statistical
measure
Baseline Endpoint Timing of
endpoint
Difference
between
groups
at end-
point (as
reported
by trial
authors)
Interven-
tion
Control N1 Interven-
tion
Control N1
Bang 2012
DEN
Mean (SD) 507 (268) 463 (197) 17 Not
reported
Not
reported
15 16 weeks “No
changes”
in naïve or
activated
CD4+ cell
counts
Giacomet
2013 ITA
Median 15 15 25 Not
reported
Not
reported
25 12 months MD 58.
1 (−114.5
to 230.7)2
Overton
2015 USA
Median 346 342 79 5513 5263 86 48 weeks P = 0.90
Wejse
2009
GNB
Mean Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
8 months MD −22
(P = 0.17)4
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Abbreviations: MD: Mean difference; SD: Standard deviation
1The number of participants stated is the number assessed for endpoint data.
2Giacomet 2013 ITA: the trial authors also reported no difference in CD4+ cell count at 3, 6, and 9 months.
3Overton 2015 USA: the trial authors reported an increase in CD4+ cell count within both treatment groups (P > 0.001).
4Wejse 2009 GNB: subset of 41 HIV-positive participants who had CD4+ cell counts at baseline and endpoint.
Table 17. Change in nutritional status parameters: vitamin D versus placebo
Trial ID Nutri-
tional
parame-
ter
Statisti-
cal Mea-
sure
Intervention Control Timing of
endpoint
Difference be-
tween groups
at endpoint
(as reported
by trial au-
thors)
Baseline End-
point
N1 Baseline Endpoint N1
Bang
2012
DEN2
25
(OH) vi-
tamin D
(ng/mL)2
Mean
(SD)
27.2 (11.
5)
31.6 (9.9) 17 29.2 (12.
4)
19.2 (13.
9)
15 16 weeks P < 0.001
Giacomet
2013 ITA
2
25
(OH) vi-
tamin D
(ng/mL)2
Median 15 Not
reported
25 15 Not
reported
25 12 months MD 12.5 (5.9
to 19) P < 0.
001
Overton
2015
USA2
25
(OH) vi-
tamin D
(ng/mL)2
Median 26.7 56.4 79 25.1 26.2 86 48 weeks P < 0.001
Stallings
2014
USA2
25
(OH) vi-
tamin D
(ng/mL)2
Mean
(SD)
10.3 (6.4) 17 (13.1) 30 11.3 (7.6) 10.5 (6.2) 28 12 months P < 0.001
Abbreviations: MD: Mean difference; SD: Standard deviation
1The number of participants stated is the number assessed for end-point data.
2Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.
Table 18. Characteristics of trials evaluating zinc supplements versus placebo
Trial ID Country Participants Baseline
ART use
Mean base-
line
blood zinc
concentra-
tion (µg/L)1
Mean base-
line CD4+
cell count
(cells/mm3)
Mean base-
line viral
load
(copies/
mL or log10
copies/mL)
Dose2 Duration of
supplemen-
tation
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Table 18. Characteristics of trials evaluating zinc supplements versus placebo (Continued)
Asda-
mongkol
2013 THA3
Thailand HIV-
positive
100% with
immunolog-
ical
discordance
80 (median)
76 (median)
183
(median)
162
(median)
Not reported 15 mg daily 6 months
Baum 2010
USA
USA HIV-
positive
62%4 60 (10)5 373 (280) 4.0 (1.0) 12 mg
(women)
15 mg (men)
18 months
Cárcamo
2006 PER
Peru HIV-
positive plus
persistent di-
arrhoea
0% 66 (median)
65 (median)
65 (median)
55 (median)
Not reported 50 mg twice
daily
14 days
Green 2005
SGP
Singapore HIV-
positive
95% 86.9 (15.0)
92.2 (18.3)
112 (62)
131 (65)
26 338 (38
335)
28 093 (41
056
50 mg daily 28 days
Lawson
2010 NIG
Nigeria HIV-pos-
itive plus ac-
tive TB
0% Not reported Not reported Not reported 90 mg
weekly6
6 months
Range 2006
TZA
Tanzania HIV-pos-
itive plus ac-
tive TB
0% Not reported 406
(median)
460
(median)
3.83
(median)
3.90
(median)
45 mg daily 8 months
Abbreviations: ART: Antiretroviral therapy; RDA: Recommended Daily Allowance; TB: Tuberculosis
1Reference value for zinc sufficiency: > 70 µg/L.
2RDA for a male aged 18 to 70 years is 11 mg daily.
3Asdamongkol 2013 THA: the trial authors stratified participants with or without low blood zinc concentrations and randomized
them to receive zinc or placebo.
4Baum 2010 USA: proportion of trial participants who were on ART and had an undetectable viral load at baseline: 30%
5Baum 2010 USA: the trial authors excluded participants with normal baseline blood zinc levels (≥ 75 µg/L)
6Lawson 2010 NIG: the trial authors randomized participants to receive either weekly doses of zinc (90 mg) and vitamin A (5000 IU),
zinc (90 mg) and placebo, or a dual placebo.
Table 19. Change in CD4 count (cells/mm3) : zinc versus placebo
Trial ID Statistical
measure
Intervention Control Timing of end-
point
Difference be-
tween groups at
endpoint (as re-
ported by trial
authors)Baseline Endpoint N
1 Baseline Endpoint N1
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Table 19. Change in CD4 count (cells/mm3) : zinc versus placebo (Continued)
Asda-
mongkol
2013 THA
Median
(IQR)
183
(151 to
213)
250
(190 to
286)
13 162
(139 to 182)
192
(162 to 254)
17 6 months Supplemen-
tation increased
medianCD4+ in
those with low
zinc at baseline
(P = 0.042) but
not those with
normal zinc (P >
0.05)
Baum
2010 USA
Mean
(SD)
385
(285)
Not
reported
104 361
(275)
Not
reported
96 18 months Reduced risk of
CD4+
< 200 cells/µL
2 with interven-
tion (RR 0.24,
95% CI 0.10 to
0.56)
Cárcamo
2006 PER
Median 66 Not
reported
- 65 Not
reported
- - Not reported
Green
2005 SGP
Mean
(SD)
113
(61)
127
(73)
30 134
(63)
156
(75)
33 28 days P = 0.91
Range
2006 TZA
Mean
(95% CI)
406
(327 to
485)
422
(331 to
512)
58 460
(351 to 569)
403
(309 to 569)
48 2 months “Not significant”
Abbreviations: CI: Confidence interval; IQR: Interquartile range; RR: Relative risk; SD: Standard deviation
1The number of participants stated is the number assessed for endpoint data.
Table 20. Change in viral load (copies/mL or log10 copies/mL): zinc versus placebo
Trial ID Statistical
measure
Intervention Control Timing of end-
point
Difference be-
tween groups
at endpoint (as
reported by
trial authors)Baseline Endpoint N
1 Baseline Endpoint N1
Baum
2010 USA
Mean
(SD)
4.0
(1.0)
Not
reported
115 4.0
(1.1)
Not
reported
116 18 months “Not affected by
supplementa-
tion”
Green
2005 SGP
Mean
(SD)
24,740
(36,856)
27,652
(39,418)
30 26,286
(40,297)
24,551
(39,013)
33 28 days P = 0.26
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Table 20. Change in viral load (copies/mL or log10 copies/mL): zinc versus placebo (Continued)
Range
2006 TZA
Mean
(95% CI)
3.83 (3.52
to 4.15)
4.28 (3.86
to 4.71)
58 3.9 (3.53 to
4.27)
4.1 (3.67 to
4.54)
48 2 months “Not
significant”
Abbreviations: CI: Confidence interval; SD: Standard deviation; TB: Tuberculosis
1The number of participants stated is the number assessed for endpoint data.
Table 21. Changes in nutritional status parameters: zinc versus placebo
Trial ID Nutri-
tional
parame-
ter
Statisti-
cal Mea-
sure
Intervention Control Timing
of
endpoint
Differ-
ence be-
tween
groups
at end-
point (as
reported
by trial
authors)
Baseline End-
point
N1 Baseline End-
point
N1
Asda-
mongkol
2013
THA2,3
Blood
zinc (µg/
L)
Median
(IQR)
80
(66 to 87)
82
(71 to
100)
13 76
(66 to 88)
74
(69 to 82)
17 6 months “higher
after zinc
supple-
menta-
tion, par-
tic-
ularly in
patients
with low
plasma
zinc levels
at
baseline”
Baum
2010
USA
Blood
zinc (µg/
L)
Mean
(SD)
40
(10)
Not
reported
Not
reported
40
(11)
Not
reported
Not
reported
18
months
Adjusted
4 regres-
sion coef-
ficient ß =
0.04; P =
0.0472
Cárcamo
2006
PER5
Blood
zinc (µg/
L)
Median 66 Not
reported
Not
reported
65 Not
reported
Not
reported
14 days Not
reported5
Green
2005
SGP5
Blood
zinc (µg/
L)
Mean
(SD)
92.2 (18.
3)
120.3
(68.0)
30 86.9 (15) 111.8
(37.9)
33 28 days P = 0.67
Abbreviations: IQR: Interquartile range; SD: Standard deviation
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1The number of participants stated is the number assessed for endpoint data.
2Asdamongkol 2013 THA: participants with or without low blood zinc concentrations were stratified and randomized to receive zinc
or placebo.
3Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.
4Baum 2010 USA: regression coefficient adjusted for C-reactive protein levels (biomarker for inflammation).
5Cárcamo 2006 PER: the trial authors reported a smaller proportion of participants in the supplemented group with low zinc levels
after 14 days of follow-up (65.6% versus 93.7%; P = 0.01).
Table 22. Characteristics of trials evaluating selenium supplements versus placebo
Trial ID Country Participants Baseline
ART use
Mean base-
line blood
selenium
concentra-
tion (µg/l)1
Mean base-
line CD4+
cell count
(cells/mm3)
Mean base-
line viral
load
(copies/
mL or log10
copies/mL)
Dose2 Duration of
supplemen-
tation
(months)
Baum 2013
BWA
Botswana HIV-
positive
0 % 65 (10)
70 (24)3
423
(median)
18 500 (me-
dian)
200 µg daily 24 months
Burbano
2002 USA
USA HIV-posi-
tive IDUs
Combina-
tion therapy
21%
HAART
46%3
Not reported
5
427 (421)
378 (295)
55,257 (147,
152)
60,905 (144,
292)
200 µg daily 12 months
Hurwitz
2007 USA
USA HIV-
positive
73% Not reported
6
417 (264)
441 (266)
24,558 (87,
051)
10,491 (20,
251)
200 µg daily 9 months
Kamwesiga
2015 RWA
Rwanda HIV-
positive
0%7 Not reported 552
(median)
527
(median)
3.8 (median)
3.9 (median)
200 µg daily 24 months
Abbreviations: ART: antiretroviral therapy; HAART: Highly active antiretroviral therapy; IDUs: injection drug users.
1Reference values used to define selenium sufficiency: > 75 µg/L or > 85 µg/L
2RDA for a male aged 18 to 70 years is 55 µg daily.
3Sales 2010 BWA in Baum 2013 BWA: Baseline selenium concentrations reported for a sub-sample of 79 trial participants.
4Burbano 2002 USA: the trial authors reported fewer ARV naive participants in the selenium group (24%) compared to the placebo
group (37%) at baseline.
5Burbano 2002 USA: participants with low baseline blood selenium levels (≤ 85 µg/L) were excluded from the trial.
6Hurwitz 2007 USA: participants with low baseline blood selenium levels (≤ 75 µg/L) were excluded from the trial.
7Kamwesiga 2015 RWA: participants who were eligible for ART were excluded from the trial.
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Table 23. Change in CD4 cell count (cells/mm3): selenium versus placebo
Trial ID Statistical
measure
Intervention Control Timing of
endpoint
Difference
between
groups
at
endpoint
(as re-
ported by
study au-
thors)Baseline Endpoint N
1 Baseline Endpoint N1
Baum
2013 BWA
Median
(IQR)
423
(347 to
539)
Not
reported
220 411
(327 to
545)
Not
reported
217 2 years Not
reported2
Burbano
2002 USA
Mean (SD) 427(421) Not
reported
Not
reported
376(295) Not
reported
Not
reported
12 months Not
reported3
Hurwitz
2007 USA
Mean (SD) 417 (264) Not
reported
Not
reported
441 (266) Not
reported
Not
reported
9 months Not
reported4
Kamwe-
siga
2015 RWA
Median
(IQR)
552 (470
to 636)
Not
reported
149 527 (465
to 610)
Not
reported
151 24 months Not
reported5
Abbreviations: CI: confidence interval; HR: hazard ratio; IQR: interquartile range; RR: risk ratio; SD: standard deviation
1The number of participants stated is the number assessed for endpoint data.
2Baum 2013 BWA: the trial authors reported no reduction in risk of CD4+ falling to < 250 cells/µL2 (HR 0.83, 95% CI 0.48 to 1.42).
3Burbano 2002 USA: the trial authors reported that 46% of participants in the placebo group versus 25% in the selenium group
experienced a decline in CD4 cell count > 50 cells/mm3 (P = 0.01).
4Hurwitz 2007 USA: the trial authors reported in a multiple regression model that increased selenium levels predicted a greater decrease
in viral load (P < 0.02), which predicted a greater increase in CD4 counts (P < 0.04).
5Kamwesiga 2015 RWA: the trial authors reported a 44 % reduction in the rate of CD4+ cell decline per month (MD 1.74, 95% CI
0.31 to 3.17). No reduction in risk of CD4+ falling to < 350 cells/µL2 (RR 0.81, 95% CI 0.61 to 1.09).
Table 24. Change in nutritional status parameters: selenium versus placebo
Trial ID Nutri-
tional
parame-
ter
Statisti-
cal mea-
sure
Intervention Control Timing of
endpoint
Comment
Baseline End-
point
N1 Baseline Endpoint N1
Burbano
2002
USA2
Blood se-
lenium
(µg/L)
- Not
reported
Not
reported
- Not
reported
Not
reported
Not
reported
12 months Not
reported 3
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Table 24. Change in nutritional status parameters: selenium versus placebo (Continued)
Hurwitz
2007
USA2
Blood se-
lenium
(µg/L)
- Not
reported
Not
reported
83 Not
reported
Not
reported
91 9 months MD 31.7
(27.
4 to 36);
P<0.001
Kamwe-
siga
2015
RWA
Blood se-
lenium
(µg/L)
- Not
reported
Not
reported
- Not
reported
Not
reported
- 24 months -
Sales
20102
Blood se-
lenium
(µg/L)4
Mean
(SD)
65 (10) 147 (15.
3)
33 70 (24) 69 (12.1) 46 6 months P<0.001
Abbreviations: MD: Mean difference; SD: Standard deviation
1The number of participants stated is the number assessed for endpoint data.
2Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.
3Burbano 2002 USA: the trial authors reported proportions of participants with blood selenium levels < 135 µg/L at the end of the
trial: 89% versus 47% (P = 0.001).
4Sales 2010: data reported on a subsample of trial participants from the trial by Baum 2013 BWA.
WH A T ’ S N E W
Last assessed as up-to-date: 18 November 2016.
Date Event Description
16 May 2017 New search has been performed We included 17 new trials in this review update, and assessed
the certainty of the evidence using the GRADE approach.
Nigel Rollins stepped down from the review author team.
Solange Durao and David Sinclair joined as review authors
16 May 2017 New citation required and conclusions have changed The original protocol for this review included studies in both
HIV-positive children and pregnant women (Irlam 2002)
. Two separate reviews on the role of micronutrient sup-
plementation for HIV-positive pregnant women, Siegfried
2012, and children, Irlam 2013, have been published. The
primary focus of this review update was therefore on the role
of micronutrient supplementation in HIV-positive men and
women who were not pregnant
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H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 4, 2005
Date Event Description
3 June 2011 Amended Paragraph added about the reviewbeing split into three
reviews
19 January 2011 Amended External source of support added.
9 November 2010 New citation required and conclusions have changed Substantial update of the review.
9 November 2010 New search has been performed Substantial update.
9 November 2010 Feedback has been incorporated External reviewers’ feedback incorporated into update
30 September 2010 New search has been performed Inclusion of 16 additional trials, assessment of Risk of
Bias using new ROB tool, and extensive updating of
text
C O N T R I B U T I O N S O F A U T H O R S
Marianne Visser (MV) initiated the review update and contributed to all stages of the review.
Solange Durao (SD) contributed to all stages of the review update.
David Sinclair (DS) contributed to the preparation of the review update for submission.
James Irlam (JI) commented on the report of the review update.
Nandi Siegfried (NS) assisted with study selection and commented on the review update.
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